




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C07K 7/06, 7/08		A2	(11) International Publication Number: <b>WO 98/40401</b>
			(43) International Publication Date: 17 September 1998 (17.09.98)
(21) International Application Number: PCT/CA98/00190		(74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).	
(22) International Filing Date: 10 March 1998 (10.03.98)			
(30) Priority Data:			
60/040,649	10 March 1997 (10.03.97)	US	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
08/915,314	20 August 1997 (20.08.97)	US	
60/060,099	26 September 1997 (26.09.97)	US	
09/030,619	25 February 1998 (25.02.98)	US	
(71) Applicant (for all designated States except US): MICROLOGIX BIOTECH INC. [CA/CA]; B.C. Research Building, 3650 Westbrook Mall, Vancouver, British Columbia V6S 2L2 (CA).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): FRASER, Janet, R. [GB/CA]; #12 - 1038 West 7th Avenue, Vancouver, British Columbia V6H 1B3 (CA). WEST, Michael, H. P. [CA/CA]; 2554 East 19th Avenue, Vancouver, British Columbia V5M 2S3 (CA). McNICOL, Patricia, J. [CA/CA]; 2559 Jasmine Court, Coquitlam, British Columbia V3E 2G5 (CA).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS



## (57) Abstract

Compositions and methods for treating infections, especially bacterial infections, are provided. Cationic peptides in combination with an antibiotic agent are administered to a patient to enhance the activity of the antibiotic agent, overcome tolerance, overcome acquired resistance, or overcome inherent resistance.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS

### 5 TECHNICAL FIELD

The present invention relates generally to methods of treating microorganism-caused infections using cationic peptides or a combination of cationic peptides and antibiotic agents, and more particularly to using these peptides and antibiotic agents to overcome acquired resistance, tolerance, and inherent resistance of an infective organism to the 10 antibiotic agent.

### BACKGROUND OF THE INVENTION

For most healthy individuals, infections are irritating, but not generally life-threatening. Many infections are successfully combated by the immune system of the 15 individual. Treatment is an adjunct and is generally readily available in developed countries. However, infectious diseases are a serious concern in developing countries and in immunocompromised individuals.

In developing countries, the lack of adequate sanitation and consequent poor hygiene provide an environment that fosters bacterial, parasitic, fungal and viral infections. 20 Poor hygiene and nutritional deficiencies may diminish the effectiveness of natural barriers, such as skin and mucous membranes, to invasion by infectious agents or the ability of the immune system to clear the agents. As well, a constant onslaught of pathogens may stress the immune system defenses of antibody production and phagocytic cells (e.g., polymorphic neutrophils) to subnormal levels. A breakdown of host defenses can also occur due to 25 conditions such as circulatory disturbances, mechanical obstruction, fatigue, smoking, excessive drinking, genetic defects, AIDS, bone marrow transplant, cancer, and diabetes. An increasingly prevalent problem in the world is opportunistic infections in individuals who are HIV positive.

Although vaccines may be available to protect against some of these 30 organisms, vaccinations are not always feasible, due to factors such as inadequate delivery

mechanisms and economic poverty, or effective, due to factors such as delivery too late in the infection, inability of the patient to mount an immune response to the vaccine, or evolution of the pathogen. For other pathogenic agents, no vaccines are available. When protection against infection is not possible, treatment of infection is generally pursued. The major 5 weapon in the arsenal of treatments is antibiotics. While antibiotics have proved effective against many bacteria and thus saved countless lives, they are not a panacea. The overuse of antibiotics in certain situations has promoted the spread of resistant bacterial strains. And of great importance, antibacterials are useless against viral infections.

10 A variety of organisms make cationic (positively charged) peptides, molecules used as part of a non-specific defense mechanism against microorganisms. When isolated, these peptides are toxic to a wide variety of microorganisms, including bacteria, fungi, and certain enveloped viruses. One cationic peptide found in neutrophils is indolicidin. While indolicidin acts against many pathogens, notable exceptions and varying degrees of toxicity exist.

15 In addition neither antibiotic therapy alone or cationic peptide therapy alone can effectively combat all infections. By expanding the categories of microorganisms that respond to therapy, or by overcoming the resistance of a microorganism to antibiotic agents, health and welfare will be improved. Additionally quality of life will be improved, due to, for example, decreased duration of therapy, reduced hospital stay including high-care 20 facilities, with the concomitant reduced risk of serious nosocomial (hospital-acquired) infections.

25 The present invention discloses cationic peptides, including analogues of indolicidin and cecropin/melittin fusion peptides, in combination with antibiotics such that the combination is either synergistic, able to overcome microorganismal tolerance, able to overcome resistance to antibiotic treatment, or further provides other related advantages.

#### SUMMARY OF THE INVENTION

The present invention generally provides the co-administration of cationic peptides with an antibiotic agent and also provides specific indolicidin analogues.

In other embodiments, the cationic peptide analogue has one or more amino acids altered to a corresponding D-amino acid, and in certain preferred embodiments, the N-terminal and/or the C-terminal amino acid is a D-amino acid. Other preferred modifications include analogues that are acetylated at the N-terminal amino acid, amidated at the C-terminal 5 amino acid, esterified at the C-terminal amino acid, and modified by incorporation of homoserine/homoserine lactone at the C-terminal amino acid. In other aspects, a composition is provided, comprising an indolicidin analogue and an antibiotic.

In addition, a device, which may be a medical device, is provided that is coated with a cationic peptide and an antibiotic agent.

10 This invention also generally provides methods for treating infections caused by a microorganism using a combination of cationic peptides and antibiotic agents. In one aspect, the method comprises administering to a patient a therapeutically effective dose of a combination of an antibiotic agent and a cationic peptide, wherein administration of an antibiotic agent alone is ineffective. Preferred antibiotics and peptides are provided.

15 In another aspect, a method of enhancing the activity of an antibiotic agent against an infection in a patient caused by a microorganism is provided, comprising administering to the patient a therapeutically effective dose of the antibiotic agent and a cationic peptide. In yet another aspect, a method is provided for enhancing the antibiotic activity of lysozyme or nisin, comprising administering lysozyme or nisin with an antibiotic 20 agent.

25 In other aspects, methods of treating an infection in a patient caused by a bacteria that is tolerant to an antibiotic agent, caused by a microorganism that is inherently resistant to an antibiotic agent; or caused by a microorganism that has acquired resistance to the antibiotic agent; comprises administering to the patient a therapeutically effective dose of the antibiotic agent and a cationic peptide, thereby overcoming tolerance, inherent or acquired resistance to the antibiotic agent.

In yet other related aspects, methods are provided for killing a microorganism that is tolerant, inherently resistant, or has acquired resistance to an antibiotic agent, comprising contacting the microorganism with the antibiotic agent and a cationic peptide,

thereby overcoming tolerance, inherent resistance or acquired resistance to the antibiotic agent.

These and other aspects of the present invention will become evident upon 5 reference to the following detailed description and attached drawings. In addition, various references are set forth below which describe in more detail certain procedures or compositions, and are therefore incorporated by reference in their entirety.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10 Figures 1A-E present time kill assay results for MBI 11CN, MBI 11F3CN, MBI 11B7CN, MBI 11F4CN, and MBI 26 plus vancomycin. The number of colony forming units  $\times 10^4$  is plotted versus time.

Figure 2 is a graph showing the stability of MBI11B7CN in heat-inactivated rabbit serum.

15 Figure 3 presents HPLC tracings showing the effects of amastatin and bestatin on peptide degradation.

Figure 4 is a chromatogram showing extraction of peptides in rabbit plasma.

Figure 5 is a graph presenting change in *in vivo* MBI 11CN levels in blood at various times after intraperitoneal injection.

20

#### DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms that are used herein.

25 The amino acid designations herein are set forth as either the standard one- or three-letter code. A capital letter indicates an L-form amino acid; a small letter indicates a D-form amino acid.

As used herein, an "antibiotic agent" refers to a molecule that tends to prevent, inhibit, or destroy life. The term "antimicrobial agent" refers to an antibiotic agent specifically directed to a microorganism.

As used herein, "cationic peptide" refers to a peptide that has a net positive charge within the pH range of 4-10. A cationic peptide is at least 5 amino acids in length and has at least one basic amino acid (e.g., arginine, lysine, histidine). Preferably, the peptide has measurable anti-microbial activity when administered alone.

5

As used herein, a "peptide analogue", "analogue", or "variant" of a cationic peptide, such as indolicidin, is at least 5 amino acids in length, has at least one basic amino acid (e.g., arginine and lysine) and has anti-microbial activity. Unless otherwise indicated, a named amino acid refers to the L-form. Basic amino acids include arginine, lysine, histidine 10 and derivatives. Hydrophobic residues include tryptophan, phenylalanine, isoleucine, leucine, valine, and derivatives.

Also included within the scope of the present invention are amino acid derivatives that have been altered by chemical means, such as methylation (e.g.,  $\alpha$  methylvaline), amidation, especially of the C-terminal amino acid by an alkylamine (e.g., 15 ethylamine, ethanolamine, and ethylene diamine) and alteration of an amino acid side chain, such as acylation of the  $\epsilon$ -amino group of lysine. Other amino acids that may be incorporated in the analogue include any of the D-amino acids corresponding to the 20 L-amino acids commonly found in proteins, imino amino acids, rare amino acids, such as hydroxylysine, or 20 non-protein amino acids, such as homoserine and ornithine. A peptide analogue may have none or one or more of these derivatives, and D-amino acids. In addition, a peptide may also be synthesized as a retro-, inverto- or retro-inverto-peptide.

As used herein "inherent resistance" of a microorganism to an antibiotic agent refers to a natural resistance to the action of the agent even in the absence of prior exposure to the agent. (R.C. Moellering Jr., *Principles of Anti-infective Therapy*; In: *Principles and 25 Practice of Infectious Diseases*, 4<sup>th</sup> Edition, Eds.; G.L. Mandell, J.E. Bennett, R. Dolin. Churchill Livingstone, New York USA, 1995, page 200).

As used herein, "acquired resistance" of a microorganism to an antibiotic agent refers to a resistance that is not inhibited by the normal achievable serum concentrations of a recommended antibiotic agent based on the recommended dosage. (NCCLS guidelines).

As used herein, "tolerance" of a microorganism to an antibiotic agent refers to when there is microstatic, rather than microcidal effect of the agent. Tolerance is measured by an MBC:MIC ratio greater than or equal to 32. (*Textbook of Diagnostic Microbiology*, Eds., C.R. Mahon and G. Manuselis, W.B. Saunders Co., Toronto Canada, 1995, page 92).

5

As noted above, this invention provides methods of treating infections caused by a microorganism, methods of killing a microorganism, and methods of enhancing the activity of an antibiotic agent. In particular, these methods are especially applicable when a microorganism is resistant to an antibiotic agent, by a mechanism, such as tolerance, inherent 10 resistance, or acquired resistance. In this invention, infections are treated by administering a therapeutically effective dose of a cationic peptide alone or in combination with an antibiotic agent to a patient with an infection. Similarly, the combination can be contacted with a microorganism to effect killing.

15 I. CATIONIC PEPTIDES

As noted above, a cationic peptide is a peptide that has a net positive charge within the pH range 4-10. A peptide is at least 5 amino acids long and preferably not more than 25, 27, 30, 35, or 40 amino acids. Peptides from 12 to 30 residues are preferred. Examples of native cationic peptides include, but are not limited to, representative peptides 20 presented in the following table.

Table 1. Cationic Peptides

Group Name	Peptide	Origin	Sequence	Accession Number	Reference*
Abaecins	Abaecin	Honey bee ( <i>Apis mellifera</i> )	YVPLNVPQQGRRPFPFTPGQQFPNPKIK WPGQY	P15450	Casteels P. et al., (1990)
Andropins	Andropin	Fruit fly ( <i>Drosophila melanogaster</i> )	VFIDILDKVENAHNAAQVGIGFAKPFKEKL INPK	P21663	Samakovlis, C. et al., (1991)
Apidaecins	Apidaecin 1A	Lymph fluid of honey bee ( <i>Apis mellifera</i> )	GNNRPVYIIPQRPPHPPRI	P11525	Casteels, P. et al., (1989)
	Apidaecin 1B	"	GNNRPVYIIPQRPPHPPRI	P11526	Casteels, P. et al., (1989)
	Apidaecin 1I	"	GNNRPIYIIPQRPPHPPRI	P11527	Casteels, P. et al., (1989)
AS	AS-48	<i>Streptococcus faecalis</i> subsp. <i>Lactifacines</i> S-48	7.4 kDa		Galvez, A., et al., (1989)
Bacteriocins	Bacteriocin	Cytoplasmic granules of bovine neutrophils	RLCRIVVIRVCR	A33799	Romeo, D. et al., (1988)
Eac	Bac5	Cytoplasmic granules of bovine neutrophils	RFRPPRIPRPPRPPFYPYPFRPPPIRPPFPIRPP FRPPLRFP	B36589	Frank, R.W. et al., (1990)
	Bac7	"	RRJRPRLPRLPRLPRLPFPFRPGPRPPIRPL PFPFRPGPRPPIRPLPFPFRPGPRPPIRPL	A36589	Frank, R.W. et al., (1990)
Bactericidins	Bactericidin B2	Tobacco hornworm larvae hemolymph ( <i>Manduca sexta</i> )	WNPFKELERAGQVRDAVISAAAPAVATV GQAAAARG*	P14662	Dickinson, L. et al., (1988)
	Bactericidin B-3	"	WNPFKELERAGQVRDAIIISAGPAVATV GQAAAARG	P14663	Dickinson, L. et al., (1988)
	Bactericidin B-4	"	WNPFKELERAGQVRDAIIISAAAPAVATV GQAAAARG*	P14664	Dickinson, L. et al., (1988)
	Bactericidin B-5P	"	WNPFKELERAGQVRDAVISAAAPAVATV QAAAARGG*	P14665	Dickinson, L., et al., (1988)
Bacteriocins	Bacteriocin C3603	<i>Streptococcus mutans</i>	4.8 kDa		Takada, K., et al., (1984)
	Bacteriocin IY52	<i>Staphylococcus aureus</i>	5 kDa		Nakamura, T., et al., (1983)

Group Name	Peptide	Origin	Sequence	Accession Number	Reference*
Bombinins	Bombinin	Yellow-bellied toad ( <i>Bombina variegata</i> )	GIGALSAKGALKGLAKGLAZHFAN*	P01505	Csordas, A., and Michl, H. (1970)
	BLP-1	Asian Toad ( <i>Bombina orientalis</i> )	GIGASILSAGKSALKGLAKGLAEHFAN*	M76483	Gibson, B.W. et al., (1991)
	BLP-2	"	GIGSAILSAGKSALKGLAKGLAEHFAN*	B41575	Gibson, B.W. et al., (1991)
Bombolitins	Bombolitin B1	Bumblebee venom ( <i>Megabombus pennsylvanicus</i> )	IKITIMLAKLQGKVLAHV*	P10521	Argiolas, A. and Pisano, J.J. (1985)
	Bombolitin BII	"	SKITDILAKLGKVLAHV*	P07493	Argiolas, A. and Pisano, J.J. (1985)
	BPTI	Bovine Pancreas Pancreatic Trypsin Inhibitor (BPTI)	RPDFCLEPPYTGPCKKARIIRYFYNAKAGL CQTFVYGGCRAKRNNNFKSAEDCMRTCG GA	P00974	Creighton, T. and Charles, I.G. (1987)
Brevinin	Brevinin-1E	European frog ( <i>Rana esculenta</i> )	FLPPLLAGLAANFLPKIFCKITRKC	S33729	Simmaco, M. et al., (1993)
	Brevinin-2E		GIMDTLKNLAKTAGKQALQSLLNKASCK LSQQC	S33730	Simmaco, M. et al., (1993)
Cecropins	Cecropin A	Silk moth ( <i>Hyalophora cecropia</i> )	KWKLFKKIEKVQQNIRDGIIKAGPAAV V GQATQIAK*	M63845	Gudmundsson, G.H. et al., (1991)
	Cecropin B	Silk moth ( <i>Hyalophora cecropia</i> )	KWKVFKKIEKMGRRNIRNGIVKAGPAAV LGEAKAL*	Z07404	Xanthopoulos, G. et al. (1988)
	Cecropin C	Fruit fly ( <i>Drosophila melanogaster</i> )	GWKKLGKRIERIGQHTRDATIQGLGIAQ QAANVAATARG*	Z11167	Tryselius, Y. et al. (1992)
Cecropin D	Silk moth pupae ( <i>Hyalophora cecropia</i> )		WNPFKELEKVGQRVVRDAVISAGPAVATV AQATALAK*	P01510	Hultmark, D. et al., (1982)
	Cecropin P <sub>1</sub>	Pig small intestine ( <i>sus scrofa</i> )	SWLSKTAKKLENSAKKRISGIAIAIQGGP R	P14661	Lee, J.-Y. et al., (1989)

Group Name	Peptide	Origin	Sequence	Accession Number	Reference*
Charybdotoxins	Charybdotoxin	Scorpion venom ( <i>Leiurus quinquestriatus hebraeus</i> )	ZFTNVSCTTSKECWSVCQRLHNTSRGKC MNKKCRCYS	P13487	Schweitz, H. et al., (1989)
Coleoptericins	Coleoptericin	Beetle ( <i>Zophobas atratus</i> )	8.1 kDa	A41711	Bulet, P. et al., (1991)
Crabolins	Crabolin	European hornet venom ( <i>Vespa crabro</i> )	FLPLILRKIVTAL*	A01781	Argiolas, A. and Pisano, J.J. (1984)
Defensins-alpha	Cryptidin 1	Mouse intestine ( <i>Mus musculus</i> )	LRDLVCYCRSRGCKGRERMNGTCRKGH LLYTLCCR	A43279	Selsted, M.E. et al., (1992)
	Cryptidin 2	"	LRDLVCYCRTRGCKRRERMNGTCRKGH LMYTLCCR	C43279	Selsted, M.E. et al., (1992)
MCP1	Rabbit alveolar macrophages ( <i>Oryctolagus cuniculus</i> )	"	VVCACRRALCLPRERRAGFCRIRGRIHPL CCRR	M28883	Selsted, M. et al., (1983)
MCP2		"	VVCACRRALCLPLERRAGFCRIRGRIHPL CCRR	M28073	Ganz, T. et al., (1989)
GNCP-1	Guinea pig ( <i>Cavia cutleri</i> )	"	RRCICCTRTCRFPYRRLGTCIFQNRVYTF CC	S21169	Yamashita, T. and Saito, K., (1989)
GNCP-2		"	RRCICCTRTCRFPYRRLGTCIFQNRVYTF CC	X63676	Yamashita, T. and Saito, K., (1989)
HNP-1	Azurophil granules of human neutrophils	"	ACYCRIPTACIAGERRYGTCTIYQGRLWAFC C	P11479	Lehrer, R. et al., (1991)
HNP-2		"	CYCRIPACIAGERRYGTCTIYQGRLWAFC C	P11479	Lehrer, R. et al., (1991)
NP-1	Rabbit neutrophils ( <i>Oryctolagus cuniculus</i> )	"	VVCACRRALCLPRERRAGFCRIRGRIHPL CCRR	P01376	Ganz, T. et al., (1989)
NP-2		"	VVCACRRALCLPLERRAGFCRIRGRIHPL CCRR	P01377	Ganz, T. et al., (1989)
RatNP-1	Rat neutrophils ( <i>Rattus norvegicus</i> )	"	VTCYCRRTRCGFRERLSGACGYRGRIVRL CCR	A60113	Eisenhauer, P.B. et al., (1989)

Group Name	Peptide	Origin	Sequence	Accession Number	Reference*
	RatNP-2	"	VTCCYCRSTRCGFRERLSSGACGYRGRIVRL		
Defensins-beta	BNBD-1	Bovine neutrophils	DFASCHTNGGICLPNRCPGHHMIQIGICFRP RVKCCRSW	127951	Eisenhauer, P.B. et al., (1989)
	BNBD-2	"	VRNHVTCRINRGFCVPIRCPGRTTRQIGTCF GPIRKCCRSW	127952	Selsted, M.E. et al., (1993)
TAP	Bovine tracheal mucusa ( <i>Bos taurus</i> )	NPVSCVRNKGICVPIRCPGSMKQIGTCVG RAVKCCRKK	P25068	Diamond, G. et al., (1991)	
	Sapecin	Flesh fly ( <i>Sarcophaga peregrina</i> )	ATCDLSSGTRGGINHSACAAHCLLRGNRGG YCNGKAVCVCRN	J04053	Hanzawa, H. et al., (1990)
Defensins-insect	Insect defensin	Dragonfly larvae ( <i>Aeschna cyanea</i> )	GFGCPLDQMQCHRHCQQTITGRSGGYCSG PLKLCTCYR	P80154	Bulet, P. et al., (1992)
	Scorpion defensin	Scorpion ( <i>Leiurus quinquestratus</i> )	GFGCPLNQGACHRHCRSIRRRGGYCAGF FKQTCTCYRN		Cocianich, S. et al., (1993)
Defensins-scorpion	Dermaseptin	South American arboreal frog ( <i>Phyllomedusa sauvagii</i> )	ALWKTMKLKGTMALHAGKAALGAAD TISQTQ	P24302	Mor, A., et al., (1991)
	Diptericins	Diptericin	Nestling-suckling blowfly ( <i>Phormia terraenovae</i> )	9 kDa	X15851
Drosocins	Drosocin	Fruit fly ( <i>Drosophila melanogaster</i> )	GKPRPYSPRPTSHPRPRPV	S35984	Bulet, P. et al., (1993)
	Esculentins	European frog ( <i>Rana esculenta</i> )	GIFSKLGRKKIKNLLISGKLNVGKEVGMDF VVRTGIDIAQCKIKGEC	S33731	Simmaco, M. et al., (1993)
Indolicidins	Indolicidin	Bovine neutrophils	ILPWKWPWWPWWR*	A42387	Selsted, M. et al., (1992)
	Lactoferricins	N terminal region of bovine lactoferrin	FKCRRWQWRMKLGAFTSITCVRRAF	M63302	Bellamy, W. et al., (1992b)
Lantibiotics	Nisin	<i>Lactococcus lactis</i> (bacterium) subsp. <i>Lactis</i>	ITISLCTPGCKTGALMGCNMKTATCHCS IHVSK	P13068	Hurst, A. (1981)
	Pep 5	<i>Staphylococcus epidermidis</i>	TAGPAIRASVKKQCQKTLKATRLFTVSCKG KNGCK	P19578	Keletta, C. et al., (1989)

Group Name	Peptide	Origin	Sequence	Accession Number	Reference*
	Subiliin	<i>Bacillus subtilis</i> (bacterium)	MSKFDDFDLDDVVVKVSKQDSKIKTPQWKSE SLCTPGCVTQALQTCFLQTLTCNCIKSK	P10946	Banerjee, S. and Hansen, J.N. (1988)
Leukocins	Leukocin A-val 187	<i>Leuconostoc gelidum</i> UAL 187 (bacterium)	KYYGNGVHCTKSGCSVNWGEAFSAGVH RLANGGNGFW	S65611	Hastings, J.W. et al., (1991)
Magainins	Magainin I	Amphibian skin ( <i>Xenopus laevis</i> )	GIGKFLHSAGKFGKAFVGEMIKS*	A29771	Zasloff, M. (1987)
	Magainin II	"	GIGKFLHSAAKKFGKAFVGEMIMNS*	A29771	Zasloff, M. (1987)
PGLa	Amphibian skin ( <i>Xenopus laevis</i> )		GMASKAGAAIAGKIAKY/ALKAL*	X13388	Kuchler, K. et al., (1989)
PGQ	Amphibian stomach ( <i>Xenopus laevis</i> )		GVLNSNVIGYLLKLGTLGALNAVLKQ		Moore, K.S. et al., (1989)
XPF	Amphibian skin ( <i>Xenopus laevis</i> )		GWASKIGQTTLGKIAKVGLKELIQPK	P07198	Sures, I. And Crippa, M. (1984)
Mastoparan	Mastoparan	Wasp venom ( <i>Vespaula lewisii</i> )	INKALAAALAKKIL*	P01514	Bernheimer, A. and Rudy, B. (1986)
Melittins	Melittin	Bee venom ( <i>Apis mellifera</i> )	GIGAVLKVLTTGLPALISWIKRKRQQ	P01504	Tosteson, M.T. and Tosteson, D.C.(1984)
Phormicins	Phormicin A	Nestling-suckling blowfly ( <i>Phormia terraenovae</i> )	ATCDLSSGTGINHSACAAHCLLRGNRGG YCNNGKGVCVCRN	P10891	Lambert, J. et al., (1989)
	Phormicin B	"	ATCDLSSGTGINHSACAAHCLLRGNRGG YCNRKGVCVRN	P10891	Lambert, J. et al., (1989)
Polyphemusins	Polyphemusin 1	Atlantic horseshoe crab ( <i>Limulus polyphemus</i> )	RRWCFRVCYRGFCYRKCR*	P14215	Miyata, T. et al., (1989)
	Polyphemusin 11	"	RRWCFRVCYRGFCYRKCR*	P14216	Miyata, T. et al., (1989)
Protegrins	Protegrin 1	Porcine leukocytes ( <i>sus scrofa</i> )	RGGRRLCYCRRRFCCVCVGR	S34385	Kokryakov, V.N. et al., (1993)
	Protegrin 11	"	RGGRRLCYCRRRFCCVCV	S34586	Kokryakov, V.N. et al., (1993)

Group Name	Peptide	Origin	Sequence	Accession Number	Reference*
	Protegrin III	"	RGGGLCYCRRRFCVCVGR	S34587	Kokryakov, V.N. et al., (1993)
Royalisins	Royalisin	Royal Jelly ( <i>Apis mellifera</i> )	VTCDLISFKQGVNDSACAANCLSLGKAG GHCEKGVCICRKTSFKDLWDKYF	P17722	Fujiwara, S. et al., (1990)
Sarcotoxins	Sarcotoxin 1A	Flesh fly ( <i>Sarcophaga peregrina</i> )	GWLLKIGKIKIERVGQHTRDATICQGLGIAQ QAANVAATAR*	P08375	Okada, M. and Natori S., (1985b)
	Sarcotoxin 1B	"	GWLLKIGKIKIERVGQHTRDATICQVIGVA QQANVAATAR*	P08376	Okada, M. and Natori S., (1985b)
Seminal plasmins	Seminalplasmin	Bovine seminal plasma ( <i>Bos taurus</i> )	SEDEKASPDKHHRFSLSRVYAKLANRLANP KLLETFLSKWIGDGRGNRSV	S08184	Reddy, E.S.P. and Bhargava, P.M. (1979)
Tachyplesins	Tachyplesin I	Horseshoe crab ( <i>Tachypleus tridentatus</i> )	KWCFCRVCYRGICYRRCR*	P23684	Nakamura, T. et al., (1988)
	Tachyplesin II	"	RWCFCRVCYRGICYRKCR*	P14214	Muta, T. et al., (1990)
Thionins	Thionin	Barley leaf ( <i>Hordeum vulgare</i> )	KSCCKDTLARNCYNTCRFAGGSRPGVCAG ACRCKIISGPCKPQPSDVK	S00825	Bohmann, H. et al., (1988)
	BTH6	"	GGKPDRLRPCIPCHYIPRPKPR	P24335	Schmidt, J.J. et al., (1992)
Toxins	Toxin 1	Waglers pit viper venom ( <i>Trimeresurus wagleri</i> )	VKDGIVVDDVNCTYFCGCRNAVCNEECTK	P01484	Bontems, F., et al., (1991)
	Toxin 2	Sahara scorpion ( <i>Androctonus australis</i> )	LKGESGYCQWASPYGNACYCKLPDHVR		
		Hector	TKGPGRCH		

Argiolas and Pisano, (1984). *JBC* 259, 10106; Argiolas and Pisano, (1985). *JBC* 260, 1437; Bansjee and Hansen, (1988). *JBC* 263, 9508; Bellamy et al., (1992). *J. Appl. Bacter.* 73, 472; Bernheimer and Rudy, (1966). *BBA* 864, 123; Bohmann et al., (1988). *EMBO J.* 7, 1559; Bontems et al., (1991). *Science* 254, 1521; Buler et al., (1991). *JBC* 266, 24320; Buler et al., (1992). *Eur. J. Biochem.* 209, 977; Buler et al., (1993). *JBC* 268, 1489; Castells et al., (1989). *EMBO J.* 8, 2387; Castells et al., (1990). *Eur. J. Biochem.* 187, 381; Cochainich et al., (1993). *BBRC* 194, 17; Creighton and Charles, (1987). *J. Mol. Biol.* 194, 11; Csendes and Michl, (1970). *Marathi Chemistry* 101, 182; Diamond et al., (1991). *PNAS* 88, 3952; Dickinson et al., (1988). *JBC* 263, 19424; Eisenhauer et al., (1989). *Infect. and Imm.* 57, 2021; Frank et al., (1990). *JBC* 265, 18871; Fujiwara et al., (1990). *JBC* 265, 11333; Gálvez et al., (1989). *Antimicrobial Agents and Chemotherapy* 33, 437; Ganz et al., (1989). *J. Immunol.* 143, 1358; Gibson et al., (1991). *JBC* 266, 23103; Gudmundsson et al., (1991). *JBC* 266, 11510; Hanzawa et al., (1990). *FEBS Letters* 269, 413; Hastings et al., (1991). *J. of Bacteriology* 173, 7491; Hultmark et al., (1982). *Eur. J. Biochem.* 127, 207; Hursl, A. (1981). *Adv. Appl. Micro.* 27, 85; Kletta et al., (1989). *Archives of Microbiology* 152, 16; Kokryakov et al., (1989). *Eur. J. Biochem.* 179, 281; Lambert et al., (1989). *PNAS* 86, 262; Lee et al., (1989). *PNAS* 86, 9159; Lehrer et al., (1991). *Cell* 64, 229; Miyata et al., (1991). *JBC* 266, 19851; Mor et al., (1991). *Biochemistry* 30, 8824; Muta et al., (1990). *J. Biochem.* 108, 261; Nakamura et al., (1988). *JBC* 263, 16709; Okada and Natori (1985). *Biochem. J.* 229, 453; Reddy and Bhargava, (1979). *Nature* 279, 725; Reichhart et al., (1989). *Eur. J. Biochem.* 182, 421; Romeo et al., (1988). *JBC* 263, 9573; Samakovlis et al., (1991). *EMBO J.* 10, 1631; Schmidt et al., (1992). *Toxicol.* 30, 1027; Schweitz et al., (1983). *JBC* 258, 14485; Selsted et al., (1989). *Biochem.* 28, 9708; Selsted et al., (1993). *FEBS Letters* 324, 159; Sures and Crippa (1984). *PNAS* 81, 380; Takada et al., (1984). *Biophysical J.* 45, 370; Tosteson and Tosteson, (1989). *Infect. and Imm.* 57, 2405; Zasthoff, M. (1987). *PNAS* 84, 5449. (1988). *Eur. J. Biochem.* 172, 371; Yamashita and Saito, (1989). *Infect. and Imm.* 57, 2405; Zasthoff, M. (1987). *PNAS* 84, 5449.

In addition to the peptides listed above, chimeras and analogues of these peptides are useful within the context of the present invention. For this invention, analogues of native cationic peptides must retain a net positive charge, but may contain D-amino acids, amino acid derivatives, insertions, deletions, and the like, some of which are discussed below. Chimeras include fusions of cationic peptide, such as the peptides of fragments thereof listed above, and fusions of cationic peptides with non-cationic peptides.

As described herein, modification of any of the residues including the N- or C-terminus is within the scope of the invention. A preferred modification of the C-terminus is amidation. Other modifications of the C-terminus include esterification and lactone formation. N-terminal modifications include acetylation, acylation, alkylation, PEGylation, myristylation, and the like. Additionally, the peptide may be modified to form a polymer-modified peptide as described below. The peptides may also be labeled, such as with a radioactive label, a fluorescent label, a mass spectrometry tag, biotin and the like.

#### A. Indolicidin and Analogues

As used herein, "indolicidin" refers to an antimicrobial cationic peptide. Indolicidins may be isolated from a variety of organisms. One indolicidin is isolated from bovine neutrophils and is a 13 amino acid peptide amidated at the carboxy-terminus in its native form (Selsted et al., *J. Biol. Chem.* 267:4292, 1992). An amino acid sequence of indolicidin is presented in SEQ ID NO: 1.

#### B. Cecropin peptides

Cecropins are cationic peptides that have antimicrobial activity against both Gram-positive and Gram-negative bacteria. Cecropins have been isolated from both invertebrates (e.g., insect hemolymph) as well as vertebrates (e.g. pig intestines). Generally, these peptides are 35 to 39 residues. An exemplary cecropin has the sequence KWKLFFKKIEKVGQNI RDGIIKAGPAVAVVGQATQIAK (SEQ ID No. \_\_\_\_). Some additional cecropin sequences are presented in Table 1. Within the context of this invention, cecropins include analogues that have one or more insertions, deletions, modified amino acids, D-amino acids and the like.

C. Melittin peptides

Melittin is a cationic peptide found in bee venom. An amino acid sequence of an exemplary melittin peptide is GIGAVLKVLTTGLPALISWIKRKKRQQ (SEQ ID No. \_\_\_\_). Like the cecropins, melittin exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria. Within the context of this invention, melittin includes analogues that have one or more insertions, deletions, modified amino acids, D-amino acids and the like.

D. Cecropin-melittin chimeric peptides

As noted herein, cationic peptides include fusion peptides of native cationic peptides and analogues of fusion peptides. In particular, fusions of cecropin and melittin are provided. An exemplary fusion has the sequence: cecropin A (residues 1-8)/melittin (residues 1-18). Other fusion peptides useful within the context of this invention are described by the general formulas below.

K W K R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> V L T T G L P A L I S (SEQ ID No. \_\_\_\_)  
K W K R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> V V T T A K P L I S S (SEQ ID No. \_\_\_\_)  
K W K R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> I L T T G L P A L I S (SEQ ID No. \_\_\_\_)  
K W K R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> G G L L S N I V T S L (SEQ ID No. \_\_\_\_)  
K W K R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> R<sub>1</sub> R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> G P I L A N L V S I V (SEQ ID No. \_\_\_\_)  
K K W W R R R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>1</sub> R<sub>2</sub> R<sub>1</sub> R<sub>1</sub> R<sub>2</sub> R<sub>2</sub> G P A L S N V (SEQ ID No. \_\_\_\_)  
K K W W R R X (SEQ ID No. \_\_\_\_)  
K K W W K X (SEQ ID No. \_\_\_\_)

wherein R<sub>1</sub> is a hydrophobic amino acid residue, R<sub>2</sub> is a hydrophilic amino acid residue, and X is from about 14 to 24 amino acid residues.

E. Drosocin and analogues

As noted herein, cationic peptides include drosocin and drosocin analogues. Drosocins are isolated from *Drosophila melanogaster*. An exemplary drosocin is a 19 amino acid peptide having the sequence: GKPRPYSPRPTSHPRPIRV (SEQ ID No. \_\_\_\_; GenBank

Accession No. S35984). Analogues of drosocin include peptides that have insertions, deletions, modified amino acids, D-amino acids and the like.

F. Peptide synthesis

Peptides may be synthesized by standard chemical methods, including synthesis by automated procedure. In general, peptide analogues are synthesized based on the standard solid-phase Fmoc protection strategy with HATU as the coupling agent. The peptide is cleaved from the solid-phase resin with trifluoroacetic acid containing appropriate scavengers, which also deprotects side chain functional groups. Crude peptide is further purified using preparative reversed-phase chromatography. Other purification methods, such as partition chromatography, gel filtration, gel electrophoresis, or ion-exchange chromatography may be used.

Other synthesis techniques, known in the art, such as the tBoc protection strategy, or use of different coupling reagents or the like can be employed to produce equivalent peptides. Peptides may be synthesized as a linear molecule or as branched molecules. Branched peptides typically contain a core peptide that provides a number of attachment points for additional peptides. Lysine is most commonly used for the core peptide because it has one carboxyl functional group and two (alpha and epsilon) amine functional groups. Other diamino acids can also be used. To synthesize these multimeric peptides, the solid phase resin is derivatized with the core matrix, and subsequent synthesis and cleavage from the resin follows standard procedures. The multimeric peptides may be used within the context of this invention as for any of the linear peptides.

G. Recombinant production of peptides

Peptides may alternatively be synthesized by recombinant production (see e.g., U.S. Patent No. 5,593,866). A variety of host systems are suitable for production of the peptide analogues, including bacteria (e.g., *E. coli*), yeast (e.g., *Saccharomyces cerevisiae*), insect (e.g., Sf9), and mammalian cells (e.g., CHO, COS-7). Many expression vectors have been developed and are available for each of these hosts. Generally, bacteria cells and vectors that are functional in bacteria are used in this invention. However, at times, it may be preferable to have vectors that are functional in other hosts. Vectors and procedures for

cloning and expression in *E. coli* are discussed herein and, for example, in Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1987) and in Ausubel et al. (*Current Protocols in Molecular Biology*, Greene Publishing Co., 1995).

A DNA sequence encoding a cationic peptide is introduced into an expression vector appropriate for the host. In preferred embodiments, the gene is cloned into a vector to create a fusion protein. The fusion partner is chosen to contain an anionic region, such that a bacterial host is protected from the toxic effect of the peptide. This protective region effectively neutralizes the antimicrobial effects of the peptide and also may prevent peptide degradation by host proteases. The fusion partner (carrier protein) of the invention may further function to transport the fusion peptide to inclusion bodies, the periplasm, the outer membrane, or the extracellular environment. Carrier proteins suitable in the context of this invention specifically include, but are not limited to, glutathione-S-transferase (GST), protein A from *Staphylococcus aureus*, two synthetic IgG-binding domains (ZZ) of protein A, outer membrane protein F,  $\beta$ -galactosidase (*lacZ*), and various products of bacteriophage  $\lambda$  and bacteriophage T7. Furthermore, the entire carrier protein need not be used, as long as the protective anionic region is present.

To facilitate isolation of the peptide sequence, amino acids susceptible to chemical cleavage (e.g., CNBr) or enzymatic cleavage (e.g., V8 protease, trypsin) are used to bridge the peptide and fusion partner. For expression in *E. coli*, the fusion partner is preferably a normal intracellular protein that directs expression toward inclusion body formation. In such a case, following cleavage to release the final product, there is no requirement for renaturation of the peptide.

In the present invention, the DNA cassette, comprising fusion partner and peptide gene, may be inserted into an expression vector, which can be a plasmid, virus or other vehicle known in the art. At minimum, the expression vector should contain a promoter sequence. However, other regulatory sequences may also be included. Such sequences include an enhancer, ribosome binding site, transcription termination signal sequence, secretion signal sequence, origin of replication, selectable marker, and the like. The regulatory sequences are operationally associated with one another to allow transcription and subsequent translation. Preferably, the expression vector is a plasmid that contains an inducible or constitutive promoter to facilitate the efficient transcription of the inserted DNA

sequence in the host. Transformation of the host cell with the recombinant DNA may be carried out by  $\text{Ca}^{++}$ -mediated techniques, by electroporation, or other methods well known to those skilled in the art.

The peptide product is isolated by standard techniques, such as affinity, size exclusion, or ionic exchange chromatography, HPLC and the like. An isolated peptide should preferably show a major band by Coomassie blue stain of SDS-PAGE that is at least 90% of the material.

## II. TESTING

Cationic peptides of the present invention are assessed either alone or in combination with an antibiotic agent or another analogue for their potential as antibiotic therapeutic agents using a series of assays. Preferably, all peptides are initially assessed *in vitro*, the most promising candidates are selected for further assessment *in vivo*, and then candidates are selected for pre-clinical studies. *In vitro* assays include measurement of antibiotic activity, toxicity, solubility, pharmacology, secondary structure, liposome permeabilization and the like. *In vivo* assays include assessment of efficacy in animal models, antigenicity, toxicity, and the like. In general, *in vitro* assays are initially performed, followed by *in vivo* assays.

Peptides that have some anti-microbial activity are preferred, although such activity may not be necessary for enhancing the activity of an antibiotic agent. Also, for *in vivo* use, peptides should preferably demonstrate acceptable toxicity profiles, as measured by standard procedures. Lower toxicity is preferred..

### A. *In vitro* assays

Cationic peptides, including indolicidin analogues, are assayed by, for example, an agarose dilution MIC assay, a broth dilution assay, time-kill assay, or equivalent methods. Antibiotic activity is measured as inhibition of growth or killing of a microorganism (e.g., bacteria, fungi).

Briefly, a candidate peptide in Mueller Hinton broth supplemented with calcium and magnesium is mixed with molten agarose. Other broths and agars may be used as long as the peptide can freely diffuse through the medium. The agarose is poured into petri

dishes or wells, allowed to solidify, and a test strain is applied to the agarose plate. The test strain is chosen, in part, on the intended application of the peptide. Thus, by way of example, if an indolicidin analogue with activity against *S. aureus* is desired, an *S. aureus* strain is used. It may be desirable to assay the analogue on several strains and/or on clinical isolates of the test species. Plates are incubated overnight and inspected visually for bacterial growth. A minimum inhibitory concentration (MIC) of a cationic peptide is the lowest concentration of peptide that completely inhibits growth of the organism. Peptides that exhibit good activity against the test strain, or group of strains, typically having an MIC of less than or equal to 16  $\mu$ g/ml are selected for further testing.

Alternatively, time kill curves can be used to determine the differences in colony counts over a set time period, typically 24 hours. Briefly, a suspension of organisms of known concentration is prepared and a candidate peptide is added. Aliquots of the suspension are removed at set times, diluted, plated on medium, incubated, and counted. MIC is measured as the lowest concentration of peptide that completely inhibits growth of the organism. In general, lower MIC values are preferred.

Candidate cationic peptides may be further tested for their toxicity to normal mammalian cells. An exemplary assay is a red blood cell (RBC) (erythrocyte) hemolysis assay. Briefly, in this assay, red blood cells are isolated from whole blood, typically by centrifugation, and washed free of plasma components. A 5% (v/v) suspension of erythrocytes in isotonic saline is incubated with different concentrations of peptide analogue. Generally, the peptide will be in a suitable formulation buffer. After incubation for approximately 1 hour at 37°C, the cells are centrifuged, and the absorbance of the supernatant at 540 nm is determined. A relative measure of lysis is determined by comparison to absorbance after complete lysis of erythrocytes using NH<sub>4</sub>Cl or equivalent (establishing a 100% value). A peptide with <10% lysis at 100  $\mu$ g/ml is suitable. Preferably, there is <5% lysis at 100  $\mu$ g/ml. Such peptides that are not lytic, or are only moderately lytic, are desirable and suitable for further screening. Other *in vitro* toxicity assays, for example measurement of toxicity towards cultured mammalian cells, may be used to assess *in vitro* toxicity.

Solubility of the peptide in formulation buffer is an additional parameter that may be examined. Several different assays may be used, such as appearance in buffer. Briefly, peptide is suspended in solution, such as broth or formulation buffer. The appearance is evaluated according to a scale that ranges from (a) clear, no precipitate, (b)

light, diffuse precipitate, to (c) cloudy, heavy precipitate. Finer gradations may be used. In general, less precipitate is more desirable. However, some precipitate may be acceptable.

Additional *in vitro* assays may be carried out to assess the potential of the peptide as a therapeutic. Such assays include peptide solubility in formulations, pharmacology in blood or plasma, serum protein binding, analysis of secondary structure, for example by circular dichroism, liposome permeabilization, and bacterial inner membrane permeabilization.

B. *In vivo* assays

Peptides, including peptide analogues, selected on the basis of the results from the *in vitro* assays can be tested *in vivo* for efficacy, toxicity and the like.

The antibiotic activity of selected peptides may be assessed *in vivo* for their ability to ameliorate microbial infections using animal models. A variety of methods and animal models are available. Within these assays, a peptide is useful as a therapeutic if inhibition of microorganismal growth compared to inhibition with vehicle alone is statistically significant. This measurement can be made directly from cultures isolated from body fluids or sites, or indirectly, by assessing survival rates of infected animals. For assessment of antibacterial activity several animal models are available, such as acute infection models including those in which (a) normal mice receive a lethal dose of microorganisms, (b) neutropenic mice receive a lethal dose of microorganisms or (c) rabbits receive an inoculum in the heart, and chronic infection models. The model selected will depend in part on the intended clinical indication of the analogue.

By way of example, in a normal mouse model, mice are inoculated ip or iv with a lethal dose of bacteria. Typically, the dose is such that 90-100% of animals die within 2 days. The choice of a microorganismal strain for this assay depends, in part, upon the intended application of the analogue, and in the accompanying examples, assays are carried out with three different *Staphylococcus* strains. Briefly, shortly before or after inoculation (generally within 60 minutes), analogue in a suitable formulation buffer is injected. Multiple injections of analogue may be administered. Animals are observed for up to 8 days post-infection and the survival of animals is recorded. Successful treatment either rescues animals from death or delays death to a statistically significant level, as compared with non-treatment control animals.

*In vivo* toxicity of a peptide is measured through administration of a range of doses to animals, typically mice, by a route defined in part by the intended clinical use. The survival of the animals is recorded and LD<sub>50</sub>, LD<sub>90-100</sub>, and maximum tolerated dose (MTD) can be calculated to enable comparison of analogues.

Furthermore, for *in vivo* use, low immunogenicity is preferred. To measure immunogenicity, peptides are injected into normal animals, generally rabbits. At various times after a single or multiple injections, serum is obtained and tested for antibody reactivity to the peptide analogue. Antibodies to peptides may be identified by ELISA, immunoprecipitation assays, Western blots, and other methods. (see, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988). No or minimal antibody reactivity is preferred. Additionally, pharmacokinetics of the analogues in animals and histopathology of animals treated with analogues may be determined.

Selection of cationic peptides as potential therapeutics is based on *in vitro* and *in vivo* assay results. In general, peptides that exhibit low toxicity at high dose levels and high efficacy at low dose levels are preferred candidates.

### III. ANTIBIOTIC AGENTS

An antibiotic agent includes any molecule that tends to prevent, inhibit or destroy life and as such, includes anti-bacterial agents, anti-fungicides, anti-viral agents, and anti-parasitic agents. These agents may be isolated from an organism that produces the agent or procured from a commercial source (e.g., pharmaceutical company, such as Eli Lilly, Indianapolis, IN; Sigma, St. Louis, MO).

Anti-bacterial antibiotic agents include, but are not limited to, penicillins, cephalosporins, carbacephems, cephemycins, carbapenems, monobactams, aminoglycosides, glycopeptides, quinolones, tetracyclines, macrolides, and fluoroquinolones. Examples of antibiotic agents include, but are not limited to, Penicillin G (CAS Registry No.: 61-33-6); Methicillin (CAS Registry No.: 61-32-5); Nafcillin (CAS Registry No.: 147-52-4); Oxacillin (CAS Registry No.: 66-79-5); Cloxacillin (CAS Registry No.: 61-72-3); Dicloxacillin (CAS Registry No.: 3116-76-5); Ampicillin (CAS Registry No.: 69-53-4); Amoxicillin (CAS Registry No.: 26787-78-0); Ticarcillin (CAS Registry No.: 34787-01-4); Carbenicillin (CAS

Registry No.: 4697-36-3); Mezlocillin (CAS Registry No.: 51481-65-3); Azlocillin (CAS Registry No.: 37091-66-0); Piperacillin (CAS Registry No.: 61477-96-1); Imipenem (CAS Registry No.: 74431-23-5); Aztreonam (CAS Registry No.: 78110-38-0); Cephalothin (CAS Registry No.: 153-61-7); Cefazolin (CAS Registry No.: 25953-19-9); Cefaclor (CAS Registry No.: 70356-03-5); Cefamandole formate sodium (CAS Registry No.: 42540-40-9); Cefoxitin (CAS Registry No.: 35607-66-0); Cefuroxime (CAS Registry No.: 55268-75-2); Cefonicid (CAS Registry No.: 61270-58-4); Cefmetazole (CAS Registry No.: 56796-20-4); Cefotetan (CAS Registry No.: 69712-56-7); Cefprozil (CAS Registry No.: 92665-29-7); Loracarbef (CAS Registry No.: 121961-22-6); Cefetamet (CAS Registry No.: 65052-63-3); Cefoperazone (CAS Registry No.: 62893-19-0); Cefotaxime (CAS Registry No.: 63527-52-6); Ceftizoxime (CAS Registry No.: 68401-81-0); Ceftriaxone (CAS Registry No.: 73384-59-5); Ceftazidime (CAS Registry No.: 72558-82-8); Cefepime (CAS Registry No.: 88040-23-7); Cefixime (CAS Registry No.: 79350-37-1); Cefpodoxime (CAS Registry No.: 80210-62-4); Cefsulodin (CAS Registry No.: 62587-73-9); Fleroxacin (CAS Registry No.: 79660-72-3); Nalidixic acid (CAS Registry No.: 389-08-2); Norfloxacin (CAS Registry No.: 70458-96-7); Ciprofloxacin (CAS Registry No.: 85721-33-1); Ofloxacin (CAS Registry No.: 82419-36-1); Enoxacin (CAS Registry No.: 74011-58-8); Lomefloxacin (CAS Registry No.: 98079-51-7); Cinoxacin (CAS Registry No.: 28657-80-9); Doxycycline (CAS Registry No.: 564-25-0); Minocycline (CAS Registry No.: 10118-90-8); Tetracycline (CAS Registry No.: 60-54-8); Amikacin (CAS Registry No.: 37517-28-5); Gentamicin (CAS Registry No.: 1403-66-3); Kanamycin (CAS Registry No.: 8063-07-8); Netilmicin (CAS Registry No.: 56391-56-1); Tobramycin (CAS Registry No.: 32986-56-4); Streptomycin (CAS Registry No.: 57-92-1); Azithromycin (CAS Registry No.: 83905-01-5); Clarithromycin (CAS Registry No.: 81103-11-9); Erythromycin (CAS Registry No.: 114-07-8); Erythromycin estolate (CAS Registry No.: 3521-62-8); Erythromycin ethyl succinate (CAS Registry No.: 41342-53-4); Erythromycin glucoheptonate (CAS Registry No.: 23067-13-2); Erythromycin lactobionate (CAS Registry No.: 3847-29-8); Erythromycin stearate (CAS Registry No.: 643-22-1); Vancomycin (CAS Registry No.: 1404-90-6); Teicoplanin (CAS Registry No.: 61036-64-4); Chloramphenicol (CAS Registry No.: 56-75-7); Clindamycin (CAS Registry No.: 18323-44-9); Trimethoprim (CAS Registry No.: 738-70-5); Sulfamethoxazole (CAS Registry No.: 723-46-6); Nitrofurantoin (CAS Registry No.: 67-20-9); Rifampin (CAS Registry No.: 13292-46-1); Mupirocin (CAS Registry No.: 12650-69-0); Metronidazole (CAS Registry No.: 443-48-

1); Cephalexin (CAS Registry No.: 15686-71-2); Roxithromycin (CAS Registry No.: 80214-83-1); Co-amoxiclavuanate; combinations of Piperacillin and Tazobactam; and their various salts, acids, bases, and other derivatives.

Table 2 presents categories of antibiotics, their mode of action and examples of antibiotics.

Table 2

Class of Antibiotic	Antibiotic	Mode of Action
<b>PENICILLINS</b>		
Natural	Penicillin G, Benzylpenicillin Penicillin V, Phenoxymethylenicillin	Blocks the formation of new cell walls in bacteria
Penicillinase resistant	Methicillin, Nafcillin, Oxacillin Cloxacillin, Dicloxacillin	
Acylamino-penicillins	Ampicillin, Amoxicillin	
Carboxy-penicillins	Ticarcillin, Carbenicillin	
Ureido-penicillins	Mezlocillin, Azlocillin, Piperacillin	
<b>CARBAPENEMS</b>	Imipenem, Meropenem	Blocks the formation of new cell walls in bacteria
<b>MONOBACTAMS</b>	Aztreonam	Blocks the formation of new cell walls in bacteria
<b>CEPHALOSPORINS</b>		Prevents formation of new cell walls in bacteria
1st Generation	Cephalothin, Cefazolin	
2nd Generation	Cefaclor, Cefamandole Cefuroxime, Cefonicid, Cefmetazole, Cefotetan, Cefprozil	
3rd Generation	Cefetamet, Cefoperazone Cefotaxime, Ceftizoxime Ceftriaxone, Ceftazidime Cefixime, Cefpodoxime, Cefsulodin	
4th Generation	Cefepime	
<b>CARBACEPHEMS</b>	Loracarbef	Prevents formation of new cell walls in bacteria
<b>CEPHAMYCINS</b>	Cefoxitin	Prevents formation of new cell walls in bacteria
<b>QUINOLONES</b>	Fleroxacin, Nalidixic Acid Norfloxacin, Ciprofloxacin Ofloxacin, Enoxacin Lomefloxacin, Cinoxacin	Inhibits bacterial DNA synthesis

Class of Antibiotic	Antibiotic	Mode of Action
<b>TETRACYCLINES</b>	Doxycycline, Minocycline, Tetracycline	Inhibits bacterial protein synthesis, binds to 30S ribosome subunit.
<b>AMINOGLYCOSIDES</b>	Amikacin, Gentamicin, Kanamycin, Netilmicin, Tobramycin, Streptomycin	Inhibits bacterial protein synthesis, binds to 30S ribosome subunit.
<b>MACROLIDES</b>	Azithromycin, Clarithromycin, Erythromycin	Inhibits bacterial protein synthesis, binds to 50S ribosome subunit
Derivatives of Erythromycin	Erythromycin estolate, Erythromycin stearate Erythromycin ethylsuccinate Erythromycin gluceptate Erythromycin lactobionate	
<b>GLYCOPEPTIDES</b>	Vancomycin, Teicoplanin	Inhibits cell wall synthesis, prevents peptidoglycan elongation.
<b>MISCELLANEOUS</b>	Chloramphenicol  Clindamycin  Trimethoprim  Sulfamethoxazole  Nitrofurantoin  Rifampin  Mupirocin	Inhibits bacterial protein synthesis, binds to 50S ribosome subunit.  Inhibits bacterial protein synthesis, binds to 50S ribosome subunit.  Inhibits the enzyme dihydrofolate reductase, which activates folic acid.  Acts as antimetabolite of PABA & inhibits synthesis of folic acid  Action unknown, but is concentrated in urine where it can act on urinary tract bacteria  Inhibits bacterial RNA polymerase  Inhibits bacterial protein synthesis

Anti-fungal agents include, but are not limited to, terbinafine hydrochloride, nystatin, amphotericin B, griseofulvin, ketoconazole, miconazole nitrate, flucytosine, fluconazole, itraconazole, clotrimazole, benzoic acid, salicylic acid, and selenium sulfide.

Anti-viral agents include, but are not limited to, amantadine hydrochloride, rimantadin, acyclovir, famciclovir, foscarnet, ganciclovir sodium, idoxuridine, ribavirin, sorivudine, trifluridine, valacyclovir, vidarabin, didanosine, stavudine, zalcitabine, zidovudine, interferon alpha, and edoxudine.

Anti-parasitic agents include, but are not limited to, pirethrins/piperonyl butoxide, permethrin, iodoquinol, metronidazole, diethylcarbamazine citrate, piperazine, pyrantel pamoate, mebendazole, thiabendazole, praziquantel, albendazole, proguanil, quinidine gluconate injection, quinine sulfate, chloroquine phosphate, mefloquine hydrochloride, primaquine phosphate, atovaquone, co-trimoxazole (sulfamethoxazole/trimethoprim), and pentamidine isethionate.

#### IV. ENHANCED ACTIVITY OF COMBINATIONS OF CATIONIC PEPTIDES AND ANTIBIOTIC AGENTS

Enhanced activity occurs when a combination of peptide and antibiotic agent potentiates activity beyond the individual effects of the peptide or antibiotic agent alone or additive effects of peptide plus antibiotic agent. Enhanced activity is especially desirable in at least four scenarios: (1) the microorganism is sensitive to the antibiotic agent, but the dosage has associated problems; (2) the microorganism is tolerant to the antibiotic agent, and is inhibited from growing but is not killed; (3) the microorganism is inherently resistant to the antibiotic agent; and (4) the microorganism has acquired resistance to the antibiotic agent. Enhanced efficacy resulting from administration of the antibiotic agent in combination with a cationic peptide in the above scenarios: (1) allows for administration of lower dosages of antibiotic agent or cationic peptide; (2) restores a cytocidal effect; (3) overcomes inherent resistance; and (4) overcomes acquired resistance.

A. Enhancement of antibiotic agent or cationic peptide activity

A synergistic combination of cationic peptide and antibiotic agent may permit a reduction in the dosage of one or both agents in order to achieve a similar therapeutic effect. This would allow smaller doses to be used, thus, decreasing the incidence of toxicity (e.g., from aminoglycosides) and lowering costs of expensive antibiotics (e.g., vancomycin). Concurrent or sequential administration of peptide and antibiotic agent is expected to provide more effective treatment of infections caused by micro-organisms (bacteria, viruses, fungi, and parasites). In particular, this could be achieved by using doses of the peptide or antibiotic agent alone would not achieve therapeutic success. Alternatively, the antibiotic agent and peptide can be administered at therapeutic doses for each, but wherein the combination of the two agents provides even more potent effects.

As used herein, "synergy" refers to the *in vitro* effect of administration of a combination of a cationic peptide and antibiotic agent such that (1) the fractional inhibitory concentration (FIC) is less than or equal to 0.5 in an FIC assay described herein; or (2) there is at least a 100-fold ( $2\log_{10}$ ) increase in killing at 24 hours for the combination as compared with the antibiotic agent alone in a time kill curve assay as described herein.

Such synergy is conveniently measured in an *in vitro* assay, such as kinetic kill studies or a fractional inhibitory concentration (FIC) assay as determined by agarose or broth dilution assay. The agarose dilution assay is preferred.

Briefly, in the dilution assay, a checkerboard array of cationic peptides and antibiotic agents titrated in doubling dilutions are inoculated with a microbial (e.g., bacterial) isolate. The FIC is determined by observing the impact of one antibiotic agent on the MIC ("minimal inhibitory concentration") of the cationic peptide and vice versa. FIC is calculated by the following formula:

$$FIC = \frac{MIC(\text{peptide in combination})}{MIC(\text{peptide alone})} + \frac{MIC(\text{antibiotic in combination})}{MIC(\text{antibiotic alone})}$$

An FIC of  $\leq 0.5$  is evidence of synergy. An additive response has an FIC value of  $> 0.5$  and less than or equal to 1, while an indifferent response has an FIC value of  $> 1$  and  $\leq 2$ . Although a synergistic effect is preferred, an additive effect may still indicate that the combination of antibiotic agent and cationic peptide are therapeutically useful.

B. Overcoming tolerance

Tolerance is associated with a defect in bacterial cellular autolytic enzymes such that an antibacterial agent demonstrates bacteriostatic rather than bactericidal activity (Mahon and Manuselis, *Textbook of Diagnostic Microbiology*, W.B. Saunders Co., Toronto, Canada, p. 92, 1995). For antibiotic agents that have only bacteriostatic activity, the administration of cationic peptides in combination with antibiotic agents can restore bactericidal activity. Alternatively, the addition of a peptide to an antibiotic agent may increase the rate of a bactericidal effect of an antibiotic.

Bactericidal effects of antibiotics can be measured *in vitro* by a variety of assays. Typically, the assay is a measurement of MBC ("minimal bactericidal concentration"), which is an extension of the MIC determination. The agarose dilution assay is adapted to provide both MBC and MIC for an antimicrobial agent alone and the agent in combination with a cationic peptide. Alternatively, kinetic time-kill (or growth) curves can be used to determine MIC and MBC.

Briefly, following determination of MIC, MBC is determined from the assay plates by swabbing the inocula on plates containing antibiotic agent in concentrations at and above the MIC, resuspending the swab in saline or medium, and plating an aliquot on agarose plates. If the number of colonies on these agarose plates is less than 0.1% of the initial inoculum (as determined by a plate count immediately after inoculation of the MIC test plates), then  $\geq 99.9\%$  killing has occurred. The MBC end point is defined as the lowest concentration of the antimicrobial agent that kills 99.9% of the test bacteria.

Thus, tolerance of a microorganism to an antimicrobial agent is indicated when the number of colonies growing on subculture plates exceeds the 0.1% cutoff for several successive concentrations above the observed MIC. A combination of antimicrobial agent and cationic peptide that breaks tolerance results in a decrease in the MBC:MIC ratio to  $< 32$ .

C. Overcoming inherent resistance

The combination of a cationic peptide with an antibiotic agent, for which a microorganism is inherently resistant (*i.e.*, the antibiotic has never been shown to be

therapeutically effective against the organism in question), is used to overcome the resistance and confer susceptibility of the microorganism to the agent. Overcoming inherent resistance is especially useful for infections where the causative organism is becoming or has become resistant to most, if not all, of the currently prescribed antibiotics. Additionally, administering a combination therapy provides more options when toxicity of an antibiotic agent and/or price are a consideration.

Overcoming resistance can be conveniently measured *in vitro*. Resistance is overcome when the MIC for a particular antibiotic agent against a particular microorganism is decreased from the resistant range to the sensitive range (according to the National Committee for Clinical Laboratory Standards (NCCLS)) (see also, Moellering, in *Principles and Practice of Infectious Diseases*, 4th edition, Mandell et al., eds. Churchill Livingstone, NY, 1995). NCCLS standards are based on microbiological data in relation to pharmacokinetic data and clinical studies. Resistance is determined when the organism causing the infection is not inhibited by the normal achievable serum concentrations of the antibiotic agent based on recommended dosage. Susceptibility is determined when the organism responds to therapy with the antibiotic agent used at the recommended dosage for the type of infection and microorganism.

#### D. Overcoming acquired resistance

Acquired resistance in a microorganism that was previously sensitive to an antibiotic agent is generally due to mutational events in chromosomal DNA, acquisition of a resistance factor carried via plasmids or phage, or transposition of a resistance gene or genes from a plasmid or phage to chromosomal DNA.

When a microorganism acquires resistance to an antibiotic, the combination of a peptide and antibiotic agent can restore activity of the antibiotic agent by overcoming the resistance mechanism of the organism. This is particularly useful for organisms that are difficult to treat or where current therapy is costly or toxic. The ability to use a less expensive or less toxic antibiotic agent, which had been effective in the past, is an improvement for certain current therapies. The re-introduction of an antibiotic agent would enable previous clinical studies and prescription data to be used in its evaluation. Activity is measured *in vitro* by MICs or kinetic kill curves and *in vivo* using animal and human clinical trials.

E. Enhancement of effect of lysozyme and nisin

The combination of lysozyme or nisin with an antibiotic may improve their antibacterial effectiveness and allow use in situations in which the single agent is inactive or inappropriate.

Lysozymes disrupt certain bacteria by cleaving the glycosidic bond between N-acetylglucosamine and N-acetylmuramic acid in the polysaccharide component of bacterial cell walls. However, lysozyme exhibits only weak antibacterial activity with a narrow spectrum of activity. The addition of an antibiotic may improve the effectiveness of this activity and broaden the spectrum of activity.

Nisins are 34-residue peptide lantibiotics with primarily anti-Gram-positive bacterial activity. Nisin is used in the food processing industry as a preservative, especially for cheese, canned fruits and vegetables. Nisin forms transient potential-dependent pores in the bacterial cytoplasmic membranes but also exhibits weak antibacterial activity with a narrow spectrum of activity. The addition of an antibiotic may improve the effectiveness of nisin and broaden the spectrum of activity.

F. In vivo assays

*In vivo* testing involves the use of animal models of infection. Typically, but not exclusively, mice are used. The test organism is chosen according to the intended combination of cationic peptide and antibiotic to be evaluated. Generally, the test organism is injected intraperitoneally (IP) or intravenously (IV) at 10 to 100 times the fifty percent lethal dose (LD<sub>50</sub>). The LD<sub>50</sub> is calculated using a method described by Reed and Muench (Reed LJ and Muench H. *The American Journal of Hygiene*, 27:493-7.). The antibiotic agent and the cationic peptide are injected IP, IV, or subcutaneously (SC) individually as well as in combination to different groups of mice. The antimicrobial agents may be given in one or multiple doses. Animals are observed for 5 to 7 days. Other models of infection may also be used according to the clinical indication for the combination of antibiotic agents.

The number of mice in each group that survive the infectious insult is determined after 5 to 7 days. In addition, when bacteria are the test organisms, bacterial colony counts from blood, peritoneal lavage fluid, fluid from other body sites, and/or tissue

from different body sites taken at various time intervals can be used to assess efficacy. Samples are serially diluted in isotonic saline and incubated for 20 - 24 hours, at 37° C, on a suitable growth medium for the bacterium.

Synergy between the cationic peptide and the antibiotic agent is assessed using a model of infection as described above. For a determination of synergy, one or more of the following should occur. The combination group should show greater survival rates compared to the groups treated with only one agent; the combination group and the antibiotic agent group have equivalent survival rates with the combination group receiving a lower concentration of antibiotic agent; the combination group has equivalent or better survival compared to an antibiotic agent group with a lower microorganismal load at various time points.

Overcoming tolerance can be demonstrated by lower bacterial colony counts at various time points in the combination group over the antibiotic agent group. This may also result in better survival rates for the combination group.

Similar animal models to those described above can be used to establish when inherent or acquired resistance is overcome. The microorganism strain used is, by definition, resistant to the antibiotic agent and so the survival rate in the antibiotic agent group will be close, if not equal, to zero percent. Thus, overcoming the inherent resistance of the microorganism to the antibiotic agent is demonstrated by increased survival of the combination group. Testing for reversing acquired resistance may be performed in a similar manner.

## V. COMBINATIONS OF PEPTIDES AND ANTIBIOTIC AGENTS

As discussed herein, cationic peptides are administered in combination with antibiotic agents. The combination enhances the activity of the antibiotic agents. Such combinations may be used to effect a synergistic result, overcome tolerance, overcome inherent resistance, or overcome acquired resistance of the microorganism to the antibiotic agent.

To achieve a synergistic effect, a combination of antibiotic agent and cationic peptide is administered to a patient or administered in such a manner as to contact the microorganism. Any combination of antibiotic agent and cationic peptide may result in a synergistic effect and, thus, is useful within the context of this invention.

In particular, certain microorganisms are preferred targets. In conjunction with these microorganisms, certain commonly used antibiotic agents are preferred to be enhanced. The table below sets out these microorganisms, antibiotic agents, and cationic peptide combinations that are preferred.

Table 3

BACTERIAL SPECIES	ANTIMICROBIAL AGENTS	PEPTIDE
<i>A. baumannii</i>	Gentamicin	MBI 21A2
<i>B. cepacia</i>	Ceftriaxone	MBI 11J02CN
<i>E. cloacae</i>	Ciprofloxacin	MBI 29A2
<i>E. faecalis</i>	Amikacin	MBI 11B16CN
<i>E. faecium</i>	Vancomycin	MBI 29
<i>P. aeruginosa</i>	Mupirocin	MBI 28
<i>P. aeruginosa</i>	Tobramycin	MBI 11G13CN
<i>S marcescens</i>	Piperacillin	MBI 11G7CN
<i>S. aureus</i>	Piperacillin	MBI 11CN
<i>S. maltophilia</i>	Tobramycin	REWH 53A5CN
MYCOSES	ANTIFUNGAL AGENTS	PEPTIDE
<i>Candida species</i>	Fluconazole	MBI 28
<i>Cryptococcus</i>	Fluconazole	MBI 29A3
<i>Aspergillus species</i>	Itraconazole	MBI 26
VIRUSES	ANTIVIRAL AGENTS	PEPTIDE
Herpes simplex virus	Acyclovir	MBI 11A2CN
Influenza A	virus Amantadine-rimantadine	MBI 21A1
PARASITES	ANTIPARASITIC AGENTS	PEPTIDE
<i>Trichomonas vaginalis</i>	Metronidazole	MBI 29
<i>Plasmodium falciparum</i>	Chloroquine	MBI 11D18CN

To overcome tolerance, a combination of antibiotic agent and cationic peptide is administered to a patient or administered in such a manner as to contact the microorganism. Any combination of antibiotic agent and cationic peptide that overcomes tolerance is useful within the context of this invention. In particular, certain microorganisms, which exhibit tolerance to specific antibiotic agents are preferred targets. The table below sets out these microorganisms, antibiotic agents, and cationic peptide combinations that are preferred.

Table 4

BACTERIAL SPECIES	ANTIMICROBIAL AGENTS	PEPTIDE
<i>Enterococcus species</i>	Ampicillin (Amino-penicillins) Piperacillin (Penicillins, antipseudomonal)	MBI 21A10
<i>Enterococcus species</i>	Gentamicin (Aminoglycosides)	MBI 29
<i>Enterococcus species</i>	Vancomycin, Teicoplanin (glycopeptides)	MBI 26
<i>Streptococcus pneumoniae</i>	Penicillins	MBI 29A3
<i>Salmonella typhi</i>	Chloramphenicol	MBI 11A1CN
<i>Campylobacter jejuni</i>	Erythromycin (Macrolides)	MBI 11B4CN

To overcome inherent resistance, a combination of antibiotic agent and cationic peptide is administered to a patient or administered in such a manner as to contact the microorganism. Any combination of antibiotic agent and cationic peptide that overcomes resistance is useful within the context of this invention. In particular, certain microorganisms, which exhibit inherent resistance to specific antibiotic agents are preferred targets. The table below sets out these microorganisms, antibiotic agents, and cationic peptide combinations that are preferred.

Table 5

BACTERIAL SPECIES	ANTIMICROBIAL AGENTS	PEPTIDE
Methicillin-resistant <i>S. aureus</i>	Amikacin	MBI 29F1
<i>S. maltophilia</i>	Gentamicin	MBI 11D18CN
<i>S. maltophilia</i>	Gentamicin	MBI 26
<i>S. maltophilia</i>	Tobramycin	MBI 29A3
Methicillin-resistant <i>S. aureus</i>	Tobramycin	MBI 21A1
<i>E. coli</i>	Mupirocin	MBI 21A1
<i>S. maltophilia</i>	Amikacin	MBI 11B16CN
<i>S. maltophilia</i>	Amikacin	MBI 26
<i>B. cepacia</i>	Amikacin	MBI 29A3
Methicillin resistant <i>S. aureus</i>	Gentamicin	MBI 11D18CN
MYCOSES	ANTIFUNGAL AGENTS	PEPTIDE
<i>Aspergillosis</i>	Fluconazole	MBI 11D18CN
<i>Candida species</i>	Griseofulvin	MBI 29

To overcome acquired resistance, a combination of antibiotic agent and cationic peptide is administered to a patient or administered in such a manner as to contact the microorganism. Any combination of antibiotic agent and cationic peptide that overcomes resistance is useful within the context of this invention. In particular, certain microorganisms, which exhibit acquired resistance to specific antibiotic agents are preferred targets. The table

below sets out these microorganisms, antibiotic agents, and cationic peptide combinations that are preferred.

Table 6

BACTERIA	ANTIMICROBIAL AGENT	PEPTIDE
<i>Enterococcus</i> spp.	Vancomycin	MBI 26
<i>P. aeruginosa</i>	Ceftriaxone	MBI 26
<i>S. aureus</i>	Ciprofloxacin	MBI 29A2
<i>E. cloacae</i>	Piperacillin	MBI 11F4CN
<i>P. aeruginosa</i>	Tobramycin	MBI 21A1
<i>P. aeruginosa</i>	Ciprofloxacin	MBI 29A3
<i>P. aeruginosa</i>	Gentamicin	MBI 11B16CN
<i>S. epidermidis</i>	Gentamicin	MBI 11D18CN
Acinetobacter spp.	Tobramycin	MBI 11F3CN
<i>Enterococcus</i> spp.	Vancomycin	MBI 11A1CN
MYCOSES	ANTIFUNGAL AGENTS	PEPTIDE
<i>Candida</i> species	Fluconazole	MBI 11CN
<i>Cryptococcus</i>	Fluconazole	MBI 11A1CN
VIRUSES	ANTIVIRAL AGENTS	PEPTIDE
Herpes simplex virus	Acyclovir	MBI 29
Respiratory Syncytial Virus (RSV)	Ribavirin	MBI 26
Influenza A virus	Amantadine-rimantadine	MBI 26
PARASITES	ANTIPARASITIC AGENTS	PEPTIDE
<i>Trichomonas vaginalis</i>	Metronidazole	MBI 29
<i>Pneumocystis carinii</i>	Cotrimoxazole	MBI 29A3
<i>Plasmodium falciparum</i>	Chloroquine	MBI 26

Additional preferred combinations for indolicidin analogues are listed below:

ANTIBIOTIC	PEPTIDE
Ciprofloxacin	MBI 11A1CN
Vancomycin	MBI 11A1CN
Piperacillin	MBI 11B9CN
Gentamicin	MBI 11B16CN
Piperacillin	MBI 11D18CN
Tobramycin	MBI 11D18CN
Vancomycin	MBI 11D18CN
Piperacillin	MBI 11E3CN
Tobramycin	MBI 11F3CN
Piperacillin	MBI 11F4CN

## VI. FORMULATIONS AND ADMINISTRATION

As noted above, the present invention provides methods for treating and preventing infections by administering to a patient a therapeutically effective amount of a

peptide analogue of indolicidin as described herein. Patients suitable for such treatment may be identified by well-established hallmarks of an infection, such as fever, pus, culture of organisms, and the like. Infections that may be treated with peptide analogues include those caused by or due to microorganisms. Examples of microorganisms include bacteria (e.g., Gram-positive, Gram-negative), fungi, (e.g., yeast and molds), parasites (e.g., protozoans, nematodes, cestodes and trematodes), viruses, and prions. Specific organisms in these classes are well known (see for example, Davis et al., *Microbiology*, 3<sup>rd</sup> edition, Harper & Row, 1980). Infections include, but are not limited to, toxic shock syndrome, diphtheria, cholera, typhus, meningitis, whooping cough, botulism, tetanus, pyogenic infections, dysentery, gastroenteritis, anthrax, Lyme disease, syphilis, rubella, septicemia and plague.

More specifically, clinical indications include, but are not limited to: 1/ infections following insertion of intravascular devices or peritoneal dialysis catheters; 2/ infection associated with medical devices or prostheses; 3/ infection during hemodialysis; 4/ *S. aureus* nasal and extra-nasal carriage; 5/ burn wound infections; 6/ surgical wounds, 7/ acne, including severe acne vulgaris; 8/ nosocomial pneumonia; 9/ meningitis; 10/ cystic fibrosis; 11/ infective endocarditis; 12/ osteomyelitis; and 13/ sepsis in an immunocompromised host.

1/ Infections following insertion of contaminated intravascular devices, such as central venous catheters, or peritoneal dialysis catheters. These catheters are cuffed or non-cuffed, although the infection rate is higher for non-cuffed catheters. Both local and systemic infection may result from contaminated intravascular devices, more than 25,000 patients develop device related bacteremia in the United States each year. The main organisms responsible are coagulase-negative staphylococci (CoNS), *Staphylococcus aureus*, *Enterococcus* spp., *E. coli* and *Candida* spp.

The peptide and/or antibiotic, preferably as an ointment or cream, can be applied to the catheter site prior to insertion of the catheter and then again at each dressing change. The peptide may be incorporated into the ointment or cream at a concentration preferably of about 0.5 to about 2% (w/v).

2/ Infection associated with medical devices or prostheses, e.g. catheter, grafts, prosthetic heart valves, artificial joints, etc. One to five percent of indwelling prostheses become infected which usually requires removal or replacement of the prostheses. The main organisms responsible for these infections are CoNS and *S. aureus*.

Preferably, the peptide and/or antibiotic can be coated, either covalently bonded or by any other means, onto the medical device either at manufacture of the device or after manufacture but prior to insertion of the device. In such an application, the peptide antibiotic is preferably applied as a 0.5 to 2% solution.

3/ Infection during hemodialysis. Infection is the second leading cause of death in patients on chronic hemodialysis. Approximately 23% of bacteremias are due to access site infections. The majority of graft infections are caused by coagulate-positive (*S. aureus*) and coagulate-negative staphylococci. To combat infection, the peptide alone or in combination with an antibiotic can be applied as an ointment or cream to the dialysis site prior to each hemodialysis procedure.

4/ *S. aureus* nasal and extra-nasal carriage. Infection by this organism may result in impetigenous lesions or infected wounds. It is also associated with increased infection rates following cardiac surgery, hemodialysis, orthopedic surgery and neutropenia, both disease induced and iatrogenic. Nasal and extra-nasal carriage of staphylococci can result in hospital outbreaks of the same staphylococci strain that is colonizing a patient's or hospital worker's nasal passage or extra-nasal site. Much attention has been paid to the eradication of nasal colonization, but the results of treatment have been generally unsatisfactory. The use of topical antimicrobial substances, such as Bacitracin, Tetracycline, or Chlorhexidine, results in the suppression of nasal colonization, as opposed to its eradication.

The peptide alone or in combination with an antibiotic are preferably applied intra-nasally, formulated for nasal application, as a 0.5 to 2% ointment, cream or solution. Application may occur once or multiple times until the colonization of staphylococci is reduced or eliminated.

5/ Burn wound infections. Although the occurrence of invasive burn wound infections has been significantly reduced, infection remains the most common cause of morbidity and mortality in extensively burned patients. Infection is the predominant determinant of wound healing, incidence of complications, and outcome of burn patients. The main organisms responsible are *Pseudomonas aeruginosa*, *S. aureus*, *Streptococcus pyogenes*, and various gram-negative organisms. Frequent debridements and establishment of an epidermis, or a surrogate such as a graft or a skin substitute, is essential for prevention of infection.

The peptide alone or in combination with antibiotics can be applied to burn wounds as an ointment or cream and/or administered systemically. Topical application may prevent systemic infection following superficial colonization or eradicate a superficial infection. The peptide is preferably administered as a 0.5 to 2% cream or ointment. Application to the skin could be done once a day or as often as dressings are changed. The systemic administration could be by intravenous, intramuscular or subcutaneous injections or infusions. Other routes of administration could also be used.

6/ Surgical wounds, especially those associated with foreign material, e.g. sutures. As many as 71% of all nosocomial infections occur in surgical patients, 40% of which are infections at the operative site. Despite efforts to prevent infection, it is estimated that between 500,000 and 920,000 surgical wound infections complicate the approximately 23 million surgical procedures performed annually in the United States. The infecting organisms are varied but staphylococci are important organisms in these infections.

The peptide alone or with an antibiotic may be applied as an ointment, cream or liquid to the wound site or as a liquid in the wound prior to and during closure of the wound. Following closure the peptide antibiotic could be applied at dressing changes. For wounds that are infected, the peptide antibiotic could be applied topically and/or systemically.

7/ Acne, including severe acne vulgaris. This condition is due to colonization and infection of hair follicles and sebaceous cysts by *Propionibacterium acne*. Most cases remain mild and do not lead to scarring although a subset of patients develop large inflammatory cysts and nodules, which may drain and result in significant scarring.

The peptide alone or with an antibiotic can be incorporated into soap or applied topically as a cream, lotion or gel to the affected areas either once a day or multiple times during the day. The length of treatment may be for as long as the lesions are present or used to prevent recurrent lesions. The peptide antibiotic could also be administered orally or systemically to treat or prevent acne lesions.

8/ Nosocomial pneumonia. Nosocomial pneumonias account for nearly 20% of all nosocomial infections. Patients most at risk for developing nosocomial pneumonia are those in an intensive care unit, patients with altered levels of consciousness, elderly patients, patients with chronic lung disease, ventilated patients, smokers and post-operative patients. In a severely compromised patient, multiantibiotic-resistant nosocomial pathogens are likely to be the cause of the pneumonia.

The main organisms responsible are *P. aeruginosa*, *S. aureus*, *Klebsiella pneumoniae* and *Enterobacter* spp. The peptide alone or in combination with other antibiotics could be administered orally or systemically to treat pneumonia. Administration could be once a day or multiple administrations per day. Peptide antibiotics could be administered directly into the lung via inhalation or via installation of an endotracheal tube.

9/ Meningitis. Bacterial meningitis remains a common disease worldwide. Approximately 25,000 cases occur annually, of which 70% occur in children under 5 years of age. Despite an apparent recent decline in the incidence of severe neurologic sequelae among children surviving bacterial meningitis, the public health problems as a result of this disease are significant worldwide. The main responsible organisms are *H. influenzae*, *Streptococcus pneumoniae* and *Neisseria meningitidis*. Community acquired drug resistant *S. pneumoniae* are emerging as a widespread problem in the United States. The peptide alone or in combination with known antibiotics could be administered orally or systemically to treat meningitis. The preferred route would be intravenously either once a day or multiple administration per day. Treatment would preferably last for up to 14 days.

10/ Cystic fibrosis. Cystic fibrosis (CF) is the most common genetic disorder of the Caucasian population. Pulmonary disease is the most common cause of premature death in cystic fibrosis patients. Optimum antimicrobial therapy for CF is not known, and it is generally believed that the introduction of better anti-pseudomonal antibiotics has been the major factor contributing to the increase in life expectancy for CF patients. The most common organisms associated with lung disease in CF are *S. aureus*, *P. aeruginosa* and *H. influenzae*.

The peptide alone or in combination with other antibiotics could be administrated orally or systemically or via aerosol to treat cystic fibrosis. Preferably, treatment is effected for up to 3 weeks during acute pulmonary disease and/or for up to 2 weeks every 2-6 months to prevent acute exacerbations.

11/ Infective endocarditis. Infective endocarditis results from infection of the heart valve cusps, although any part of the endocardium or any prosthetic material inserted into the heart may be involved. It is usually fatal if untreated. Most infections are nosocomial in origin, caused by pathogens increasingly resistant to available drugs. The main organisms responsible are *Viridans streptococci*, *Enterococcus* spp, *S. aureus* and CoNS.

The peptide alone or in combination with other antibiotics could be administered orally or systemically to treat endocarditis, although systemic administration would be preferred. Treatment is preferably for 2-6 weeks in duration and may be given as a continuous infusion or multiple administration during the day.

12/ Osteomyelitis. In early acute disease the vascular supply to the bone is compromised by infection extending into surrounding tissue. Within this necrotic and ischemic tissue, the bacteria may be difficult to eradicate even after an intense host response, surgery, and/or antibiotic therapy. The main organisms responsible are *S. aureus*, *E. coli*, and *P. aeruginosa*.

The peptide antibiotic could be administered systemically alone or in combination with other antibiotics. Treatment would be 2-6 weeks in duration. The peptide antibiotic could be given as a continuous infusion or multiple administration during the day. Peptide antibiotic could be used as an antibiotic-impregnated cement or as antibiotic coated beads for joint replacement procedures.

13/ Sepsis in immunocompromised host. Treatment of infections in patients who are immunocompromised by virtue of chemotherapy-induced granulocytopenia and immunosuppression related to organ or bone marrow transplantation is always a big challenge. The neutropenic patient is especially susceptible to bacterial infection, so antibiotic therapy should be initiated promptly to cover likely pathogens, if infection is suspected. Organisms likely to cause infections in granulocytopenic patients are: *S. epidermidis*, *S. aureus*, *S. viridans*, *Enterococcus spp*, *E. coli*, *Klebsiella spp*, *P. aeruginosa* and *Candida spp*.

The peptide alone or with an antibiotic is preferably administered orally or systemically for 2-6 weeks in duration. The peptide antibiotic could be given as a continuous infusion or multiple administration during the day.

Effective treatment of infection may be examined in several different ways. The patient may exhibit reduced fever, reduced number of organisms, lower level of inflammatory molecules (e.g., IFN- $\gamma$ , IL-12, IL-1, TNF), and the like.

The *in vivo* therapeutic efficacy from administering a cationic peptide and antibiotic agent in combination is based on a successful clinical outcome and does not require 100% elimination of the organisms involved in the infection. Achieving a level of antimicrobial activity at the site of infection that allows the host to survive or eradicate the

microorganism is sufficient. When host defenses are maximally effective, such as in an otherwise healthy individual, only a minimal antimicrobial effect may suffice. Thus, reducing the organism load by even one log (a factor of 10) may permit the defenses of the host to control the infection. In addition, clinical therapeutic success may depend more on augmenting an early bactericidal effect than on the long-term effect. These early events are a significant and critical part of therapeutic success, because they allow time for the host defense mechanisms to activate. This is especially true for life-threatening infections (e.g. meningitis) and other serious chronic infections (e.g. infective endocarditis).

Peptides and antibiotic agents of the present invention are preferably administered as a pharmaceutical composition. Briefly, pharmaceutical compositions of the present invention may comprise one or more of the peptide analogues described herein, in combination with one or more physiologically acceptable carriers, diluents, or excipients. As noted herein, the formulation buffer used may affect the efficacy or activity of the peptide analogue.

The antibiotic agent may be a cytokine, antiviral agent (e.g. acyclovir; amantadine hydrochloride; didanosine; edoxudine; famciclovir; foscarnet; ganciclovir; idoxuridine; interferon; lamivudine; nevirapine; penciclovir; podophyllotoxin; ribavirin; rimantadine; sorivudine; stavudine; trifluridine; vidarabine; zalcitabine and zidovudine); an antiparasitic agent (e.g., 8-hydroxyquinoline derivatives; cinchona alkaloids; nitroimidazole derivatives; piperazine derivatives; pyrimidine derivatives and quinoline derivatives); parasitic agent (e.g., albendazole; atovaquone; chloroquine phosphate; diethylcarbamazine citrate; eflornithine; halofantrine; iodoquinol; ivermectin; mebendazole; mefloquine hydrochloride; melarsoprol B; metronidazole; niclosamide; nifurtimox; paromomycin; pentamidine isethionate; piperazine; praziquantel; primaquine phosphate; proguanil; pyrantel pamoate; pyrimethamine; pyrvium pamoate; quinidine gluconate; quinine sulfate; sodium stibogluconate; suramin and thiabendazole); antifungal agent (e.g., allylamines; imidazoles; pyrimidines and triazoles, 5-fluorocytosine; amphotericin B; butoconazole; chlorphenesin; ciclopirox; clioquinol; clotrimazole; econazole; fluconazole; flucytosine; griseofulvin; itraconazole; ketoconazole; miconazole; naftifine hydrochloride; nystatin; selenium sulfide; sulconazole; terbinafine hydrochloride; terconazole; tioconazole; tolnaftate and undecylenate).

The compositions may be administered in a delivery vehicle. For example, the composition can be encapsulated in a liposome (*see, e.g.*, WO 96/10585; WO 95/35094), complexed with lipids, encapsulated in slow-release or sustained release vehicles, such as poly-galactide, and the like. Within other embodiments, compositions may be prepared as a lyophilizate, utilizing appropriate excipients to provide stability.

Pharmaceutical compositions of the present invention may be administered in various manners. For example, cationic peptides with or without antibiotic agents may be administered by intravenous injection, intraperitoneal injection or implantation, subcutaneous injection or implantation, intradermal injection, lavage, inhalation, implantation, intramuscular injection or implantation, intrathecal injection, bladder wash-out, suppositories, pessaries, topical (*e.g.*, creams, ointments, skin patches, eye drops, ear drops, shampoos) application, enteric, oral, or nasal route. The combination is preferably administered intravenously. Systemic routes include intravenous, intramuscular or subcutaneous injection (including a depot for long-term release), intraocular or retrobulbar, intrathecal, intraperitoneal (*e.g.* by intraperitoneal lavage), transpulmonary using aerosolized or nebulized drug or transdermal. Topical routes include administration in the form of salves, ophthalmic drops, ear drops, or irrigation fluids (*for, e.g.* irrigation of wounds). The compositions may be applied locally as an injection, drops, spray, tablets, cream, ointment, gel, and the like. They may be administered as a bolus or as multiple doses over a period of time.

The level of peptide in serum and other tissues after administration can be monitored by various well-established techniques such as bacterial, chromatographic or antibody based, such as ELISA, assays.

Pharmaceutical compositions of the present invention are administered in a manner appropriate to the infection or disease to be treated. The amount and frequency of administration will be determined by factors such as the condition of the patient, the cause of the infection, and the severity of the infection. Appropriate dosages may be determined by clinical trials, but will generally range from about 0.1 to 50 mg/kg. The general range of dosages for the antibiotic agents are presented below.

41  
Table 7

ANTIMICROBIAL AGENT	DOSE RANGE
Ciprofloxacin	400-1500mg/day
Gentamicin	3 mg/kg/day
Tobramycin	3 mg/kg/day
Imipenem	1500 mg/kg every 12 h
Piperacillin	24 g/day
Vancomycin, Teicoplanin	6-30 mg/kg/day
Streptomycin	500mg-1g/ every 12 h
Methicillin	100-300 mg/day
Ampicillin, Amoxicillin	250-500 mg/ every 8 h
Penicillin	200,000 units/day
Ceftriaxone	4 g/day
Cefotaxime	12 g/day
Metronidazole	4 g/day
Tetracycline	500 mg/every 6 h
Rifampin	600 mg/day
Fluconazole	150-400 mg/day
Acyclovir	200-400 mg/day
Ribavirin	20 mg/ml (aerosol).
Amantadine-rimantadine	200 mg/day
Metronidazole	2 g/day
Cotrimoxazole	15-20 mg/kg/day
Chloroquine	800 mg/day

In addition, the compositions of the present invention may be used in the manner of common disinfectants or in any situation in which microorganisms are undesirable. For example, these peptides may be used as surface disinfectants, coatings, including covalent bonding, for medical devices, coatings for clothing, such as to inhibit growth of bacteria or repel mosquitoes, in filters for air purification, such as on an airplane, in water purification, constituents of shampoos and soaps, food preservatives, cosmetic preservatives, media preservatives, herbicide or insecticides, constituents of building materials, such as in silicone sealant, and in animal product processing, such as curing of animal hides. As used herein, "medical device" refers to any device for use in a patient, such as an implant or prosthesis. Such devices include, stents, tubing, probes, cannulas, catheters, synthetic vascular grafts, blood monitoring devices, artificial heart valves, needles, and the like.

For these purposes, typically the peptides alone or in conjunction with an antibiotic are included in compositions commonly employed or in a suitable applicator, such as for applying to clothing. They may be incorporated or impregnated into the material during manufacture, such as for an air filter, or otherwise applied to devices. The peptides

and antibiotics need only be suspended in a solution appropriate for the device or article. Polymers are one type of carrier that can be used.

The peptides, especially the labeled analogues, may be used in image analysis and diagnostic assays or for targeting sites in eukaryotic multicellular and single cell cellular organisms and in prokaryotes. As a targeting system, the analogues may be coupled with other peptides, proteins, nucleic acids, antibodies and the like.

The following examples are offered by way of illustration, and not by way of limitation.

43  
EXAMPLES

EXAMPLE 1

SYNTHESIS PURIFICATION AND CHARACTERIZATION OF CATIONIC PEPTIDES AND ANALOGUES

Peptide synthesis is based on the standard solid-phase Fmoc protection strategy. The instrument employed is a 9050 Plus PepSynthesiser (PerSeptive BioSystems Inc.). Polyethylene glycol polystyrene (PEG-PS) graft resins are employed as the solid phase, derivatized with an Fmoc-protected amino acid linker for C-terminal amide synthesis. HATU (O-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) is used as the coupling reagent. During synthesis, coupling steps are continuously monitored to ensure that each amino acid is incorporated in high yield. The peptide is cleaved from the solid-phase resin using trifluoroacetic acid and appropriate scavengers and the crude peptide is purified using preparative reversed-phase chromatography. Typically the peptide is prepared as the trifluoroacetate salt, but other salts, such as acetate, chloride and sulfate, can also be prepared by salt exchange.

All peptides are analyzed by mass spectrometry to ensure that the product has the expected molecular mass. The product should have a single peak accounting for >95% of the total peak area when subjected to analytical reversed-phase high performance liquid chromatography (RP-HPLC), a separation method that depends on the hydrophobicity of the peptide. In addition, the peptide should show a single band accounting for >90% of the total band intensity when subjected to acid-urea gel electrophoresis, a separation method based on the charge to mass ration of the peptide.

Peptide content, the amount of the product that is peptide rather than retained water, salt or solvent, is measured by quantitative amino acid analysis, free amine derivatization or spectrophotometric quantitation. Amino acid analysis also provides information on the ratio of amino acids present in the peptide, which assists in confirming the authenticity of the peptide.

Peptide analogues and their names are listed below. In this list, and elsewhere, the amino acids are denoted by the one-letter amino acid code and lower case letters represent the D-form of the amino acid.

11A9CN	I L R W P W W P W W P W R R K
11A10CN	W W R W P W W P W R R K
11B19CN	I L R W P W R R W P W R R K
11B20	I L R W P W W P W R R K M I L R W P W W P W R R K A A
11D19CN	C L R W P W W P W R R K
11F5CN	I L R R W V W W V W R R K
11F6CN	I L R W W V W W V W W R R K
11G24CN	L W P W W P W R R K
11G25CN	L R W W W P W R R K
11G26CN	L R W P W W P W
11G27CN	W P W W P W R R K
11G28CN	R W W W P W R R K
11J01CN	R R I W K P K W R L P K R
11J02CN	W R W W K P K W R W P K W

CN suffix = amidated C-terminus

### EXAMPLE 2

#### SYNTHESIS OF MODIFIED PEPTIDES

Cationic peptides, such as indolicidin analogues, are modified to alter the physical properties of the original peptide, either by use of modified amino acids in synthesis or by post-synthetic modification. Such modifications include: acetylation at the N-terminus, Fmoc-derivatized N-terminus, polymethylation, peracetylation, and branched derivatives.

*α-N-terminal acetylation.* Prior to cleaving the peptide from the resin and deprotecting it, the fully protected peptide is treated with N-acetylimidazole in DMF for 1 hour at room temperature, which results in selective reaction at the α-N-terminus. The peptide is then deprotected/cleaved and purified as for an unmodified peptide.

*Fmoc-derivatized α-N-terminus.* If the final Fmoc deprotection step is not carried out, the α-N-terminus Fmoc group remains on the peptide. The peptide is then side-chain deprotected/cleaved and purified as for an unmodified peptide.

*Polymethylation.* The purified peptide in a methanol solution is treated with excess sodium bicarbonate, followed by excess methyl iodide. The reaction mixture is stirred overnight at room temperature, extracted with organic solvent, neutralized and purified as for an unmodified peptide. Using this procedure, a peptide is not fully methylated; methylation of MBI 11CN yielded an average of 6 methyl groups. Thus, the modified peptide is a mixture of methylated products.

*Peracetylation.* A purified peptide in DMF solution is treated with N-acetylimidazole for 1 hour at room temperature. The crude product is concentrated, dissolved

in water, lyophilized, re-dissolved in water and purified as for an unmodified peptide. Complete acetylation of primary amine groups is observed.

*Four/eight branch derivatives.* The branched peptides are synthesized on a four or eight branched core bound to the resin. Synthesis and deprotection/cleavage proceed as for an unmodified peptide. These peptides are purified by dialysis against 4 M guanidine hydrochloride then water, and analyzed by mass spectrometry.

### EXAMPLE 3

#### *IN VITRO ASSAYS TO MEASURE CATIONIC PEPTIDE ACTIVITY*

A cationic peptide may be tested for antimicrobial activity alone before assessing its enhancing activity with antibiotic agents. Preferably, the peptide has measurable antimicrobial activity.

##### *Agarose Dilution Assay*

The agarose dilution assay measures antimicrobial activity of peptides and peptide analogues, which is expressed as the minimum inhibitory concentration (MIC) of the peptides.

In order to mimic *in vivo* conditions, calcium and magnesium supplemented Mueller Hinton broth is used in combination with a low EEO agarose as the bacterial growth medium. Agarose, rather than agar, is used as the charged groups in agar prevent peptide diffusion through the media. The media is autoclaved and then cooled to 50 - 55° C in a water bath before aseptic addition of antimicrobial solutions. The same volume of different concentrations of peptide solution are added to the cooled molten agarose that is then poured to a depth of 3 - 4 mm.

The bacterial inoculum is adjusted to a 0.5 McFarland turbidity standard (PML Microbiological) and then diluted 1:10 before application on to the agarose plate. The final inoculum applied to the agarose is approximately  $10^4$  CFU in a 5 - 8 mm diameter spot. The agarose plates are incubated at 35 - 37°C for 16 to 20 hours.

The MIC is recorded as the lowest concentration of peptide that completely inhibits growth of the organism as determined by visual inspection. Representative MICs for various indolicidin analogues against bacteria are shown in Table 8 and representative MICs against *Candida* are shown in Table 9 below.

Table 8

## 1. MBI 11A9CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	8
<i>E. cloacae</i>	ECL007	128
<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 2. MBI 11A10CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	64
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	4
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	64
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 3. MBI 11B7ACN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	2
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	1
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	8
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 4. MBI 11B7CNF12

Organism	Organism #	MIC (µg/ml)

<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 5. MBI 11B19CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	32
<i>K. pneumoniae</i>	KP001	64
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 6. MBI 11B20

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	32
<i>E. cloacae</i>	ECL007	128
<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	8
<i>E. faecalis</i>	EFS008	32
<i>K. pneumoniae</i>	KP001	64
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	32
<i>S. aureus</i>	SA093	4
<i>S. epidermidis</i>	SE010	32
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 7. MBI 11D19CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	8
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	4
<i>E. faecalis</i>	EFS008	64
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	8
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 8. MBI 11F4

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	8
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	16
<i>S. marcescens</i>	SMS003	>128

## 9. MBI 11F5CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	8
<i>P. aeruginosa</i>	PA004	32
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	16
<i>S. marcescens</i>	SMS003	>128

## 10. MBI 11F6CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	16
<i>E. cloacae</i>	ECL007	64

<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	16
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	16
<i>S. aureus</i>	SA093	8
<i>S. epidermidis</i>	SE010	8
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 11. MBI 11G24CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 12. MBI 11G25CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	2
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	64
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	2
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 13. MBI 11G26CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	2
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	4
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	0.5
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	128
<i>S. marcescens</i>	SMS003	>128

## 14. MBI 11G27CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	2
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	8
<i>E. faecalis</i>	EFS008	32
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	8
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 15. MBI 11G28CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	2
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	4
<i>E. faecalis</i>	EFS008	32
<i>K. pneumoniae</i>	KP001	64
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 16. MBI 11H01CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	2
<i>E. cloacae</i>	ECL007	>128

<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	8
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	2
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 17. MBI 11H02CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 18. MBI 11H03CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	8
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 19. MBI 11H04CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	8
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	64
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	16
<i>S. maltophilia</i>	SMA002	>128
<i>S. marcescens</i>	SMS003	>128

## 20. MBI 11H05CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	8
<i>P. aeruginosa</i>	PA004	128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	16
<i>S. marcescens</i>	SMS003	>128

## 21. MBI 11H06CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	8
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	64
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	8
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	8
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 22. MBI 11H07CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	8
<i>E. cloacae</i>	ECL007	>128

<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	4
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	128
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	8
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	16
<i>S. maltophilia</i>	SMA002	128
<i>S. marcescens</i>	SMS003	>128

## 23. MBI 11H08CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	8
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	32
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	32
<i>S. marcescens</i>	SMS003	>128

## 24. MBI 11H09CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	32
<i>E. faecalis</i>	EFS001	4
<i>E. faecalis</i>	EFS008	64
<i>K. pneumoniae</i>	KP001	64
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	8
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	16
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 25. MBI 11H10CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 26. MBI 11H11CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	4
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 27. MBI 11H12CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128
<i>E. coli</i>	ECO005	16
<i>E. faecalis</i>	EFS001	2
<i>E. faecalis</i>	EFS008	8
<i>K. pneumoniae</i>	KP001	16
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	4
<i>S. maltophilia</i>	SMA002	64
<i>S. marcescens</i>	SMS003	>128

## 28. MBI 11J01CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	>128

<i>E. coli</i>	ECO005	64
<i>E. faecalis</i>	EFS001	128
<i>E. faecalis</i>	EFS008	>128
<i>K. pneumoniae</i>	KP001	>128
<i>P. aeruginosa</i>	PA004	>128
<i>S. aureus</i>	SA014	16
<i>S. aureus</i>	SA093	2
<i>S. epidermidis</i>	SE010	32
<i>S. maltophilia</i>	SMA002	>128
<i>S. marcescens</i>	SMS003	>128

## 29. MBI 11J02CN

Organism	Organism #	MIC (µg/ml)
<i>A. calcoaceticus</i>	AC002	4
<i>E. cloacae</i>	ECL007	64
<i>E. coli</i>	ECO005	4
<i>E. faecalis</i>	EFS001	4
<i>E. faecalis</i>	EFS008	16
<i>K. pneumoniae</i>	KP001	4
<i>P. aeruginosa</i>	PA004	32
<i>S. aureus</i>	SA014	2
<i>S. aureus</i>	SA093	1
<i>S. epidermidis</i>	SE010	2
<i>S. maltophilia</i>	SMA002	8
<i>S. marcescens</i>	SMS003	>128

51  
**Table 9**

Organism	MBI 11CN MIC (µg/ml)	MBI 11B7CN MIC (µg/ml)
<i>C. albicans</i> CA001	128	64
<i>C. albicans</i> CA002	64	32
<i>C. albicans</i> CA003	128	64
<i>C. albicans</i> CA004	64	32
<i>C. albicans</i> CA005	128	32
<i>C. albicans</i> CA006	128	64
<i>C. albicans</i> CA007	128	64
<i>C. albicans</i> CA008	64	32
<i>C. albicans</i> CA009	64	32
<i>C. albicans</i> CA010	128	64
<i>C. albicans</i> CA011	64	64
<i>C. albicans</i> CA012	128	64
<i>C. albicans</i> CA013	128	64
<i>C. albicans</i> CA014	64	32
<i>C. albicans</i> CA015	128	64
<i>C. albicans</i> CA016	128	64
<i>C. albicans</i> CA017	128	64
<i>C. albicans</i> CA018	128	64
<i>C. albicans</i> CA019	128	64
<i>C. albicans</i> CA020	128	32
<i>C. albicans</i> CA021	128	32
<i>C. albicans</i> CA022	32	32
<i>C. albicans</i> CA023	128	64
<i>C. albicans</i> CA024	16	8
<i>C. glabrata</i> CGL001	>128	128
<i>C. glabrata</i> CGL002	>128	128
<i>C. glabrata</i> CGL003	>128	128
<i>C. glabrata</i> CGL004	>128	128
<i>C. glabrata</i> CGL005	>128	128
<i>C. glabrata</i> CGL009	>128	128
<i>C. glabrata</i> CGL010	>128	128
<i>C. krusei</i> CKR001	0.5	1
<i>C. tropicalis</i> CTR001	4	4
<i>C. tropicalis</i> CTR002	4	8
<i>C. tropicalis</i> CTR003	8	8
<i>C. tropicalis</i> CTR004	4	8
<i>C. tropicalis</i> CTR005	4	4
<i>C. tropicalis</i> CTR006	16	8
<i>C. tropicalis</i> CTR007	16	8
<i>C. tropicalis</i> CTR008	8	4
<i>C. tropicalis</i> CTR009	8	4

*Broth Dilution Assay*

Typically 100  $\mu$ l of calcium and magnesium supplemented Mueller Hinton broth is dispensed into each well of a 96-well microtitre plate and 100  $\mu$ l volumes of two-fold serial dilutions of the peptide are prepared across the plate. One row of wells receives no 5 peptide and is used as a growth control. Each well is inoculated with approximately  $5 \times 10^5$  CFU of bacteria and the plate is incubated at 35 - 37°C for 16-20 hours. The MIC is recorded at the lowest concentration of peptide that completely inhibits growth of the organism as determined by visual inspection.

*Time Kill Assay*

10 Time kill curves are used to determine the antimicrobial activity of cationic peptides over a time interval. Briefly, in this assay, a suspension of microorganisms equivalent to a 0.5 McFarland Standard is prepared in 0.9% saline. This suspension is then diluted such that when added to a total volume of 9 ml of cation-adjusted Mueller Hinton broth, the inoculum size is  $1 \times 10^6$  CFU/ml. An aliquot of 0.1 ml is removed from each tube 15 at pre-determined intervals up to 24 hours, diluted in 0.9% saline and plated in triplicate to determine viable colony counts. The number of bacteria remaining in each sample is plotted over time to determine the rate of cationic peptide killing. Generally a three or more  $\log_{10}$  reduction in bacterial counts in the antimicrobial suspension compared to the growth controls indicate an adequate bactericidal response.

20 As shown in Figures 1A-D, most of the peptides demonstrate a three or more  $\log_{10}$  reduction in bacterial counts in the antimicrobial suspension compared to the growth controls, indicating that these peptides have met the criteria for a bactericidal response.

EXAMPLE 4

## 25 ASSAYS TO MEASURE ENHANCED ACTIVITY OF ANTIBIOTIC AGENT

## AND CATIONIC PEPTIDE COMBINATIONS

*Killing Curves*

Time kill curves resulting from combination of cationic peptide and antibiotic agent are compared to that resulting from agent alone.

30 The assay is performed as described above except that duplicate tubes are set up for each concentration of the antibiotic agent alone and of the combination of antibiotic

agent and cationic peptide. Synergy is demonstrated by at least a 100-fold ( $2 \log_{10}$ ) increase in killing at 24 hours by the antibiotic agent and cationic peptide combination compared to the antibiotic agent alone. A time kill assay is shown in Figure 1E for MBI 26 in combination with vancomycin against a bacterial strain. The combination of peptide and 5 antibiotic agent gave greater killing than either peptide or antibiotic agent alone.

*FIC Measurements*

In this method, synergy is determined using the agarose dilution technique. An array of plates or tubes, each containing a combination of peptide and antibiotic in a unique concentration mix, is inoculated with bacterial isolates. When performing solid phase 10 assays, calcium and magnesium supplemented Mueller Hinton broth is used in combination with a low EEO agarose as the bacterial growth medium. Broth dilution assays can also be used to determine synergy. Synergy is determined for cationic peptides in combination with a number of conventional antibiotic agents, for example, penicillins, cephalosporins, carbapenems, monobactams, aminoglycosides, macrolides, fluoroquinolones, nisin and 15 lysozyme.

Synergy is expressed as a fractional inhibitory concentration (FIC), which is calculated according to the equation below. An  $FIC \leq 0.5$  is evidence of synergy. An additive response has an  $FIC$  value  $> 0.5$  and  $\leq 1$ , while an indifferent response has an  $FIC$  value  $> 1$  and  $\leq 2$ .

$$20 \quad FIC = \frac{MIC \text{ (peptide in combination)}}{MIC \text{ (peptide alone)}} + \frac{MIC \text{ (antibiotic in combination)}}{MIC \text{ (antibiotic alone)}}$$

Tables 10, 11 and 12 present combinations of cationic peptides and antibiotic agents that display an  $FIC$  value of less than or equal to 1. Although  $FIC$  is measured *in vitro* 25 and synergy defined as an  $FIC$  of less than or equal to 0.5, an additive effect may be therapeutically useful. As shown below, although all the microorganisms are susceptible (NCCLS breakpoint definitions) to the tested antibiotic agents, the addition of the cationic peptide improves the efficacy of the antibiotic agent.

Table 10

30

Microorganism	Strain	Antibiotic	FIC	Peptide
<i>S. aureus</i>	SA014	Ciprofloxacin	0.63	MBI 26
<i>S. aureus</i>	SA014	Ciprofloxacin	0.75	MBI 28
<i>S. aureus</i>	SA014	Ciprofloxacin	1.00	MBI 11A2CN

Micr organism	Strain	Antibiotic	FIC	Peptide
<i>S. aureus</i>	SA093	Ciprofloxacin	0.75	MBI 11A2CN
<i>S. aureus</i>	SA7609	Clindamycin	0.25	MBI 26
<i>S. aureus</i>	SA7609	Methicillin	0.56	MBI 26
<i>S. aureus</i>	SA7610	Clindamycin	0.63	MBI 26
<i>S. aureus</i>	SA7610	Methicillin	0.31	MBI 26
<i>S. aureus</i>	SA7795	Ampicillin	0.52	MBI 26
<i>S. aureus</i>	SA7795	Clindamycin	0.53	MBI 26
<i>S. aureus</i>	SA7796	Ampicillin	1.00	MBI 26
<i>S. aureus</i>	SA7796	Clindamycin	0.51	MBI 26
<i>S. aureus</i>	SA7817	Ampicillin	0.50	MBI 26
<i>S. aureus</i>	SA7818	Ampicillin	1.00	MBI 26
<i>S. aureus</i>	SA7818	Erythromycin	0.15	MBI 26
<i>S. aureus</i>	SA7818	Erythromycin	0.15	MBI 26
<i>S. aureus</i>	SA7821	Erythromycin	0.50	MBI 26
<i>S. aureus</i>	SA7821	Erythromycin	0.50	MBI 26
<i>S. aureus</i>	SA7822	Ampicillin	0.25	MBI 26
<i>S. aureus</i>	SA7823	Ampicillin	0.25	MBI 26
<i>S. aureus</i>	SA7824	Ampicillin	1.00	MBI 26
<i>S. aureus</i>	SA7825	Ampicillin	1.00	MBI 26
<i>S. aureus</i>	SA7825	Erythromycin	1.00	MBI 26
<i>S. aureus</i>	SA7825	Erythromycin	1.00	MBI 26
<i>S. aureus</i>	SA7834	Ampicillin	0.53	MBI 26
<i>S. aureus</i>	SA7834	Clindamycin	0.56	MBI 26
<i>S. aureus</i>	SA7835	Ampicillin	0.53	MBI 26
<i>S. aureus</i>	SA7836	Ampicillin	0.75	MBI 26
<i>S. aureus</i>	SA7837	Ampicillin	1.00	MBI 26
<i>S. aureus</i>	SAATCC25293	Methicillin	0.50	MBI 26
<i>S. aureus</i>	SAATCC29213	Methicillin	0.31	MBI 26
<i>S. aureus</i>	SAW1133	Methicillin	0.75	MBI 26
<i>S. epidermidis</i>	SE8406	Clindamycin	0.50	MBI 26
<i>S. epidermidis</i>	SE8416	Ampicillin	0.52	MBI 31
<i>S. epidermidis</i>	SE8416	Clindamycin	0.56	MBI 26
<i>S. epidermidis</i>	SE8505	Ampicillin	1.00	MBI 26
<i>S. epidermidis</i>	SE8565	Ampicillin	1.00	MBI 26
<i>S. epidermidis</i>	SH8575	Ampicillin	0.27	MBI 31
<i>S. haemolyticus</i>	SA7797	Ampicillin	0.50	MBI 31
<i>S. haemolyticus</i>	SA7817	Ampicillin	0.26	MBI 31
<i>S. haemolyticus</i>	SA7818	Ampicillin	0.52	MBI 31
<i>S. haemolyticus</i>	SA7834	Ampicillin	0.52	MBI 31
<i>S. haemolyticus</i>	SA7835	Ampicillin	0.50	MBI 31
<i>S. haemolyticus</i>	SH8459	Ampicillin	0.52	MBI 26
<i>S. haemolyticus</i>	SH8472	Ampicillin	0.56	MBI 26
<i>S. haemolyticus</i>	SH8563	Ampicillin	0.75	MBI 26

Microorganism	Strain	Antibiotic	FIC	Peptide
<i>S. haemolyticus</i>	SH8564	Ampicillin	0.62	MBI 26
<i>S. haemolyticus</i>	SH8575	Ampicillin	0.75	MBI 26
<i>S. haemolyticus</i>	SH8576	Ampicillin	0.62	MBI 26
<i>S. haemolyticus</i>	SH8578	Ampicillin	1.00	MBI 26
<i>S. haemolyticus</i>	SH8597	Ampicillin	1.00	MBI 31

Table 11

Microorganism	Strain	Teicoplanin (µg/ml)		MBI 26 (µg/ml)	
		Alone	+ MBI 26	Alone	+ Teicoplanin
<i>E. faecium</i> 97001	VanB	0.5	0.25	64	4
<i>E. faecium</i> 97002	VanB	0.5	0.25	64	1
<i>E. faecium</i> 97003	VanB	0.5	0.25	64	1
<i>E. faecium</i> 97005	VanB	1	0.25	64	2
<i>E. faecium</i> 97006	VanB	0.5	0.5	64	4
<i>E. faecium</i> 97007	VanB	0.5	0.25	64	1
<i>E. faecium</i> 97008	VanB	0.5	0.25	64	4
<i>E. faecium</i> 97009	VanB	0.5	0.25	32	1
<i>E. faecium</i> 97010	VanB	0.5	0.25	64	4
<i>E. faecium</i> 97011	VanB	0.5	0.25	64	4
<i>E. faecium</i> 97012	VanB	8	0.25	64	4
<i>E. faecium</i> 97013	VanB	8	0.25	64	8
<i>E. faecium</i> 97014	VanB	8	0.25	32	4
<i>E. faecium</i> 97015	VanB	0.5	0.25	64	4
<i>E. faecium</i> 97016	VanB	0.5	0.25	64	4
<i>E. faecalis</i> 97040	VanB	0.5	0.25	64	8
<i>E. faecalis</i> 97041	VanB	1	0.25	64	8
<i>E. faecalis</i> 97042	VanB	1	0.25	64	8
<i>E. faecalis</i> 97043	VanB	0.5	0.25	64	8

Table 12

## 1. Amikacin

Peptide	Organism	FIC	Amikacin MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Amikacin
MBI 11B16CN	<i>A. baumannii</i> ABI001	0.50	32	0.125	32	16
	<i>A. baumannii</i> ABI003	0.53	16	0.5	16	8
	<i>P. aeruginosa</i> PA022	0.38	64	8	64	16
	<i>P. aeruginosa</i> PA037	0.25	16	2	>128	32
	<i>S. maltophilia</i> SMA018	0.31	128	8	32	8
	<i>S. maltophilia</i> SMA022	0.09	>128	8	>128	16
	<i>E. faecalis</i> EFS008	0.28	32	8	8	0.25
MBI 21A2	<i>A. baumannii</i> ABI001	0.52	64	32	8	0.125
	<i>A. baumannii</i> ABI003	0.52	16	8	8	4
	<i>P. aeruginosa</i> PA022	0.50	64	16	8	2
	<i>S. maltophilia</i> SMA018	0.50	>128	64	16	4
	<i>S. maltophilia</i> SMA022	0.25	>128	32	>128	32
	<i>E. faecium</i> EFM004	0.56	128	64	>128	16
	<i>E. faecalis</i> EFS008	0.50	64	32	>128	0.125
	<i>S. aureus</i> SA025 MRSA	0.56	32	2	2	1
	<i>S. epidermidis</i> SE003	0.38	32	4	>128	64
MBI 26	<i>A. baumannii</i> ABI001	0.50	32	8	8	2
	<i>A. baumannii</i> ABI003	0.38	16	2	8	2
	<i>S. maltophilia</i> SMA021	0.13	128	8	32	2
	<i>S. maltophilia</i> SMA037	0.19	128	16	>128	16
MBI 27	<i>A. baumannii</i> ABI003	0.52	16	0.25	8	4
	<i>B. cepacia</i> BC005	0.50	64	16	>128	64
	<i>S. maltophilia</i> SMA037	0.31	64	4	64	16
	<i>S. maltophilia</i> SMA060	0.50	>128	0.125	16	8
	<i>E. faecalis</i> EFS008	0.53	32	1	4	2
MBI 29A3	<i>B. cepacia</i> BC003	0.50	32	8	>128	64
	<i>B. cepacia</i> BC005	0.38	128	32	>128	32
	<i>S. maltophilia</i> SMA036	0.38	>128	32	64	16
	<i>S. maltophilia</i> SMA063	0.56	>128	16	8	4
	<i>S. maltophilia</i> SMA064	0.56	>128	16	8	4
	<i>E. faecium</i> EFM004	0.56	128	8	8	4
MBI 29F1	<i>A. baumannii</i> ABI001	0.51	32	0.25	8	4
	<i>A. baumannii</i> ABI003	0.63	16	2	4	2
	<i>E. coli</i> ECO022	0.51	16	0.125	4	2
	<i>P. aeruginosa</i> PA022	0.53	128	64	4	0.125
	<i>S. maltophilia</i> SMA021	0.31	128	8	8	2
	<i>S. maltophilia</i> SMA022	0.31	>128	16	16	4
	<i>E. faecium</i> EFM004	0.38	>128	32	32	8
	<i>E. faecalis</i> EFS008	0.28	64	16	4	0.125
	<i>S. aureus</i> SA014 MRSA	0.53	32	16	4	0.125
	<i>S. epidermidis</i> SE002	0.38	64	16	32	4
	<i>S. epidermidis</i> SE003	0.50	64	16	32	8

## 2. Ceftriaxone

Peptide	Organism	FIC	Ceftriaxone MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Ceftriaxone
MBI 11B7CN	<i>A. baumannii</i> ABI002	0.50	32	8	32	8
	<i>A. baumannii</i> ABI006	0.25	128	16	32	4
	<i>B. cepacia</i> BC003	0.52	32	16	>128	4
	<i>P. aeruginosa</i> PA008	0.25	128	16	128	16
	<i>P. aeruginosa</i> PA024	0.50	64	32	>128	0.125
	<i>S. maltophilia</i> SMA020	0.75	>128	64	16	8
	<i>S. maltophilia</i> SMA021	0.50	>128	64	32	8
	<i>S. maltophilia</i> SMA023	0.38	128	32	128	16
MBI 11J02CN	<i>A. baumannii</i> ABI005	0.56	16	8	8	0.5
	<i>B. cepacia</i> BC003	0.50	16	4	>128	64
	<i>E. cloacae</i> ECL014	0.38	128	16	32	8
	<i>E. cloacae</i> ECL015	0.50	64	16	32	8
	<i>P. aeruginosa</i> PA008	0.50	64	0.125	64	32
	<i>P. aeruginosa</i> PA039	0.50	64	16	64	16
	<i>S. aureus</i> SA025 MRSA	0.52	8	0.125	2	1
	<i>S. epidermidis</i> SE012	0.50	64	16	4	1
	<i>S. epidermidis</i> SE073	0.38	128	16	4	1
MBI 26	<i>A. baumannii</i> ABI002	0.50	64	16	8	2
	<i>A. baumannii</i> ABI005	0.56	16	8	2	0.125
	<i>B. cepacia</i> BC003	0.50	16	8	>128	0.125
	<i>E. cloacae</i> ECL014	0.50	128	32	8	2
	<i>E. cloacae</i> ECL015	0.19	64	4	32	4
	<i>K. pneumoniae</i> KP003	0.56	8	4	16	1
	<i>P. aeruginosa</i> PA008	0.13	64	8	128	0.125
	<i>P. aeruginosa</i> PA024	0.50	16	4	128	32
	<i>S. maltophilia</i> SMA019	0.50	>128	64	4	1
	<i>S. maltophilia</i> SMA020	0.38	>128	32	4	1
	<i>S. aureus</i> SA025 MRSA	0.52	8	0.125	1	0.5
	<i>S. epidermidis</i> SE007	0.27	8	2	32	0.5
	<i>S. epidermidis</i> SE012	0.27	64	16	64	1

## 3. Ciprofloxacin

Peptide	Organism	FIC	Ciprofloxacin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Ciprofloxacin
MBI 11A1CN	<i>S. aureus</i> SA10	0.53	32	16	128	4
	<i>S. aureus</i> SA11	0.50	64	32	>128	1
MBI 11D18CN	<i>P. aeruginosa</i> PA24	0.31	16	4	>128	16
	<i>P. aeruginosa</i> PA77	0.50	2	0.5	128	32
MBI 21A1	<i>S. aureus</i> SA25	0.16	4	0.125	32	4
	<i>S. aureus</i> SA93	0.50	32	8	4	1
	<i>P. aeruginosa</i> PA4	0.50	0.5	0.125	128	32
	<i>P. aeruginosa</i> PA41	0.50	4	1	16	4

MBI 21A2	<i>S. aureus</i> SA25 <i>S. aureus</i> SA93 <i>P. aeruginosa</i> PA4 <i>P. aeruginosa</i> PA41	0.50 0.38 0.50 0.50	2 32 0.5 4	0.5 8 0.125 1	16 16 >128 64	4 2 64 16
MBI 26	<i>S. aureus</i> SA11 <i>P. aeruginosa</i> PA41 <i>P. aeruginosa</i> PA77 <i>A. calcoaceticus</i> 1 <i>A. calcoaceticus</i> 6 <i>E. cloacae</i> 13 <i>E. cloacae</i> 15 <i>E. cloacae</i> 16 <i>P. aeruginosa</i> 23 <i>P. aeruginosa</i> 24 <i>S. maltophilia</i> 34 <i>S. maltophilia</i> 35	0.50 0.50 0.56 0.51 0.50 0.27 0.38 0.38 0.53 0.53 0.25 0.50	64 4 2 0.5 1 1 1 2 1 1 2 2	32 1 0.125 0.25 0.25 0.25 0.25 0.25 0.5 0.5 0.25 0.5	128 128 128 >64 >32 >128 >32 >32 >32 >32 >32 >32	0.125 32 64 1 16 4 8 16 2 2 8 16
MBI 27	<i>S. aureus</i> SA10 <i>S. aureus</i> SA93 <i>P. aeruginosa</i> PA4	0.75 0.63 0.75	32 32 0.5	8 4 0.25	2 2 32	1 1 8
MBI 28	<i>S. aureus</i> SA11 <i>S. aureus</i> SA25 <i>P. aeruginosa</i> PA24	0.63 0.56 0.75	32 2 32	16 0.125 8	64 2 64	8 1 32
MBI 29	<i>S. aureus</i> SA10 <i>S. aureus</i> SA93 <i>P. aeruginosa</i> PA41 <i>P. aeruginosa</i> PA77 <i>A. calcoaceticus</i> 5 <i>A. calcoaceticus</i> 9 <i>E. cloacae</i> 14 <i>E. cloacae</i> 15 <i>P. aeruginosa</i> 30 <i>P. aeruginosa</i> 31 <i>S. maltophilia</i> 34 <i>S. maltophilia</i> 35 <i>S. maltophilia</i> 36	0.38 0.50 0.52 0.50 0.56 0.56 0.50 0.50 0.56 0.53 0.27 0.63 0.56	32 32 8 2 2 2 1 1 4 16 2 2 8	4 8 4 0.5 1 1 0.25 0.25 0.25 0.5 0.5 0.5 0.5	4 2 8 64 16 16 >16 >16 >16 >16 >16 >16 >16	1 0.5 0.125 16 1 1 8 8 16 16 0.5 16 16
MBI 29A2	<i>S. aureus</i> SA10 <i>S. aureus</i> SA93 <i>P. aeruginosa</i> PA24	0.52 0.50 0.63	32 32 32	0.5 8 16	4 2 64	2 0.5 8
MBI 29A3	<i>S. aureus</i> SA10 <i>S. aureus</i> SA25 <i>P. aeruginosa</i> PA24 <i>P. aeruginosa</i> PA41	0.75 0.63 0.50 0.63	32 4 32 4	16 2 16 0.5	2 1 64 8	0.5 0.125 0.125 4

## 4. Gentamicin

Peptide	Organism	FIC	Gentamicin MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Gentamicin
MBI 11A1CN	<i>S. maltophilia</i> SMA019	0.31	8	2	>128	16
	<i>S. maltophilia</i> SMA020	0.31	8	2	>128	16
	<i>E. faecium</i> EFM004	0.28	>128	64	32	1
	<i>S. aureus</i> SA014 MRSA	0.56	32	2	8	4
	<i>S. epidermidis</i> SE074	0.51	128	1	32	16
MBI 11B16CN	<i>A. baumannii</i> ABI001	0.31	64	4	16	4
	<i>A. baumannii</i> ABI002	0.31	32	2	16	4
	<i>A. calcoaceticus</i> AC001	0.25	8	1	32	4
	<i>P. aeruginosa</i> PA022	0.38	32	8	64	8
	<i>P. aeruginosa</i> PA041	0.31	8	2	>128	16
	<i>S. maltophilia</i> SMA016	0.31	>128	64	>128	16
	<i>S. maltophilia</i> SMA019	0.38	64	8	32	8
	<i>E. faecalis</i> EFS008	0.38	>128	64	4	0.5
	<i>S. aureus</i> SA014 MRSA	0.53	32	1	8	4
MBI 11D18CN	<i>A. baumannii</i> ABI001	0.27	64	16	32	0.5
	<i>A. baumannii</i> ABI002	0.56	16	8	32	2
	<i>E. coli</i> ECO006	0.27	64	16	8	0.125
	<i>K. pneumonia</i> KP020	0.50	64	32	32	0.125
	<i>P. aeruginosa</i> PA022	0.52	16	8	8	0.125
	<i>P. aeruginosa</i> PA041	0.14	8	0.125	64	8
	<i>S. maltophilia</i> SMA016	0.38	128	16	64	16
	<i>S. maltophilia</i> SMA019	0.19	32	4	8	0.5
	<i>E. faecium</i> EFM004	0.05	>128	8	8	0.125
	<i>E. faecalis</i> EFS008	0.19	128	8	2	0.25
	<i>S. aureus</i> SA014 MRSA	0.13	32	2	2	0.125
	<i>S. aureus</i> SA025 MRSA	0.14	64	1	1	0.125
	<i>S. epidermidis</i> SE071	0.27	16	4	8	0.125
	<i>S. epidermidis</i> SE074	0.09	64	4	4	0.125
MBI 21A2	<i>A. baumannii</i> ABI002	0.56	32	16	8	0.5
	<i>P. aeruginosa</i> PA022	0.50	32	8	8	2
	<i>S. maltophilia</i> SMA019	0.50	64	16	16	4
	<i>S. maltophilia</i> SMA020	0.50	64	16	16	4
	<i>S. maltophilia</i> SMA021	0.50	64	16	16	4
	<i>S. aureus</i> SA025 MRSA	0.63	64	32	8	1
MBI 26	<i>A. baumannii</i> ABI001	0.50	64	16	8	2
	<i>A. baumannii</i> ABI002	0.53	16	0.5	8	4
	<i>P. aeruginosa</i> PA041	0.63	8	1	64	32
	<i>S. maltophilia</i> SMA016	0.25	>128	32	>128	32
	<i>S. maltophilia</i> SMA017	0.38	64	16	16	2

MBI 27	<i>A. baumannii</i> ABI002	0.52	32	0.5	8	4
	<i>P. aeruginosa</i> PA022	0.52	32	16	8	0.125
	<i>S. maltophilia</i> SMA016	0.50	>128	64	64	16
	<i>S. maltophilia</i> SMA017	0.52	128	64	8	0.125
	<i>E. faecalis</i> EFS008	0.38	>128	64	4	0.5
	<i>S. aureus</i> SA014 MRSA	0.50	32	0.125	2	1
MBI 29	<i>S. maltophilia</i> SMA019	0.53	32	16	4	0.125
	<i>S. maltophilia</i> SMA020	0.53	32	16	4	0.125
	<i>E. faecalis</i> EFS008	0.38	128	32	1	0.125
	<i>S. epidermidis</i> SE074	0.50	128	0.5	4	2
MBI 29A3	<i>S. maltophilia</i> SMA019	0.31	64	16	2	0.125
	<i>S. maltophilia</i> SMA021	0.31	64	16	2	0.125
MBI 29F1	<i>P. aeruginosa</i> PA023	0.52	8	0.125	128	64
	<i>S. maltophilia</i> SMA016	0.56	>128	16	32	16
	<i>S. maltophilia</i> SMA017	0.53	64	32	4	0.125
Deber A2KA2	<i>A. baumannii</i> ABI001	0.53	64	32	>128	8
	<i>A. baumannii</i> ABI002	0.50	64	32	>128	0.125
	<i>A. calcoaceticus</i> AC001	0.56	8	4	>128	16
	<i>P. aeruginosa</i> PA022	0.52	32	16	>128	4
	<i>P. aeruginosa</i> PA041	0.50	16	8	>128	0.125
	<i>S. maltophilia</i> SMA017	0.50	128	64	>128	0.125
	<i>S. maltophilia</i> SMA020	0.50	128	64	>128	0.125

### 5. Mupirocin

Peptide	Organism	FIC	Mupirocin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Mupirocin
MBI 11A1CN	<i>E. coli</i> SBECO2	0.05	>100	30	128	2
	<i>E. coli</i> ECO1	0.14	>100	10	32	4
MBI 11A3CN	<i>E. coli</i> SBECO1	0.43	100	30	64	8
MBI 11B4CN	<i>E. coli</i> SBECO1	0.36	100	30	8	0.5
	<i>E. coli</i> SBECO2	0.09	>100	30	32	2
MBI 11D18CN	<i>E. coli</i> SBECO1	0.36	100	30	2	0.125
	<i>E. coli</i> SBECO2	0.06	>100	30	16	0.5
	<i>P. aeruginosa</i> SBPA1	0.35	>100	100	128	32
	<i>P. aeruginosa</i> PA4	0.53	>100	30	128	64
	<i>S. marcescens</i> SBSM1	0.16	>100	100	>128	16
	<i>S. marcescens</i> SBSM2	0.35	>100	100	>128	64
MBI 11G13CN	<i>E. coli</i> SBECO2	0.16	>100	30	64	8
	<i>E. coli</i> ECO5	0.43	100	30	64	8
MBI 21A1	<i>E. coli</i> SBECO2	0.28	>100	30	8	2
	<i>E. coli</i> ECO3	0.28	100	3	8	2
	<i>P. aeruginosa</i> SBPA1	0.53	>100	30	64	32

MBI 26	<i>E. coli</i> SBEKO2	0.16	>100	30	8	1
	<i>E. coli</i> ECO5	0.43	100	30	8	1
	<i>P. aeruginosa</i> PA2	0.51	>100	10	128	64
	<i>P. aeruginosa</i> PA4	0.23	>100	100	>128	32
	<i>S. aureus</i> SBSA4	0.28	>100	30	32	8
MBI 27	<i>E. coli</i> SBEKO2	0.51	>100	10	4	2
	<i>P. aeruginosa</i> PA2	0.25	>100	0.1	64	16
	<i>P. aeruginosa</i> PA4	0.50	>100	0.3	32	16
	<i>S. aureus</i> SBSA3	0.23	100	10	16	2
	<i>S. aureus</i> SBSA4	0.50	>100	0.3	4	2
MBI 28	<i>E. coli</i> SBEKO1	0.50	100	0.1	4	2
	<i>E. coli</i> ECO2	0.33	100	30	4	0.125
	<i>P. aeruginosa</i> SBPA1	0.53	>100	30	32	16
	<i>P. aeruginosa</i> PA4	0.50	>100	3	32	16
	<i>S. aureus</i> SBSA4	0.51	>100	10	4	2
MBI 29	<i>S. marcescens</i> SBSM1	0.23	>100	100	>128	32
	<i>S. aureus</i> SBSA3	0.35	100	10	16	4
	<i>S. aureus</i> SBSA4	0.51	>100	10	4	2
MBI 29A3	<i>P. aeruginosa</i> PA2	0.50	>100	0.1	32	16
	<i>P. aeruginosa</i> PA3	0.50	>100	0.1	16	8
	<i>S. marcescens</i> SBSM1	0.16	>100	100	>128	16
	<i>S. marcescens</i> SBSM2	0.35	>100	100	>128	64

## 6. Piperacillin

Peptide	Organism	FIC	Piperacillin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Piperacillin
MBI 11B7CN	<i>E. cloacae</i> 6	0.56	>128	16	32	16
	<i>E. cloacae</i> 9	0.50	>128	1	32	16
	<i>E. cloacae</i> 10	0.50	>128	0.5	32	16
	<i>S. maltophilia</i> 5	0.50	>128	64	>128	64
	<i>S. maltophilia</i> 9	0.50	>128	64	>128	64
	<i>S. maltophilia</i> 11	0.38	>128	64	>128	32
	<i>S. marcescens</i> 1	0.27	32	8	>128	4
	<i>P. aeruginosa</i> 23	0.56	32	2	128	64
	<i>H. influenzae</i> 1	0.50	64	32	>128	0.125
	<i>H. influenzae</i> SB1	0.50	0.5	0.25	>128	0.125
	<i>S. aureus</i> 19 MRSA	0.50	128	32	4	1

MBI 11B9CN	<i>A. calcoaceticus</i> 3	0.56	64	32	32	2
	<i>S. maltophilia</i> 5	0.50	>128	64	>128	64
	<i>S. maltophilia</i> 13	0.38	>128	64	>128	32
	<i>S. marcescens</i> SB1	0.26	64	16	>128	2
	<i>P. aeruginosa</i> 15	0.50	>128	64	>128	64
	<i>P. aeruginosa</i> 23	0.13	128	16	64	0.5
	<i>H. influenzae</i> 3	0.50	0.5	0.25	>128	0.125
	<i>H. influenzae</i> SB1	0.50	0.5	0.25	>128	0.125
	<i>S. aureus</i> 19 MRSA	0.38	128	16	4	1
	<i>S. aureus</i> SB2MRSA	0.56	128	8	2	1
MBI 11CN	<i>P. aeruginosa</i> 22	0.52	>128	4	64	32
	<i>P. aeruginosa</i> 23	0.53	128	64	128	4
	<i>S. aureus</i> 18 MRSA	0.50	>128	0.5	32	16
	<i>S. aureus</i> 19 MRSA	0.38	>128	64	8	1
MBI 11D18CN	<i>A. calcoaceticus</i> 3	0.38	64	8	32	8
	<i>E. cloacae</i> 9	0.31	>128	16	64	16
	<i>E. cloacae</i> 10	0.50	>128	64	32	8
	<i>S. maltophilia</i> 2	0.50	64	16	32	8
	<i>S. marcescens</i> 1	0.14	64	8	>128	4
	<i>P. aeruginosa</i> 23	0.38	128	32	64	8
	<i>P. aeruginosa</i> 41	0.56	64	32	>128	16
	<i>H. influenzae</i> 3	0.53	0.5	0.25	>128	8
	<i>H. influenzae</i> SB1	0.52	0.5	0.25	>128	4
	<i>S. aureus</i> 19 MRSA	0.38	128	16	4	1
	<i>S. aureus</i> SB2MRSA	0.50	128	32	2	0.5
	<i>S. maltophilia</i> 11	0.51	>128	2	128	64
MBI 11E3CN	<i>S. marcescens</i> SB1	0.26	64	16	>128	2
	<i>P. aeruginosa</i> 23	0.27	128	32	64	1
	<i>P. aeruginosa</i> 32	0.63	64	32	64	8
	<i>H. influenzae</i> 1	0.52	64	32	>128	4
	<i>H. influenzae</i> 2	0.31	32	8	>128	16
	<i>S. aureus</i> 19 MRSA	0.50	>128	64	4	1
	<i>P. aeruginosa</i> 23	0.51	128	64	64	0.5
MBI 11F3CN	<i>P. aeruginosa</i> 41	0.63	32	4	128	64
	<i>S. aureus</i> 19 MRSA	0.38	>128	32	4	1
	<i>S. aureus</i> SB3MRSA	0.50	>128	64	8	2
	<i>E. cloacae</i> 10	0.52	>128	4	16	8
MBI 11F4CN	<i>S. maltophilia</i> 2	0.53	64	32	16	0.5
	<i>S. marcescens</i> 1	0.25	>128	64	>128	0.5
	<i>P. aeruginosa</i> 7	0.38	>128	64	64	8
	<i>P. aeruginosa</i> 23	0.31	>128	64	64	4
	<i>H. influenzae</i> SB1	0.50	0.5	0.25	>128	0.125
	<i>S. aureus</i> 19 MRSA	0.53	128	4	4	2

MBI 11G7CN	<i>A. calcoaceticus</i> 3	0.50	128	32	64	16
	<i>S. marcescens</i> 1	0.25	64	16	>128	1
	<i>P. aeruginosa</i> 7	0.50	>128	64	>128	64
	<i>P. aeruginosa</i> 23	0.50	128	64	>128	1
	<i>H. influenzae</i> SB1	0.52	0.5	0.25	>128	4
	<i>S. aureus</i> 18 MRSA	0.50	>128	64	32	8
	<i>S. aureus</i> 19 MRSA	0.56	128	64	8	0.5
MBI 21A2	<i>E. coli</i> 1	0.53	>128	8	4	2
	<i>S. maltophilia</i> 6	0.38	>128	64	128	16
	<i>S. maltophilia</i> 14	0.53	128	4	32	16
	<i>S. marcescens</i> 1	0.27	64	16	>128	4
	<i>P. aeruginosa</i> 23	0.19	64	8	>128	16
	<i>H. influenzae</i> 1	0.31	64	4	>128	64
	<i>H. influenzae</i> 2	0.38	128	32	>128	32
	<i>S. aureus</i> 19 MRSA	0.51	128	64	>128	2
	<i>S. aureus</i> SB2MRSA	0.56	128	64	32	2
MBI 26	<i>S. maltophilia</i> 3	0.50	128	32	16	4
	<i>S. marcescens</i> 1	0.50	64	32	>128	0.5
	<i>P. aeruginosa</i> 7	0.25	>128	32	>128	32
	<i>P. aeruginosa</i> 41	0.53	64	32	128	4
	<i>H. influenzae</i> 1	0.53	64	32	>128	8
	<i>H. influenzae</i> 2	0.51	128	64	>128	2
	<i>S. aureus</i> 19 MRSA	0.16	128	16	32	1
	<i>S. aureus</i> SB3MRSA	0.31	128	64	>128	16
	<i>A. calcoaceticus</i> 7	0.25	32	4	>32	8
	<i>A. calcoaceticus</i> 8	0.19	64	4	>32	8
	<i>E. cloacae</i> 13	0.16	128	4	>32	8
	<i>P. aeruginosa</i> 23	0.27	256	4	>64	32
	<i>P. aeruginosa</i> 28	0.14	>512	16	>128	32
	<i>S. maltophilia</i> 34	0.25	>512	4	>32	16
	<i>S. maltophilia</i> 35	0.26	>256	4	>32	16

MBI 29	<i>S. marcescens</i> 1	0.14	64	32	>128	4
	<i>P. aeruginosa</i> 7	0.53	128	4	16	8
	<i>P. aeruginosa</i> 23	0.50	128	32	16	4
	<i>P. aeruginosa</i> 41	0.56	64	32	64	4
	<i>H. influenzae</i> 1	0.51	32	16	16	0.125
	<i>S. aureus</i> 11 MRSA	0.50	>128	0.5	16	8
	<i>A. calcoaceticus</i> 2	0.50	>512	4	16	8
	<i>A. calcoaceticus</i> 7	0.25	32	4	>16	4
	<i>E. cloacae</i> 16	0.50	>512	4	>16	16
	<i>E. cloacae</i> 17	0.50	>512	4	>16	16
	<i>P. aeruginosa</i> 28	0.13	>512	8	>64	16
	<i>P. aeruginosa</i> 29	0.27	512	8	>32	16
	<i>S. maltophilia</i> 34	0.25	>512	4	>16	8
	<i>S. maltophilia</i> 38	0.28	>512	32	>32	16
	<i>S. maltophilia</i> 40	0.25	>512	4	>32	16
	<i>S. maltophilia</i> 42	0.25	>512	4	>16	8

### 7. Tobramycin

Peptide	Organism	FIC	Tobramycin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Tobramycin
MBI 11A1CN	<i>P. aeruginosa</i> PA026	0.50	8	4	>128	0.125
	<i>P. aeruginosa</i> PA032	0.50	16	8	>128	0.5
	<i>S. maltophilia</i> SMA029	0.16	128	4	>128	32
	<i>S. maltophilia</i> SMA030	0.27	128	2	>128	64
	<i>S. aureus</i> SA014	0.50	>128	0.125	16	8
	<i>S. aureus</i> SA025	0.50	>128	0.125	8	4
	<i>S. haemolyticus</i> SHA001	0.52	4	2	8	0.125
	<i>S. haemolyticus</i> SHA005	0.51	8	4	16	0.125
MBI 11B9CN	<i>A. baumannii</i> ABI001	0.50	16	4	32	8
	<i>B. cepacia</i> BC002	0.38	>128	64	>128	32
	<i>P. aeruginosa</i> PA008	0.50	32	0.125	128	64
	<i>P. aeruginosa</i> PA025	0.56	32	2	128	64
	<i>S. maltophilia</i> SMA029	0.13	64	4	>128	16
MBI 11CN	<i>A. baumannii</i> ABI001	0.50	16	4	64	16
	<i>E. coli</i> ECO006	0.53	8	4	8	0.25
	<i>P. aeruginosa</i> PA032	0.52	16	8	>128	4
	<i>S. maltophilia</i> SMA029	0.51	128	64	>128	2
	<i>S. maltophilia</i> SMA035	0.38	32	4	128	32
MBI 11D18CN	<i>A. baumannii</i> ABI001	0.31	16	4	64	4
	<i>A. baumannii</i> ABI002	0.53	8	4	16	0.5
	<i>S. maltophilia</i> SMA027	0.19	32	4	>128	16
	<i>S. maltophilia</i> SMA029	0.16	128	4	32	4
	<i>S. aureus</i> SA018 MRSA	0.56	64	4	32	16
	<i>S. haemolyticus</i> SHA001	0.53	4	0.125	2	1

MBI 11F3CN	<i>A. baumannii</i> ABI001	0.53	16	0.5	32	16
	<i>A. baumannii</i> ABI002	1.00	4	2	16	8
	<i>P. aeruginosa</i> PA032	0.50	16	4	>128	64
	<i>S. maltophilia</i> SMA029	0.28	128	32	128	4
	<i>S. maltophilia</i> SMA030	0.26	128	1	128	32
	<i>S. aureus</i> SA014 MRSA	0.51	>128	2	4	2
	<i>S. haemolyticus</i> SHA005	0.56	4	0.25	4	2
MBI 11G13CN	<i>A. baumannii</i> ABI001	0.50	16	4	128	32
	<i>P. aeruginosa</i> PA022	0.56	8	4	>128	16
	<i>S. maltophilia</i> SMA029	0.50	128	64	>128	0.125
	<i>S. maltophilia</i> SMA030	0.50	128	64	>128	0.125
	<i>S. aureus</i> SA025 MRSA	0.50	>128	0.125	4	2
MBI 21A1	<i>B. cepacia</i> BC001	0.25	128	32	>128	0.25
	<i>P. aeruginosa</i> PA022	0.53	8	4	4	0.125
	<i>P. aeruginosa</i> PA026	0.51	8	4	16	0.125
	<i>S. maltophilia</i> SMA029	0.28	128	4	128	32
	<i>S. maltophilia</i> SMA030	0.16	128	4	>128	32
	<i>S. aureus</i> SA014 MRSA	0.50	>128	0.125	32	16
	<i>S. aureus</i> SA025 MRSA	0.50	>128	0.125	2	1
	<i>S. haemolyticus</i> SHA001	0.50	2	0.5	16	4
	<i>S. haemolyticus</i> SHA005	0.38	4	1	32	4
MBI 22A1	<i>S. maltophilia</i> SMA030	0.26	128	1	32	8
	<i>S. maltophilia</i> SMA031	0.25	128	0.5	32	8
	<i>S. aureus</i> SA014 MRSA	0.27	>128	4	8	2
	<i>S. epidermidis</i> SE072	0.50	>128	0.125	16	8
	<i>S. epidermidis</i> SE073	0.50	>128	0.125	16	8
	<i>S. epidermidis</i> SE080	0.56	32	16	2	0.125
MBI 26	<i>S. maltophilia</i> SMA029	0.05	128	4	>128	4
	<i>S. maltophilia</i> SMA030	0.05	128	4	>128	4
	<i>S. epidermidis</i> SE067	0.38	>128	64	2	0.25
	<i>S. epidermidis</i> SE068	0.27	>128	4	2	0.5
MBI 27	<i>E. coli</i> ECO006	0.56	8	0.5	8	4
	<i>S. maltophilia</i> SMA029	0.50	64	16	16	4
	<i>S. maltophilia</i> SMA031	0.53	128	4	16	8
MBI 29	<i>A. baumannii</i> ABI001	0.53	16	8	4	0.125
	<i>E. coli</i> ECO004	0.53	2	1	4	0.125
	<i>E. coli</i> ECO006	0.53	8	4	4	0.125
	<i>K. pneumoniae</i> KP008	0.52	0.5	0.25	8	0.125
	<i>P. aeruginosa</i> PA030	0.52	16	8	8	0.125
	<i>S. maltophilia</i> SMA031	0.50	>128	0.25	16	8
	<i>S. maltophilia</i> SMA032	0.53	128	4	16	8
	<i>S. epidermidis</i> SE072	0.53	>128	8	16	8

MBI 29A3	<i>P. aeruginosa</i> PA022	0.56	8	4	4	0.25
	<i>P. aeruginosa</i> PA028	0.50	32	16	32	0.125
	<i>P. aeruginosa</i> PA029	0.51	32	16	16	0.125
	<i>S. maltophilia</i> SMA029	0.28	128	4	16	4
	<i>S. maltophilia</i> SMA030	0.28	128	4	16	4
REWH 53A5CN	<i>S. maltophilia</i> SMA029	0.08	128	2	>128	16
	<i>S. maltophilia</i> SMA030	0.13	128	0.25	>128	32
	<i>S. aureus</i> SA014 MRSA	0.50	>128	0.125	16	8

## 8. Vancomycin

Peptide	Organism	FIC	Vancomycin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Vancomycin
MBI 11A1CN	<i>E. faecalis</i> EFS001	0.53	1	0.5	4	0.125
	<i>E. faecalis</i> EFS006	0.50	8	4	128	0.25
	<i>E. faecalis</i> EFS007	0.50	4	2	128	0.5
	<i>E. faecalis</i> EFS010	0.27	16	4	128	2
	<i>E. faecalis</i> EFS012	0.25	>128	32	64	8
	<i>E. faecalis</i> EFS014	0.51	128	1	4	2
	<i>E. faecium</i> EFM004	0.50	>128	0.5	32	16
	<i>E. faecium</i> EFM007	0.28	128	4	64	16
	<i>E. faecium</i> EFM009	0.25	32	4	64	8
	<i>E. faecalis</i> EFS001	0.38	1	0.125	8	2
MBI 11D18CN	<i>E. faecalis</i> EFS004	0.50	2	0.5	8	2
	<i>E. faecalis</i> EFS011	0.50	64	32	64	0.125
	<i>E. faecalis</i> EFS012	0.38	>128	64	16	2
	<i>E. faecalis</i> EFS014	0.16	128	4	4	0.5
	<i>E. faecium</i> EFM004	0.50	>128	64	8	2
	<i>E. faecium</i> EFM009	0.52	64	32	8	0.125
	<i>E. faecium</i> EFM010	0.28	>128	64	8	0.25
	<i>E. faecium</i> EFM011	0.50	>128	64	8	2
	<i>E. faecalis</i> EFS007	0.56	2	1	16	1
MBI 21A1	<i>E. faecalis</i> EFS012	0.16	128	16	32	1
	<i>E. faecalis</i> EFS013	0.28	128	32	32	1
	<i>E. faecium</i> EFM010	0.56	64	32	32	2
	<i>E. faecalis</i> EFS005	0.31	16	4	>128	16
MBI 26	<i>E. faecalis</i> EFS012	0.07	>128	2	16	1
	<i>E. faecalis</i> EFS013	0.07	>128	2	16	1
	<i>E. faecium</i> EFM010	0.31	32	2	32	8
	<i>E. faecium</i> EFM011	0.31	32	2	32	8
	<i>E. faecium</i> EFM012	0.31	32	2	64	16
	<i>E. faecium</i> EFM014	0.27	>128	4	32	8
	<i>E. faecium</i> EFM016	0.51	128	1	8	4

MBI 29	<i>E. faecalis</i> EFS005	0.38	16	4	32	4
	<i>E. faecalis</i> EFS010	0.38	64	16	2	0.25
	<i>E. faecalis</i> EFS012	0.50	>128	64	2	0.5
	<i>E. faecium</i> EFM005	0.53	128	4		4
	<i>E. faecium</i> EFM016	0.51	128	1	4	2
MBI 29A3	<i>E. faecalis</i> EFS003	0.56	4	2	32	2
	<i>E. faecalis</i> EFS005	0.28	16	4	32	1
	<i>E. faecalis</i> EFS011	0.50	16	4	32	8
	<i>E. faecalis</i> EFS014	0.52	64	1	1	0.5
	<i>E. faecium</i> EFM006	0.52	>128	4	4	2

### EXAMPLE 5

#### OVERCOMING TOLERANCE BY ADMINISTERING A COMBINATION OF ANTIBIOTIC AGENT AND CATIONIC PEPTIDE

5 Tolerance to an antibiotic agent is associated with a defect in bacterial cellular autolytic enzymes such that an antimicrobial agent is bacteriostatic rather than bactericidal. Tolerance is indicated when a ratio of minimum bactericidal concentration (MBC) to minimum inhibitory concentration (MIC) (MBC:MIC) is  $\geq 32$ .

10 The agarose dilution assay is adapted to provide both the MBC and MIC for an antimicrobial agent alone and an agent in combination with a peptide. Following determination of MIC, MBC is determined from the agarose dilution assay plates by swabbing the inocula on plates at and above the MIC and resuspending the swab in 1.0 ml of saline. A 0.01 ml aliquot is plated on agarose medium (subculture plates) and the resulting colonies are counted. If the number of colonies is less than 0.1% of the initial inoculum (as 15 determined by a plate count immediately after inoculation of the MIC test plates), then  $\geq 99.9\%$  killing has occurred. The MBC end point is defined as the lowest concentration of the antimicrobial agent that kills 99.9% of the test bacteria.

20 Thus, tolerance of a microorganism to an antimicrobial agent occurs when the number of colonies growing on subculture plates exceeds the 0.1% cutoff for several successive concentrations above the observed MIC. A combination of antimicrobial agent and cationic peptide that breaks tolerance results in a decrease in the MBC:MIC ratio to  $< 32$ . Table 13 shows that the combination of Vancomycin and MBI 26 overcomes the tolerance of the organisms listed.

Table 13

Organism	Vancomycin			Vancomycin + MBI 26		
	MIC ( $\mu$ g/ml)	MBC ( $\mu$ g/ml)	MBC/MIC	MIC ( $\mu$ g/ml)	MBC ( $\mu$ g/ml)	MBC/MIC
<i>E. casseliflavus</i> ECA001	2	>128	>64	0.5	2	4
<i>E. faecium</i> EFM001	0.5	>128	>256	0.5	0.5	1
<i>E. faecium</i> EFM020	1	>128	>128	0.5	4	8
<i>E. faecalis</i> EFS001	1	>128	>128	0.5	4	8
<i>E. faecalis</i> EFS004	1	>128	>128	1	2	2
<i>E. faecalis</i> EFS007	4	128	32	2	2	1
<i>E. faecalis</i> EFS009	4	>128	>32	4	4	1
<i>E. faecalis</i> EFS015	1	>128	>128	0.5	0.5	1

EXAMPLE 65      OVERCOMING INHERENT RESISTANCE BY ADMINISTERING A COMBINATION OF  
ANTIBIOTIC AGENT AND CATIONIC PEPTIDE

Peptides are tested for their ability to overcome the inherent antimicrobial resistance of microorganisms, including those encountered in hospital settings, to specific 10 antimicrobials. Overcoming resistance is demonstrated when the antibiotic agent alone exhibits minimal or no activity against the microorganism, but when used in combination with a cationic peptide, results in susceptibility of the microorganism.

The agarose dilution assay described above is used to determine the minimum inhibitory concentration (MIC) of antimicrobial agents and cationic peptides, alone and in 15 combination. Alternatively, the broth dilution assay or time kill curves can be used to determine MICs. Tables 14-17 present MIC values for antibiotic agents alone and in combination with peptide at the concentration shown. In all cases, the microorganism is inherently resistant to its mode of action, thus, the antibiotic agent is not effective against the test microorganism. In addition, the antibiotic agent is not clinically prescribed against the 20 test microorganism.

In the data presented below, the MIC values for the antibiotic agents when administered in combination with peptide are decreased, from equal to or above the resistant breakpoint to below it.

69  
Table 14

Microorganism	Erythromycin MIC (µg/ml)		MBI 26 MIC (µg/ml)	
	Alone	+ MBI 26	Alone	+ Erythro.
<i>A. calcoaceticus</i> AC001	32	1	16	8
<i>K. pneumoniae</i> KP001	32	0.25	16	8
<i>K. pneumoniae</i> KP002	256	0.5	64	32
<i>P. aeruginosa</i> PA041	128	4	64	32

Table 15

Microorganism	Vancomycin MIC (µg/ml)		MBI 26 MIC (µg/ml)	
	Alone	+ MBI 26	Alone	+ Vancomycin
<i>E. gallinarum</i> 97044 VanC	8	2	8	0.5
<i>E. gallinarum</i> 97046 VanC	32	1	2	4
<i>E. gallinarum</i> 97047 VanC	128	16	64	8
<i>E. gallinarum</i> 97048 VanC	32	4	2	2
<i>E. gallinarum</i> 97049 VanC	128	4	64	16
<i>E. casseliflavus</i> 97056 VanC	8	2	8	1
<i>E. casseliflavus</i> 97057 VanC	4	2	2	0.5
<i>E. casseliflavus</i> 97058 VanC	2	1	4	0.25
<i>E. casseliflavus</i> 97059 VanC	4	2	32	0.5
<i>E. casseliflavus</i> 97060 VanC	2	2	0.5	0.25

5

Table 16

Microorganism	Teicoplanin MIC (µg/ml)		MBI 26 MIC (µg/ml)	
	Alone	+ MBI 26	Alone	+ Vancomycin
<i>E. gallinarum</i> 97044 VanC	0.5	0.25	64	1
<i>E. gallinarum</i> 97046 VanC	1	0.25	8	1
<i>E. gallinarum</i> 97047 VanC	8	0.25	64	32
<i>E. gallinarum</i> 97048 VanC	0.5	0.25	8	1
<i>E. gallinarum</i> 97049 VanC	2	0.25	64	32
<i>E. casseliflavus</i> 97056 VanC	0.5	0.25	64	2
<i>E. casseliflavus</i> 97057 VanC	0.5	0.25	64	0.5
<i>E. casseliflavus</i> 97058 VanC	0.5	0.25	32	0.5
<i>E. casseliflavus</i> 97059 VanC	0.5	0.25	64	1
<i>E. casseliflavus</i> 97060 VanC	0.5	0.25	64	1

Table 17

## 1. Amikacin

Peptide	Organism	FIC	Amikacin MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Amikacin
MBI 11B16CN	<i>A. baumannii</i> ABI001	0.25	32	4	32	4
	<i>S. maltophilia</i> SMA018	0.31	128	8	32	8
	<i>S. maltophilia</i> SMA022	0.14	>128	4	>128	32
	<i>S. aureus</i> SA014 MRSA	0.75	32	8	8	4
	<i>S. aureus</i> SA025 MRSA	0.63	32	4	8	4
MBI 21A2	<i>S. maltophilia</i> SMA018	0.53	>128	8	16	8
	<i>S. maltophilia</i> SMA060	0.31	>128	16	>128	64
	<i>S. aureus</i> SA025 MRSA	0.56	32	2	2	1
MBI 26	<i>S. maltophilia</i> SMA022	0.19	128	8	64	8
	<i>S. maltophilia</i> SMA037	0.19	128	16	>128	16
MBI 27	<i>A. baumannii</i> ABI001	1.00	32	16	8	4
	<i>B. cepacia</i> BC005	0.50	64	16	>128	64
	<i>S. maltophilia</i> SMA036	0.56	>128	16	64	32
	<i>S. maltophilia</i> SMA037	0.31	64	4	64	16
	<i>S. aureus</i> SA025 MRSA	0.75	32	16	2	0.5
MBI 29A3	<i>B. cepacia</i> BC003	0.63	32	16	>128	32
	<i>B. cepacia</i> BC005	0.38	128	32	>128	32
	<i>S. maltophilia</i> SMA036	0.53	>128	8	64	32
	<i>S. maltophilia</i> SMA063	0.56	>128	16	8	4
MBI 29F1	<i>A. baumannii</i> ABI001	0.75	32	16	8	2
	<i>S. maltophilia</i> SMA018	0.56	128	8	4	2
	<i>S. maltophilia</i> SMA021	0.31	128	8	8	2
	<i>S. aureus</i> SA014 MRSA	0.53	32	16	4	0.125
	<i>S. aureus</i> SA025 MRSA	0.63	32	16	1	0.125
Deber A2KA2	<i>A. baumannii</i> ABI001	0.63	32	16	>128	32
	<i>S. aureus</i> SA025 MRSA	0.50	32	0.125	16	8

## 2. Ceftriaxone

Peptide	Organism	FIC	Ceftriaxone MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Ceftriaxone
MBI 11B7CN	<i>P. aeruginosa</i> PA008	0.50	128	0.125	128	64
	<i>S. maltophilia</i> SMA021	0.50	>128	1	32	16
	<i>S. maltophilia</i> SMA023	0.56	128	8	128	64
MBI 11J02CN	<i>P. aeruginosa</i> PA008	0.50	64	0.125	64	32
	<i>P. aeruginosa</i> PA039	0.52	64	1	64	32
MBI 26	<i>P. aeruginosa</i> PA008	0.13	64	8	128	0.125
	<i>P. aeruginosa</i> PA024	0.50	16	4	128	32
	<i>S. maltophilia</i> SMA021	0.25	>128	1	8	2

5

## 3. Gentamicin

Peptide	Organism	FIC	Gentamicin MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Gentamicin
MBI 11B16CN	<i>S. aureus</i> SA014 MRSA	0.53	32	1	8	4
MBI 27	<i>S. aureus</i> SA014 MRSA	0.50	32	0.125	2	1

## 4. Mupirocin

Peptide	Organism	FIC	Mupirocin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Mupirocin
MBI 11B4CN	<i>E. coli</i> ECO3	0.53	100	3	16	8
MBI 11D18CN	<i>E. coli</i> ECO3	0.26	100	1	4	1
MBI 21A1	<i>E. coli</i> ECO1	0.50	>100	3	2	1
	<i>E. coli</i> ECO2	0.53	100	3	2	1
	<i>E. coli</i> ECO3	0.28	100	3	8	2
MBI 26	<i>E. coli</i> ECO1	0.50	>100	3	2	1
MBI 27	<i>P. aeruginosa</i> PA2	0.25	>100	0.1	64	16
	<i>P. aeruginosa</i> PA4	0.50	>100	0.3	32	16
MBI 28	<i>E. coli</i> SBECO1	0.50	100	0.1	4	2
	<i>P. aeruginosa</i> PA4	0.50	>100	3	32	16
MBI 29A3	<i>P. aeruginosa</i> SBPA2	0.50	>100	0.1	16	8
	<i>P. aeruginosa</i> PA2	0.50	>100	0.1	32	16
	<i>P. aeruginosa</i> PA3	0.50	>100	0.1	16	8
	<i>P. aeruginosa</i> PA4	0.50	>100	0.1	16	8

## 5. Piperacillin

Peptide	Organism	FIC	Piperacillin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Piperacillin
MBI 11B7CN	<i>S. aureus</i> 19 MRSA	0.50	128	0.5	4	2
MBI 11D18CN	<i>S. aureus</i> 19 MRSA	0.52	128	2	4	2
MBI 11E3CN	<i>S. aureus</i> 19 MRSA	0.51	>128	2	4	2
MBI 11F3CN	<i>S. aureus</i> 19 MRSA	0.51	>128	2	4	2
	<i>S. aureus</i> SB3MRSA	0.52	>128	4	8	4
MBI 11F4CN	<i>S. aureus</i> 19 MRSA	0.53	128	4	4	2
MBI 11G7CN	<i>S. aureus</i> 19 MRSA	0.25	128	0.5	8	2
MBI 21A2	<i>S. aureus</i> 19 MRSA	0.25	128	0.5	>128	64
MBI 26	<i>S. aureus</i> 19 MRSA	0.13	128	0.5	32	4
MBI 29	<i>S. aureus</i> 18 MRSA	0.52	>128	4	16	8

## 5. Tobramycin

Peptide	Organism	FIC	Tobramycin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Tobramycin
MBI 11A1CN	<i>S. aureus</i> SA014	0.50	>128	0.125	16	8
	<i>S. aureus</i> SA025	0.50	>128	0.125	8	4
	<i>S. haemolyticus</i> SHA005	0.51	8	4	16	0.125
MBI 11D18CN	<i>S. aureus</i> SA018 MRSA	0.56	64	4	32	16
MBI 11F3CN	<i>S. aureus</i> SA014 MRSA	0.51	>128	2	4	2
MBI 11G13CN	<i>S. aureus</i> SA025 MRSA	0.50	>128	0.125	4	2
MBI 21A1	<i>S. aureus</i> SA014 MRSA	0.50	>128	0.125	32	16
	<i>S. aureus</i> SA025 MRSA	0.50	>128	0.125	2	1
MBI 22A1	<i>S. aureus</i> SA014 MRSA	0.27	>128	4	8	2

EXAMPLE 7OVERCOMING ACQUIRED RESISTANCE BY ADMINISTERING A COMBINATION OF  
ANTIBIOTIC AGENT AND CATIONIC PEPTIDE

An antibiotic agent can become ineffective against a previously susceptible 5 microorganism if the microorganism acquires resistance to the agent. However, acquired resistance can be overcome when the agent is administered in combination with a cationic peptide. For example vancomycin resistant enterococci (VRE) become susceptible to vancomycin when it is used in combination with a cationic peptide such as MBI 26. This 10 combination is likely to be effective against other organisms acquiring resistance to vancomycin including but not limited to strains of methicillin resistant *S. aureus* (MRSA).

Similarly teicoplanin resistant enterococci become susceptible to teicoplanin when teicoplanin is used in combination with cationic peptides such as MBI 26.

As described previously, the agarose dilution assay is used to determine the MIC for antibiotic agents administered alone and in combination with cationic peptide. 15 Alternatively the broth dilution assay or time kill curves can be employed. Tables 18 and 19 presents results showing that administration of a cationic peptide in combination with an antibiotic agent overcomes acquired resistance. Table 20 presents results showing administration of MBI 26 in combination with teicoplanin against teicoplanin resistant enterococci.

20

Table 18

Microorganism	Strain	Antibiotic agent	MIC alone ( $\mu$ g/ml)	MIC comb. ( $\mu$ g/ml)	Peptide	Peptide MIC
<i>A. calcoaceticus</i>	002	Tobramycin	8	1	MBI 29	4
<i>A. calcoaceticus</i>	003	Ceftazidime	32	2	MBI 26	32
<i>A. calcoaceticus</i>	003	Ceftazidime	32	2	MBI 29	8
<i>A. calcoaceticus</i>	003	Ciprofloxacin	8	1	MBI 29	16
<i>A. calcoaceticus</i>	004	Ciprofloxacin	8	4	MBI 26	4
<i>A. calcoaceticus</i>	010	Ceftazidime	32	2	MBI 26	32
<i>E. faecium</i>	ATCC 29212	Mupirocin	100	0.1	MBI 11CN	8
<i>E. faecium</i>	ATCC 29212	Mupirocin	100	0.1	MBI 11G13CN	32
<i>P. aeruginosa</i>	PA41	Ciprofloxacin	4	0.125	MBI 21A1	16
<i>P. aeruginosa</i>	PA41	Ciprofloxacin	4	1	MBI 21A2	16
<i>P. aeruginosa</i>	PA41	Ciprofloxacin	8	2	MBI 28	8
<i>P. aeruginosa</i>	001	Piperacillin	128	64	MBI 27	8
<i>P. aeruginosa</i>	023	Piperacillin	128	64	MBI 29	8
<i>P. aeruginosa</i>	024	Tobramycin	64	1	MBI 29	8
<i>P. aeruginosa</i>	025	Ceftazidime	64	16	MBI 29	8

Microorganism	Strain	Antibiotic agent	MIC alone ( $\mu$ g/ml)	MIC c. mb. ( $\mu$ g/ml)	Peptide	Peptide MIC
<i>P. aeruginosa</i>	027	Imipenem	16	8	MBI 29	16
<i>P. aeruginosa</i>	028	Imipenem	16	8	MBI 29	16
<i>S. haemolyticus</i>	SH8578	Erythromycin	8	0.5	MBI 31	1
<i>S. aureus</i>	SA7338	Ampicillin	2	0.25	MBI 26	0.25
<i>S. aureus</i>	SA7609	Erythromycin	32	0.5	MBI 26	1
<i>S. aureus</i>	SA7835	Erythromycin	8	0.125	MBI 26	2
<i>S. aureus</i>	SA7795	Erythromycin	32	1	MBI 26	8
<i>S. aureus</i>	SA7796	Erythromycin	32	1	MBI 26	2
<i>S. aureus</i>	SA7795	Erythromycin	32	4	MBI 31	0.125
<i>S. aureus</i>	SA7818	Erythromycin	32	2	MBI 31	0.125
<i>S. aureus</i>	SA7796	Erythromycin	32	2	MBI 31	0.125
<i>S. aureus</i>	SA7834	Methicillin	32	8	MBI 26	4
<i>S. aureus</i>	SA7835	Methicillin	32	4	MBI 26	16
<i>S. aureus</i>	SA7796	Methicillin	16	2	MBI 31	16
<i>S. aureus</i>	SA7797	Methicillin	16	2	MBI 31	16
<i>S. aureus</i>	SA7823	Methicillin	16	2	MBI 31	0.5
<i>S. aureus</i>	SA7834	Methicillin	64	1	MBI 31	32
<i>S. aureus</i>	SA7835	Methicillin	64	2	MBI 31	16
<i>S. aureus</i>	SA007	Piperacillin	128	64	MBI 27	0.5
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.1	MBI 11D18CN	2
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.1	MBI 11G13CN	8
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.1	MBI 21A1	16
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.3	MBI 21A10	32
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.1	MBI 21A2	32
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.1	MBI 26	4
<i>S. aureus</i>	MRSA 9	Mupirocin	>100	0.1	MBI 27	2
<i>S. aureus</i>	MRSA 13	Mupirocin	100	3	MBI 10CN	4
<i>S. aureus</i>	MRSA 13	Mupirocin	100	0.1	MBI 11CN	16
<i>S. aureus</i>	MRSA 13	Mupirocin	100	3	MBI 11F1CN	8
<i>S. aureus</i>	014	Ciprofloxacin	8	0.125	MBI 21A2	4
<i>S. aureus</i>	MRSA 17	Mupirocin	>100	1 0.3	MBI 10CN	1 2
<i>S. aureus</i>	MRSA 17	Mupirocin	>100	1	MBI 11A1CN	32
<i>S. aureus</i>	MRSA 17	Mupirocin	>100	1	MBI 11G13CN	16
<i>S. aureus</i>	MRSA 17	Mupirocin	>100	0.3	MBI 27	2
<i>S. aureus</i>	MRSA 17	Mupirocin	>100	0.1	MBI 29A3	4
<i>S. aureus</i>	093	Ciprofloxacin	32	0.125	MBI 21A1	2
<i>S. aureus</i>	093	Ciprofloxacin	32	1	MBI 21A2	4
<i>S. aureus</i>	SA 7818	Methicillin	16	4	MBI 26	2
<i>S. epidermidis</i>	SE8497	Clindamycin	32	0.125	MBI 26	2
<i>S. epidermidis</i>	SE8403	Erythromycin	8	0.125	MBI 26	2
<i>S. epidermidis</i>	SE8410	Erythromycin	32	0.5	MBI 26	1
<i>S. epidermidis</i>	SE8411	Erythromycin	32	0.5	MBI 26	1
<i>S. epidermidis</i>	SE8497	Erythromycin	32	0.125	MBI 26	1
<i>S. epidermidis</i>	SE8503	Erythromycin	32	0.5	MBI 26	1
<i>S. epidermidis</i>	SE8565	Erythromycin	32	0.5	MBI 26	1
<i>S. epidermidis</i>	SE8403	Erythromycin	8	0.125	MBI 31	2
<i>S. epidermidis</i>	SE8410	Erythromycin	32	0.5	MBI 31	1
<i>S. epidermidis</i>	SE8411	Erythromycin	32	0.5	MBI 31	1
<i>S. epidermidis</i>	SE8497	Erythromycin	32	0.125	MBI 31	1

Microorganism	Strain	Antibiotic agent	MIC alone ( $\mu$ g/ml)	MIC c mb. ( $\mu$ g/ml)	Peptide	Peptide MIC
<i>S. epidermidis</i>	SE8503	Erythromycin	32	0.5	MBI 31	1
<i>S. epidermidis</i>	SE8565	Erythromycin	32	0.5	MBI 31	1
<i>S. haemolyticus</i>	SH8459	Ampicillin	0.5	0.25	MBI 26	0.25
<i>S. haemolyticus</i>	SH8472	Ampicillin	2	0.25	MBI 26	16
<i>S. haemolyticus</i>	SH8564	Ampicillin	64	0.25	MBI 26	32
<i>S. haemolyticus</i>	SH8575	Ampicillin	0.5	0.25	MBI 26	8
<i>S. haemolyticus</i>	SH8578	Ampicillin	0.5	0.25	MBI 26	4
<i>S. haemolyticus</i>	SH8597	Clindamycin	16	0.125	MBI 26	1
<i>S. haemolyticus</i>	SH8463	Erythromycin	8	0.5	MBI 26	0.5
<i>S. haemolyticus</i>	SH8472	Erythromycin	8	0.5	MBI 26	0.5
<i>S. haemolyticus</i>	SH8575	Erythromycin	32	2	MBI 26	0.5
<i>S. haemolyticus</i>	SH8578	Erythromycin	8	0.5	MBI 26	01
<i>S. haemolyticus</i>	SH8597	Erythromycin	32	0.5	MBI 26	0.5
<i>S. haemolyticus</i>	SH8463	Erythromycin	8	0.5	MBI 31	0.5
<i>S. haemolyticus</i>	SH8472	Erythromycin	8	0.5	MBI 31	0.5
<i>S. haemolyticus</i>	SH8564	Erythromycin	32	2	MBI 31	0.5
<i>S. haemolyticus</i>	SH8575	Erythromycin	32	2	MBI 31	0.5
<i>S. haemolyticus</i>	SH8563	Methicillin	64	0.25	MBI 26	2
<i>S. maltophilia</i>	034	Tobramycin	8	1	MBI 29	4
<i>S. maltophilia</i>	037	Tobramycin	32	4	MBI 29	16
<i>S. maltophilia</i>	039	Ciprofloxacin	4	2	MBI 29	16
<i>S. maltophilia</i>	041	Tobramycin	16	1	MBI 29	8
<i>S. maltophilia</i>	043	Imipenem	>256	4	MBI 29	16
<i>S. maltophilia</i>	044	Piperacillin	>512	16	MBI 26	32

75  
Table 19

Microorganism	Strain	Teicoplanin (µg/ml)		MBI 26 (µg/ml)	
		Alone	+ MBI 26	Alone	+ Teicoplanin
<i>E. faecium</i> 97017	VanA	32	0.25	64	4
<i>E. faecium</i> 97018	VanA	32	0.25	64	8
<i>E. faecium</i> 97019	VanA	32	0.5	64	16
<i>E. faecium</i> 97020	VanA	32	0.5	64	16
<i>E. faecium</i> 97021	VanA	32	0.5	64	32
<i>E. faecium</i> 97022	VanA	32	0.5	64	4
<i>E. faecium</i> 97023	VanA	32	0.25	64	4
<i>E. faecium</i> 97024	VanA	32	0.25	64	8
<i>E. faecium</i> 97025	VanA	32	0.5	16	4
<i>E. faecium</i> 97026	VanA	32	0.5	64	16
<i>E. faecium</i> 97027	VanA	32	8	64	8
<i>E. faecium</i> 97028	VanA	32	0.25	8	8
<i>E. faecium</i> 97029	VanA	32	0.25	64	8
<i>E. faecium</i> 97030	VanA	32	0.25	64	32
<i>E. faecium</i> 97031	VanA	32	0.25	64	32
<i>E. faecium</i> 97032	VanA	32	0.25	64	8
<i>E. faecium</i> 97033	VanA	32	0.25	64	8
<i>E. faecium</i> 97034	VanA	32	0.25	64	8
<i>E. faecium</i> 97035	VanA	32	0.25	64	0.5
<i>E. faecium</i> 97036	VanA	8	0.25	8	4
<i>E. faecalis</i> 97050	VanA	32	0.25	64	8
<i>E. faecalis</i> 97051	VanA	32	0.25	64	8
<i>E. faecalis</i> 97052	VanA	32	0.25	64	8
<i>E. faecalis</i> 97053	VanA	32	0.25	64	8
<i>E. faecalis</i> 97054	VanA	32	0.25	64	8
<i>E. faecalis</i> 97055	VanA	32	0.25	64	8

Table 20

## 1. Amikacin

Peptide	Organism	FIC	Amikacin MIC ( $\mu\text{g/ml}$ )		Peptide MIC ( $\mu\text{g/ml}$ )	
			Alone	+ Peptide	Alone	+ Amikacin
MBI 11B16CN	<i>P. aeruginosa</i> PA022	0.38	64	8	64	16
MBI 21A2	<i>P. aeruginosa</i> PA022	0.50	64	16	8	2
	<i>E. faecium</i> EFM020	0.56	32	2	128	64
	<i>E. faecalis</i> EFS008	0.19	64	8	>128	16
MBI 26	<i>E. faecium</i> EFM004	0.56	128	8	64	32
	<i>E. faecium</i> EFM020	0.75	32	8	64	32
MBI 27	<i>E. faecium</i> EFM004	0.75	64	16	16	8
	<i>E. faecium</i> EFM020	0.63	32	4	16	8
	<i>E. faecalis</i> EFS008	0.56	32	16	4	0.25
MBI 29A3	<i>E. faecium</i> EFM004	0.56	128	8	8	4
	<i>E. faecium</i> EFM020	1.00	32	16	4	2
MBI 29F1	<i>E. faecium</i> EFM004	0.53	>128	8	32	16
	<i>E. faecalis</i> EFS008	0.19	64	4	4	0.5
Deber A2KA2	<i>E. faecalis</i> EFS008	0.19	64	8	>128	16

## 2. Ceftriaxone

Peptide	Organism	FIC	Ceftriaxone MIC ( $\mu\text{g/ml}$ )		Peptide MIC ( $\mu\text{g/ml}$ )	
			Alone	+ Peptide	Alone	+ Ceftriaxone
MBI 11B7CN	<i>A. baumannii</i> ABI002	0.50	32	8	32	8
	<i>A. baumannii</i> ABI005	0.56	16	8	16	1
MBI 11J02CN	<i>A. baumannii</i> ABI005	0.56	16	8	8	0.5
	<i>A. lwoffii</i> ALW007	0.75	16	4	4	2
	<i>B. cepacia</i> BC003	0.63	16	8	>128	32
	<i>E. cloacae</i> ECL014	0.50	128	0.25	32	16
	<i>E. cloacae</i> ECL015	0.52	64	1	32	16
MBI 26	<i>A. baumannii</i> ABI005	0.53	16	0.5	2	1
	<i>A. baumannii</i> ABI006	0.56	128	8	2	1
	<i>B. cepacia</i> BC003	0.50	16	8	>128	0.125
	<i>E. cloacae</i> ECL015	0.19	64	4	32	4

5

## 3. Ciprofloxacin

Peptide	Organism	FIC	Ciprofloxacin MIC ( $\mu\text{g/ml}$ )		Peptide MIC ( $\mu\text{g/ml}$ )	
			Alone	+ Peptide	Alone	+ Ciprofloxacin
MBI 11A1CN	<i>S. aureus</i> SA10	0.50	32	0.125	128	64
	<i>S. aureus</i> SA25	0.53	4	0.125	16	8
MBI 11D18CN	<i>P. aeruginosa</i> PA77	0.50	2	0.5	128	32
MBI 21A1	<i>S. aureus</i> SA25	0.16	4	0.125	32	4
	<i>P. aeruginosa</i> PA41	0.50	4	1	16	4
	<i>P. aeruginosa</i> PA77	1.00	2	1	32	16
MBI 21A2	<i>S. aureus</i> SA25	0.56	2	1	16	1
	<i>P. aeruginosa</i> PA41	0.50	4	1	64	16
	<i>P. aeruginosa</i> PA77	0.63	2	0.25	64	32

MBI 26	<i>A. calcoaceticus</i> 5 <i>E. cloacae</i> 16 <i>E. cloacae</i> 17 <i>P. aeruginosa</i> PA41 <i>P. aeruginosa</i> PA77 <i>P. aeruginosa</i> 30 <i>P. aeruginosa</i> 31 <i>S. maltophilia</i> 34 <i>S. maltophilia</i> 35	0.38 0.38 0.38 0.50 0.56 0.09 0.27 0.25 0.50	2 2 2 4 2 4 16 2 2	0.25 0.25 0.25 1 0.125 0.25 0.25 0.25 0.5	>32 >32 >32 128 128 >32 >32 >32 >32	16 16 16 32 64 2 16 8 16
MBI 27	<i>S. aureus</i> SA25	0.75	4	1	2	1
MBI 28	<i>S. aureus</i> SA25	0.56	2	0.125	2	1
MBI 29	<i>A. calcoaceticus</i> 3 <i>A. calcoaceticus</i> 4 <i>E. cloacae</i> 16 <i>E. cloacae</i> 17 <i>S. aureus</i> SA10 <i>S. aureus</i> SA14 <i>P. aeruginosa</i> PA41 <i>P. aeruginosa</i> PA77 <i>P. aeruginosa</i> 30 <i>P. aeruginosa</i> 31 <i>S. maltophilia</i> 34 <i>S. maltophilia</i> 35	0.63 0.63 0.63 0.75 0.50 0.63 0.63 0.50 0.56 0.53 0.63 0.63	8 8 2 2 32 8 8 2 4 16 2 2	1 1 0.25 1 0.125 1 1 0.5 0.25 0.5 0.25 0.25	>16 >16 >16 16 4 8 8 64 >16 >16 >16 >16	16 16 16 4 2 4 4 16 16 16 16 16
MBI 29A2	<i>S. aureus</i> SA10 <i>S. aureus</i> SA25 <i>P. aeruginosa</i> PA41 <i>P. aeruginosa</i> PA77	0.52 0.63 1.00 1.00	32 4 4 2	0.5 0.5 2 1	4 2 8 16	2 1 4 8
MBI 29A3	<i>S. aureus</i> SA25 <i>P. aeruginosa</i> PA41	0.75 0.63	4 4	1 0.5	1 8	0.5 4

## 4. Gentamicin

Peptide	Organism	FIC	Gentamicin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Gentamicin
MBI 11B16CN	<i>A. baumannii</i> ABI001	0.31	64	4	16	4
	<i>A. baumannii</i> ABI002	0.31	32	2	16	4
	<i>A. calcoaceticus</i> AC001	0.25	8	1	32	4
	<i>P. aeruginosa</i> PA023	0.56	8	4	>128	16
	<i>P. aeruginosa</i> PA041	0.31	8	2	>128	16
	<i>S. maltophilia</i> SMA017	0.16	64	2	128	16
	<i>S. maltophilia</i> SMA019	0.51	64	0.5	32	16
MBI 21A2	<i>A. calcoaceticus</i> AC001	1.00	8	4	16	8
	<i>P. aeruginosa</i> PA022	0.56	32	2	8	4
	<i>S. maltophilia</i> SMA020	0.50	64	0.125	16	8
	<i>S. maltophilia</i> SMA021	0.50	64	0.125	16	8

MBI 26	<i>A. baumannii</i> ABI001	0.56	64	4	8	4
	<i>A. baumannii</i> ABI002	0.53	16	0.5	8	4
	<i>P. aeruginosa</i> PA023	0.75	8	4	>128	64
	<i>P. aeruginosa</i> PA041	0.75	8	4	64	16
	<i>S. maltophilia</i> SMA017	0.52	64	1	16	8
	<i>S. maltophilia</i> SMA019	0.53	64	2	4	2
MBI 27	<i>A. baumannii</i> ABI002	0.52	32	0.5	8	4
	<i>A. calcoaceticus</i> AC001	0.63	8	1	8	4
	<i>P. aeruginosa</i> PA023	0.50	16	4	32	8
	<i>P. aeruginosa</i> PA041	1.00	8	4	16	8
	<i>S. maltophilia</i> SMA019	0.50	64	0.125	8	4
	<i>S. maltophilia</i> SMA020	0.50	64	0.125	8	4
MBI 29A3	<i>A. baumannii</i> ABI002	0.75	16	4	2	1
	<i>P. aeruginosa</i> PA041	1.00	8	4	8	4
MBI 29F1	<i>A. calcoaceticus</i> AC001	0.75	8	2	8	4
	<i>P. aeruginosa</i> PA023	0.52	8	0.125	128	64
Deber A2KA2	<i>A. calcoaceticus</i> AC001	0.56	8	4	>128	16
	<i>P. aeruginosa</i> PA041	0.50	16	4	>128	64

### 5. Mupirocin

Peptide	Organism	FIC	Mupirocin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Mupirocin
MBI 27	<i>S. aureus</i> SBSA4	0.50	>100	0.3	4	2

### 6. Piperacillin

Peptide	Organism	FIC	Piperacillin MIC (µg/ml)		Peptide MIC (µg/ml)	
			Alone	+ Peptide	Alone	+ Psiperacillin
MBI 11B7CN	<i>S. maltophilia</i> 2	1.00	32	16	128	8
	<i>S. marcescens</i> 1	0.27	32	8	>128	4
	<i>H. influenzae</i> 1	0.13	64	8	>128	1
MBI 11B9CN	<i>A. calcoaceticus</i> 3	0.75	64	16	32	16
	<i>S. maltophilia</i> 2	0.75	64	16	32	16
	<i>S. marcescens</i> SB1	0.26	64	16	>128	2
	<i>P. aeruginosa</i> 12	0.75	>128	64	128	64
	<i>P. aeruginosa</i> 15	0.50	>128	64	>128	64
MBI 11CN	<i>A. calcoaceticus</i> 3	1.00	32	16	64	32
	<i>S. maltophilia</i> 2	0.75	64	16	64	32
	<i>P. aeruginosa</i> 22	0.52	>128	4	64	32
	<i>P. aeruginosa</i> 23	0.53	128	64	128	4
MBI 11D18CN	<i>A. calcoaceticus</i> 3	0.38	64	8	32	8
	<i>E. cloacae</i> 9	0.31	>128	16	64	16
	<i>E. cloacae</i> 10	0.56	>128	16	32	16
	<i>S. maltophilia</i> 2	0.50	64	16	32	8
	<i>S. maltophilia</i> 14	0.63	128	16	16	8
	<i>S. marcescens</i> 1	0.14	64	8	>128	4
	<i>P. aeruginosa</i> 23	0.56	128	64	64	4

MBI 11E3CN	<i>A. calcoaceticus</i> 3	0.75	32	16	32	8
	<i>S. maltophilia</i> 3	0.75	64	16	32	16
	<i>S. maltophilia</i> 4	0.75	64	16	32	16
	<i>S. marcescens</i> SB1	0.26	64	16	>128	2
	<i>P. aeruginosa</i> 7	1.00	128	64	64	32
	<i>P. aeruginosa</i> 23	0.27	128	32	64	1
	<i>H. influenzae</i> 1	0.38	64	8	>128	64
	<i>H. influenzae</i> 2	0.31	32	8	>128	16
MBI 11F3CN	<i>A. calcoaceticus</i> 3	0.63	32	16	32	4
	<i>S. maltophilia</i> 2	0.75	64	16	32	16
	<i>P. aeruginosa</i> 7	1.00	128	64	128	64
	<i>P. aeruginosa</i> 23	0.51	128	64	64	0.5
MBI 11F4CN	<i>E. cloacae</i> 10	0.52	>128	4	16	8
	<i>S. maltophilia</i> 2	0.50	64	16	16	4
	<i>S. marcescens</i> 1	0.08	>128	16	>128	4
	<i>P. aeruginosa</i> 7	0.38	>128	64	64	8
	<i>P. aeruginosa</i> 23	0.31	>128	64	64	4
	<i>H. influenzae</i> 1	0.75	32	16	>128	64
MBI 11G7CN	<i>A. calcoaceticus</i> 3	0.63	128	16	64	32
	<i>S. maltophilia</i> 2	0.75	64	16	64	16
	<i>S. marcescens</i> 1	0.25	64	16	>128	1
	<i>P. aeruginosa</i> 7	0.50	>128	64	>128	64
	<i>P. aeruginosa</i> 23	0.50	128	64	>128	1
	<i>H. influenzae</i> 1	0.75	32	16	>128	64
MBI 21A2	<i>E. coli</i> 1	0.53	>128	8	4	2
	<i>S. maltophilia</i> 3	0.75	64	16	32	16
	<i>S. maltophilia</i> 11	0.75	32	8	128	64
	<i>S. marcescens</i> 1	0.27	64	16	>128	4
	<i>H. influenzae</i> 1	0.31	64	4	>128	64
	<i>H. influenzae</i> 2	0.28	128	4	>128	64
MBI 26	<i>S. maltophilia</i> 2	0.75	64	16	4	2
	<i>S. maltophilia</i> 4	0.63	128	16	16	8
	<i>S. marcescens</i> 1	0.09	64	2	>128	16
	<i>P. aeruginosa</i> 7	0.25	>128	32	>128	32
	<i>H. influenzae</i> 1	0.19	64	4	>128	32
	<i>H. influenzae</i> 2	0.19	128	16	>128	16
	<i>A. calcoaceticus</i> 2	0.50	>512	4	32	16
	<i>A. calcoaceticus</i> 7	0.25	32	4	>32	8
	<i>E. cloacae</i> 13	0.16	128	4	>32	8
	<i>E. cloacae</i> 19	0.31	64	4	>32	16
	<i>P. aeruginosa</i> 23	0.27	256	4	>64	32
	<i>P. aeruginosa</i> 26	0.56	128	8	>32	32
	<i>S. maltophilia</i> 35	0.26	>256	4	>32	16
	<i>S. maltophilia</i> 41	0.52	>512	16	>32	32

MBI 29	<i>S. marcescens</i> 1	0.09	64	16	>128	8
	<i>P. aeruginosa</i> 23	0.63	128	64	16	2
	<i>H. influenzae</i> 1	0.51	32	16	16	0.125
	<i>A. calcoaceticus</i> 2	0.50	>512	4	16	8
	<i>A. calcoaceticus</i> 7	0.25	32	4	>16	4
	<i>E. cloacae</i> 16	0.50	>512	4	>16	16
	<i>E. cloacae</i> 17	0.50	>512	4	>16	16
	<i>P. aeruginosa</i> 23	0.63	128	64	>32	8
	<i>P. aeruginosa</i> 24	0.50	>512	4	>16	16
	<i>S. maltophilia</i> 34	0.25	>512	4	>16	8
	<i>S. maltophilia</i> 35	0.50	>512	4	>16	16

## 7. Tobramycin

Peptide	Organism	FIC	Tobramycin MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Tobramycin
MBI 11A1CN	<i>P. aeruginosa</i> PA026	0.50	8	4	>128	0.125
	<i>S. maltophilia</i> SMA029	0.16	128	4	>128	32
	<i>S. maltophilia</i> SMA030	0.27	128	2	>128	64
MBI 11B9CN	<i>A. baumannii</i> ABI001	0.50	16	4	32	8
	<i>E. coli</i> ECO006	0.75	8	4	32	8
	<i>P. aeruginosa</i> PA008	0.50	32	0.125	128	64
	<i>P. aeruginosa</i> PA025	0.56	32	2	128	64
	<i>S. maltophilia</i> SMA027	0.63	8	4	>128	32
	<i>S. maltophilia</i> SMA031	0.19	64	4	>128	32
MBI 11CN	<i>A. baumannii</i> ABI001	0.50	16	4	64	16
	<i>E. coli</i> ECO006	0.53	8	4	8	0.25
	<i>P. aeruginosa</i> PA032	0.50	16	4	>128	64
	<i>S. maltophilia</i> SMA029	0.27	128	2	>128	64
	<i>S. maltophilia</i> SMA030	0.27	128	2	>128	64
MBI 11D18CN	<i>A. baumannii</i> ABI001	0.31	16	4	64	4
	<i>A. baumannii</i> ABI002	0.53	8	4	16	0.5
	<i>P. aeruginosa</i> PA032	1.00	8	4	64	32
	<i>S. maltophilia</i> SMA027	0.19	32	4	>128	16
	<i>S. maltophilia</i> SMA029	0.27	128	2	32	8
	<i>S. epidermidis</i> SE080	0.75	16	4	2	1
MBI 11F3CN	<i>A. baumannii</i> ABI001	0.53	16	0.5	32	16
	<i>P. aeruginosa</i> PA032	0.50	16	4	>128	64
	<i>S. maltophilia</i> SMA029	0.26	128	1	128	32
	<i>S. maltophilia</i> SMA030	0.26	128	1	128	32
MBI 11G13CN	<i>A. baumannii</i> ABI001	0.50	16	4	128	32
	<i>P. aeruginosa</i> PA022	0.56	8	4	>128	16
MBI 21A1	<i>P. aeruginosa</i> PA022	0.53	8	4	4	0.125
	<i>P. aeruginosa</i> PA026	0.51	8	4	16	0.125
	<i>P. aeruginosa</i> PA030	0.52	16	0.25	16	8
	<i>P. aeruginosa</i> PA032	0.63	8	1	64	32
	<i>S. maltophilia</i> SMA029	0.28	128	4	128	32
	<i>S. maltophilia</i> SMA030	0.16	128	4	>128	32
MBI 22A1	<i>A. baumannii</i> ABI001	0.75	16	4	4	2
	<i>S. maltophilia</i> SMA029	0.51	128	1	16	8
	<i>S. maltophilia</i> SMA029	0.50	128	0.125	32	16
	<i>S. epidermidis</i> SE072	0.50	>128	0.125	16	8
	<i>S. epidermidis</i> SE073	0.50	>128	0.125	16	8

MBI 26	<i>P. aeruginosa</i> PA031	0.75	16	4	32	16
	<i>S. maltophilia</i> SMA027	0.50	16	4	>128	64
	<i>S. epidermidis</i> SE068	0.27	>128	4	2	0.5
	<i>S. epidermidis</i> SE071	0.50	>128	0.125	16	8
MBI 27	<i>E. coli</i> ECO006	0.56	8	0.5	8	4
	<i>S. maltophilia</i> SMA027	1.00	8	4	32	16
	<i>S. maltophilia</i> SMA031	0.53	128	4	16	8
MBI 29	<i>E. coli</i> ECO006	0.53	8	4	4	0.125
	<i>P. aeruginosa</i> PA032	1.00	8	4	128	64
	<i>S. maltophilia</i> SMA031	0.50	>128	0.25	16	8
	<i>S. maltophilia</i> SMA032	0.53	128	4	16	8
MBI 29A3	<i>E. coli</i> ECO006	0.75	8	2	4	2
	<i>P. aeruginosa</i> PA022	0.56	8	4	4	0.25
	<i>S. maltophilia</i> SMA027	0.75	16	4	32	16
	<i>S. maltophilia</i> SMA029	0.28	128	4	16	4
REWH 53A5CN	<i>S. maltophilia</i> SMA029	0.13	128	0.25	>128	32
	<i>S. maltophilia</i> SMA030	0.13	128	0.25	>128	32

## 8. Vancomycin

Peptide	Organism	FIC	Vancomycin MIC ( $\mu$ g/ml)		Peptide MIC ( $\mu$ g/ml)	
			Alone	+ Peptide	Alone	+ Vancomycin
MBI 11A1CN	<i>E. faecalis</i> EFS003	0.63	8	4	>128	32
	<i>E. faecalis</i> EFS006	0.50	8	4	128	0.25
	<i>E. faecalis</i> EFS010	0.13	16	1	128	8
	<i>E. faecalis</i> EFS014	0.51	128	1	4	2
	<i>E. faecium</i> EFM004	0.50	>128	0.5	32	16
	<i>E. faecium</i> EFM007	0.28	128	4	64	16
	<i>E. faecium</i> EFM009	0.25	32	4	64	8
MBI 11D18CN	<i>E. faecalis</i> EFS003	0.75	8	2	64	32
	<i>E. faecalis</i> EFS007	0.63	8	1	16	8
	<i>E. faecalis</i> EFS009	0.75	8	2	8	4
	<i>E. faecium</i> EFM004	0.50	>128	0.5	8	4
	<i>E. faecium</i> EFM007	0.50	>128	0.5	8	4
	<i>E. faecium</i> EFM009	0.52	64	1	8	4
	<i>E. faecium</i> EFM010	0.50	>128	1	8	4
MBI 21A1	<i>E. faecalis</i> EFS012	0.09	128	4	32	2
	<i>E. faecalis</i> EFS013	0.09	128	4	32	2
	<i>E. faecium</i> EFM010	0.56	64	4	32	16

MBI 26	<i>E. faecalis</i> EFS005	0.31	16	4	>128	16
	<i>E. faecalis</i> EFS010	0.27	64	1	4	1
	<i>E. faecalis</i> EFS011	0.25	16	2	>128	32
	<i>E. faecium</i> EFM004	0.25	>128	0.125	64	16
	<i>E. faecium</i> EFM010	0.53	128	1	32	16
	<i>E. faecium</i> EFM011	0.31	32	2	32	8
MBI 29	<i>E. faecalis</i> EFS012	0.50	>128	1	2	1
	<i>E. faecalis</i> EFS013	0.50	>128	1	2	1
	<i>E. faecium</i> EFM005	0.53	128	4	8	4
	<i>E. faecium</i> EFM009	0.75	16	4	8	4
	<i>E. faecium</i> EFM010	0.63	32	4	8	4
	<i>E. faecium</i> EFM016	0.51	128	1	4	2
MBI 29A3	<i>E. faecalis</i> EFS005	0.19	16	1	32	4
	<i>E. faecalis</i> EFS011	0.50	16	4	32	8
	<i>E. faecalis</i> EFS014	0.52	64	1	1	0.5
	<i>E. faecium</i> EFM006	0.52	>128	4	4	2

These data show that acquired resistance can be overcome. For example, the acquired resistance of *S. aureus*, a Gram-positive organism, to piperacillin is overcome when 5 it is combined with MBI 27 and acquired resistance to ciprofloxacin is overcome with peptides MBI 21A1 or MBI 21A2. Similar results are obtained for peptides MBI 26 and MBI 31 in combination with methicillin and erythromycin, and for peptide MBI 26 in combination with vancomycin or teicoplanin against resistant enterococci.

10

### EXAMPLE 8

#### SYNERGY OF CATIONIC PEPTIDES AND LYSOZYME OR NISIN

The effectiveness of lysozyme or nisin is improved when either agent is administered in combination with an antibiotic agent. The improvement is demonstrated by measurement of the MICs of lysozyme or nisin alone and in combination with the antibiotic, 15 whereby the lysozyme or nisin, or antibiotic, MIC is lower in combination than alone. The MICs can be measured by the agarose dilution assay, the broth dilution assay or by time kill curves.

20

### ERYTHROCYTE HEMOLYSIS BY CATIONIC PEPTIDES

A red blood cell (RBC) lysis assay is used to group peptides according to their ability to lyse RBC under standardized conditions compared with MBI 11CN and

Gramicidin-S. Peptide samples and washed sheep RBC are prepared in isotonic saline with the final pH adjusted to between 6 and 7. Peptide samples and RBC suspension are mixed together to yield solutions that are 1% (v/v) RBC and 5, 50 or 500  $\mu$ g/ml peptide. The assay is performed as described above. Each set of assays also includes MBI 11CN (500  $\mu$ g/ml) and Gramicidin-S (5  $\mu$ g/ml) as "low lysis" and "high lysis" controls, respectively.

5 MBI11B7CN, MBI11F3CN and MBI11F4CN are tested using this procedure and the results are presented in Table 21 below.

Table 21

Peptide	% lysis at 5 $\mu$ g/ml	% lysis at 50 $\mu$ g/ml	% lysis at 500 $\mu$ g/ml
MBI 11B7CN	4	13	46
MBI 11F3CN	1	6	17
MBI 11F4CN	4	32	38
MBI 11CN	N/D	N/D	9
Gramicidin-S	30	N/D	N/D

10 N/D = not done

Peptides that at 5  $\mu$ g/ml lyse RBC to an equal or greater extent than Gramicidin-S, the "high lysis" control, are considered to be highly lytic. Peptides that at 500  $\mu$ g/ml lyse RBC to an equal to or lesser extent than MBI 11CN, the "low lysis" control, 15 are considered to be non-lytic. The three analogues tested are all "moderately lytic" as they cause more lysis than MBI 11CN and less than Gramicidin S. In addition one of the analogues, MBI 11F3CN, is significantly less lytic than the other two variants at all three concentrations tested.

A combination of cationic peptide and antibiotic agent is tested for toxicity 20 towards eukaryotic cells by measuring the extent of lysis of mammalian red blood cells. Briefly, red blood cells are separated from whole blood by centrifugation, washed free of plasma components, and resuspended to a 5% (v/v) suspension in isotonic saline. The peptide and antibiotic agent are pre-mixed in isotonic saline, or other acceptable solution, and an aliquot of this solution is added to the red blood cell suspension. Following incubation 25 with constant agitation at 37°C for 1 hour, the solution is centrifuged, and the absorbance of the supernatant is measured at 540 nm, which detects released hemoglobin. Comparison to the  $A_{540}$  for a 100% lysed standard provides a relative measure of hemoglobin release from

red blood cells, indicating the lytic ability of the cationic peptide and antibiotic agent combination.

5

### EXAMPLE 10

#### PHARMACOLOGY OF CATIONIC PEPTIDES IN PLASMA AND BLOOD

The *in vitro* lifetime of free peptides in plasma and in blood is determined by measuring the amount of peptide present after set incubation times. Blood is collected from sheep, treated with an anticoagulant (not heparin) and, for plasma preparation, centrifuged to remove cells. Formulated peptide is added to either the plasma fraction or to whole blood and incubated. Following incubation, peptide is identified and quantified directly by reversed phase HPLC or an antibody-based assay. The antibiotic agent is quantified by a suitable assay, selected on the basis of its structure. Chromatographic conditions are as described above. Extraction is not required as the free peptide peak does not overlie any peaks from blood or plasma.

A 1 mg/mL solution of MBI 11B7CN in isotonic saline is added to freshly prepared heat-inactivated rabbit serum, to give a final peptide concentration of 100  $\mu$ g/mL and is incubated at 32°C. The peptide levels detected at various incubation times are shown in Figure 2.

20 A series of peptide stability studies are performed to investigate the action of protease inhibitors on peptide degradation. Peptide is added to rabbit serum or plasma, either with or without protease inhibitors, then incubated at 22°C for 3 hrs. Protease inhibitors tested include amastatin, bestatin, COMPLETE protease inhibitor cocktail, leupeptin, pepstatin A and EDTA. Amastatin and bestatin at 100  $\mu$ M prevent the degradation of MBI 11B7CN in plasma over 3 hrs. For this experiments 10 mM stock solutions of amastatin and bestatin are prepared in dimethylsulfoxide. These solutions are diluted 1:100 in heat-inactivated rabbit serum and incubated at 22°C for 15 mins prior to addition of peptide. MBI 11B7CN is added to the serum at a final concentration of 100  $\mu$ g/mL and incubated for 3 hrs at 22°C. After the incubation period, the serum samples are analyzed on an analytical C<sub>8</sub> 30 column (Waters Nova Pak C<sub>8</sub> 3.9 x 170 mm) with detection at 280 nm. In Figure 3, MBI 11B7CN elutes at 25 min and shows differing degrees of degradation.

Peptide is extracted from plasma using C<sub>8</sub> Sep Pak cartridges at peptide concentrations between 0 and 50 µg/mL. Each extraction also contains MBI 11CN at 10 µg/mL as an internal standard. Immediately after addition of the peptides to fresh rabbit plasma, the samples are mixed then diluted 1:10 with a 1% aqueous trifluoroacetic acid (TFA) solution, to give a final TFA concentration of 0.1%. Five hundred µL of this solution is immediately loaded onto a C<sub>8</sub> Sep Pak cartridge and eluted with 0.1% TFA in 40% acetonitrile/60% H<sub>2</sub>O. Twenty µL of this eluant is loaded onto a 4.6 x 45 mm analytical C<sub>18</sub> column and is eluted with an acetonitrile gradient of 25% to 65% over 8 column volumes. The peptides are detected at 280 nm. As shown in Figure 4, MBI 11B7CN and MBI 11CN elute at 5 and 3 min respectively. Moreover, MBI 11B7CN is detected over background at concentrations of 5 µg/mL and above.

The *in vivo* lifetime of the cationic peptide and antibiotic agent combination is determined by administration, typically by intravenous or intraperitoneal injection, of 80-100% of the maximum tolerable dose of the combination in a suitable animal model, typically a mouse. At set times post-injection, each group of animals are anesthetized, blood is drawn, and plasma obtained by centrifugation. The amount of peptide or agent in the plasma supernatant is analyzed as for the *in vitro* determination. (Figure 5).

#### EXAMPLE 11

##### 20 TOXICITY OF CATIONIC PEPTIDES *IN VIVO*

The acute, single dose toxicity of various indolicidin analogues is tested in Swiss CD1 mice using various routes of administration. In order to determine the inherent toxicities of the peptide analogues in the absence of any formulation/delivery vehicle effects, the peptides are all administered in isotonic saline with the final pH between 6 and 7.

25 *Intraperitoneal route.* Groups of 6 mice are injected with peptide doses of between 80 and 5 mg/kg in 500 µL dose volumes. After peptide administration, the mice are observed for a period of 5 days, at which time the dose causing 50% mortality (LD<sub>50</sub>), the dose causing 90-100% mortality (LD<sub>90-100</sub>) and maximum tolerated dose (MTD) levels are determined. The LD<sub>50</sub> values are calculated using the method of Reed and Muench (*J. of Amer. Hyg.* 27: 493-497, 1938). The results presented in Table 22 show that the LD<sub>50</sub> values for MBI 11CN and analogues range from 21 to 52 mg/kg.

Table 22

Peptide	LD <sub>50</sub>	LD <sub>90-100</sub>	MTD
MBI 11CN	34 mg/kg	40 mg/kg	20 mg/kg
MBI 11B7CN	52 mg/kg	>80 mg/kg	30 mg/kg
MBI 11E3CN	21 mg/kg	40 mg/kg	<20 mg/kg
MBI 11F3CN	52 mg/kg	80 mg/kg	20 mg/kg

The single dose toxicity of a cationic peptide and antibiotic agent combination is examined in outbred ICR mice. Intraperitoneal injection of the combination in isotonic saline is carried out at increasing dose levels. The survival of the animals is monitored for 7 days. The number of animals surviving at each dose level is used to determine the maximum tolerated dose (MTD). In addition, the MTD can be determined after administration of the peptide and agent by different routes, at different time points, and in different formulations.

*Intravenous route.* Groups of 6 mice are injected with peptide doses of approximately 20, 16, 12, 8, 4 and 0 mg/kg in 100  $\mu$ l volumes (4 ml/kg). After administration, the mice are observed for a period of 5 days, at which time the LD<sub>50</sub>, LD<sub>90-100</sub> and MTD levels are determined. The results from the IV toxicity testing of MBI 11CN and three analogues are shown in Table 23. The LD<sub>50</sub>, LD<sub>90-100</sub> and MTD values range from 5.8 to 15 mg/kg, 8 to 20 mg/kg and <4 to 12 mg/kg respectively.

Table 23

Peptide	LD <sub>50</sub>	LD <sub>90-100</sub>	MTD
MBI 11CN	5.8 mg/kg	8.0 mg/kg	<4 mg/kg
MBI 11B7CN	7.5 mg/kg	16 mg/kg	4 mg/kg
MBI 11F3CN	10 mg/kg	12 mg/kg	8 mg/kg
MBI 11F4CN	15 mg/kg	20 mg/kg	12 mg/kg

In addition, mice are multiply injected by an intravenous route with MBI 11CN. In one representative experiment, peptide administered in 10 injections of 0.84 mg/kg at 5 minute intervals is not toxic. However, two injections of peptide at 4.1 mg/kg administered with a 10 minute interval results in 60% toxicity.

*Subcutaneous route.* The toxicity of MBI 11CN is also determined after subcutaneous (SC) administration. For SC toxicity testing, groups of 6 mice are injected with peptide doses of 128, 96, 64, 32 and 0 mg/kg in 300  $\mu$ L dose volumes (12 mL/kg). After administration, the mice are observed for a period of 5 days. None of the animals died at any

of the dose levels within the 5 day observation period. Therefore, the LD<sub>50</sub>, LD<sub>90-100</sub> and MTD are all taken to be greater than 128 mg/kg. Mice receiving higher dose levels showed symptoms similar to those seen after IV injection suggesting that peptide entered the systemic circulation. These symptoms are reversible, disappearing in all mice by the second day of 5 observations.

To assess the impact of dosing mice with peptide analogue, a series of histopathology investigations can be carried out. Groups of mice are administered analogue at dose levels that are either at, below the MTD, or above the MTD, a lethal dose. Multiple injections may be used to mimic possible treatment regimes. Groups of control mice are not 10 injected or injected with buffer only.

Following injection, mice are sacrificed at specified times and their organs immediately placed in a 10% balanced formalin solution. Mice that die as a result of the toxic effects of the analogue also have their organs preserved immediately. Tissue samples are taken and prepared as stained micro-sections on slides which are then examined 15 microscopically. Damage to tissues is assessed and this information can be used to develop improved analogues, improved methods of administration or improved dosing regimes.

Mice given a non-lethal dose are always lethargic, with raised fur and evidence of edema and hypertension, but recover to normal within two hours. Tissues from these animals indicate that there is some damage to blood vessels, particularly within the liver and 20 lung at both the observation times, but other initial abnormalities returned to normal within the 150 minute observation time. It is likely that blood vessel damage is a consequence of continuous exposure to high circulating peptide levels.

In contrast, mice given a lethal dose have completely normal tissues and organs, except for the liver and heart of the ip and iv dosed mice, respectively. In general, 25 this damage is identified as disruption of the cells lining the blood vessels. It appears as though the rapid death of mice is due to this damage, and that the peptide did not penetrate beyond that point. Extensive damage to the hepatic portal veins in the liver and to the coronary arterioles in the heart is observed.

88  
EXAMPLE 12*IN VIVO EFFICACY OF CATIONIC PEPTIDES*

Cationic peptides are tested for their ability to rescue mice from lethal bacterial infections. The animal model used is an intraperitoneal (ip) inoculation of mice 5 with  $10^6$ - $10^8$  Gram-positive organisms with subsequent administration of peptide. The three pathogens investigated, methicillin-sensitive *S. aureus* (MSSA), methicillin-resistant *S. aureus* (MRSA), or *S. epidermidis*, are injected ip into mice. For untreated mice, death occurs within 12-18 hours with MSSA and *S. epidermidis* and within 6-10 hours with MRSA.

Peptide is administered by two routes, intraperitoneally, at one hour post-10 infection, or intravenously, with single or multiple doses given at various times pre- and post-infection.

*MSSA infection.* In a typical protocol, groups of 10 mice are infected intraperitoneally with a  $LD_{90-100}$  dose ( $5.2 \times 10^6$  CFU/mouse) of MSSA (Smith, ATCC # 19640) injected in brain-heart infusion containing 5% mucin. This strain of *S. aureus* is not 15 resistant to any common antibiotics. At 60 minutes post-infection, formulated MBI 10CN or MBI 11CN, is injected intraperitoneally at a range of dose levels. An injection of formulation alone serves as a negative control and administration of ampicillin serves as a positive control. The survival of the mice is monitored at 1, 2, 3 and 4 hrs post-infection and twice daily thereafter for a total of 8 days.

MBI 10CN is maximally active against MSSA (70-80% survival) at doses of 20 15 to 38 mg/kg, although 100% survival is not achieved. Below 15 mg/kg, there is clear dose-dependent survival. At these lower dose levels, there appears to be an animal-dependent threshold, as the mice either die by day 2 or survive for the full eight day period. MBI 11CN, on the other hand, rescued 100% of the mice from MSSA infection at a dose level of 25 36 mg/kg, and was therefore as effective as ampicillin. There was little or no activity at any of the lower dose levels, which indicates that a minimum bloodstream peptide level must be achieved during the time that bacteria are a danger to the host.

*S. epidermidis infection.* Peptide analogues generally have lower MIC values 30 against *S. epidermidis* *in vitro*, therefore, lower blood peptide levels might be more effective against infection.

In a typical protocol, groups of 10 mice are injected intraperitoneally with an LD<sub>90-100</sub> dose ( $2.0 \times 10^8$  CFU/mouse) of *S. epidermidis* (ATCC # 12228) in brain-heart infusion broth containing 5% mucin. This strain of *S. epidermidis* is 90% lethal after 5 days. At 15 mins and 60 mins post-infection, various doses of formulated MBI 11CN are injected 5 intravenously via the tail vein. An injection of formulation only serves as the negative control and injection of gentamicin serves as the positive control; both are injected at 60 minutes post-infection. The survival of the mice is monitored at 1, 2, 3, 4, 6 and 8 hrs post-infection and twice daily thereafter for a total of 8 days.

MBI 11CN prolongs the survival of the mice. Efficacy is observed at all three 10 dose levels with treatment 15 minutes post-infection, however, there is less activity at 30 minutes post-infection and no significant effect at 60 minutes post-infection. Time of administration appears to be important in this model system, with a single injection of 6mg/kg 15 minutes post-infection giving the best survival rate.

15 *MRSA infection.* MRSA infection, while lethal in a short period of time, requires a much higher bacterial load than MSSA. In a typical protocol, groups of 10 mice are injected intraperitoneally with a LD<sub>90-100</sub> dose ( $4.2 \times 10^7$  CFU/mouse) of MRSA (ATCC # 33591) in brain-heart infusion containing 5% mucin. The MBI 11CN treatment protocols are as follows, with the treatment times relative to the time of infection:

- 20 • 0 mg/kg Formulation alone (negative control), injected at 0 mins
- 5 mg/kg Three 5.5 mg/kg injections at -5, +55, and +115 mins
- 1 mg/kg (2 hr) Five 1.1 mg/kg injections at -5, +55, +115, +175 and +235 mins
- 1 mg/kg (20 min) Five 1.1 mg/kg injections at -10, -5, 0, +5, and +10 mins
- Vancomycin (positive control) injected at 0 mins

25 Survival of mice is recorded at 1, 2, 3, 4, 6, 8, 10, 12, 20, 24 and 30 hrs post-infection and twice daily thereafter for a total of 8 days. There was no change in the number of surviving mice after 24 hrs. The 1 mg/kg (20 min) treatment protocol, with injections 5 minutes apart centered on the infection time, delayed the death of the mice to a significant extent with one survivor remaining at the end of the study.

30

It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made

90

without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

We claim:

1. An indolicidin analogue selected from the group consisting of:

MBI 11A9: Ile Leu Arg Trp Pro Trp Trp Pro Trp Trp Pro Trp Arg Arg Lys;  
MBI 11A10: Trp Trp Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys;  
MBI 11B19: Ile Leu Arg Trp Pro Trp Arg Arg Trp Pro Trp Arg Arg Lys;  
MBI 11B20: Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys Met Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys Met Ala Ala;  
MBI 11D19: Cys Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys;  
MBI 11F5: Ile Leu Arg Arg Trp Val Trp Trp Val Trp Arg Arg Lys;  
MBI 11F6: Ile Leu Arg Trp Trp Val Trp Trp Val Trp Trp Arg Arg Lys;  
MBI 11G25: Leu Arg Trp Trp Trp Pro Trp Arg Arg Lys;  
MBI 11G26: Leu Arg Trp Pro Trp Trp Pro Trp;  
MBI 11G28: Arg Trp Trp Trp Pro Trp Arg Arg Lys;  
MBI 11J01: Arg Arg Ile Trp Lys Pro Lys Trp Arg Leu Pro Lys Arg; and  
MBI 11J02: Trp Arg Trp Trp Lys Pro Lys Trp Arg Trp Pro Lys Trp;

2. An indolicidin analogue selected from the group consisting of: MBI 11G24: Leu Trp Pro Trp Trp Pro Trp Arg Arg Lys and MBI 11G27: Trp Pro Trp Trp Pro Trp Arg Arg Lys.

3. The indolicidin analogue according to either of claims 1 or 2, wherein the analogue has one or more amino acids altered to a corresponding D-amino acid.

4. The indolicidin analogue according to claim 3, wherein the N-terminal and/or C-terminal amino acid is a D-amino acid.

5. The indolicidin analogue according to any one of claims 1-4, wherein the analogue is acetylated at the N-terminal amino acid.

6. The indolicidin analogue according to any one of claims 1-5, wherein the analogue is amidated at the C-terminal amino acid.

7. The indolicidin analogue according to any one of claims 1-5, wherein the analogue is esterified at the C-terminal amino acid.

8. The indolicidin analogue according to any one of claims 1-5, wherein the analogue is modified by incorporation of homoserine/homoserine lactone at the C-terminal amino acid.

9. An isolated nucleic acid molecule whose sequence comprises one or more coding sequences of an indolicidin analogue according to either of claims 1 or 2.

10. An expression vector comprising a promoter in operable linkage with the nucleic acid molecule of claim 9.

11. A host cell transfected or transformed with the expression vector of claim 10.

12. A pharmaceutical composition comprising at least one indolicidin analogue according to any of claims 1-8 and a physiologically acceptable buffer.

13. The pharmaceutical composition according to claim 12, further comprising an antibiotic agent.

14. The pharmaceutical composition according to claim 13, wherein the antibiotic is selected from the group consisting of penicillins, cephalosporins, carbacephems, cephamycins, carbapenems, monobactams, quinolones, tetracyclines, aminoglycosides, macrolides, glycopeptides, chloramphenicols, glycylcyclines, licosamides and fluoroquinolones.

15. A pharmaceutical composition comprising a physiologically acceptable buffer and a combination of a cationic peptide and an antibiotic, wherein the combination is selected from the group consisting of:

Ile Leu Lys Lys Phe Pro Phe Phe Pro Phe Arg Arg Lys and ciprofloxacin.

Ile Leu Lys Lys Phe Pro Phe Phe Pro Phe Arg Arg Lys and vancomycin.

Ile Leu Arg Arg Trp Pro Trp Trp Pro Trp Arg Arg Arg and piperacillin.

Ile Leu Arg Trp Pro Trp Trp Pro Trp Arg Arg Lys Ile Met Ile Leu Lys Lys Ala Gly Ser and gentamicin.

Trp Arg Ile Trp Lys Pro Lys Trp Arg Leu Pro Lys Trp and vancomycin.

Trp Arg Ile Trp Lys Pro Lys Trp Arg Leu Pro Lys Trp and tobramycin.

Trp Arg Ile Trp Lys Pro Lys Trp Arg Leu Pro Lys Trp and piperacillin.

Ile Leu Lys Lys Trp Pro Trp Trp Pro Trp Arg Arg Lys and piperacillin.

Ile Leu Lys Lys Trp Val Trp Trp Pro Trp Arg Arg Lys and tobramycin and

Ile Leu Arg Trp Val Trp Trp Val Trp Arg Arg Lys and piperacillin.

16. A device coated with a composition comprising a cationic peptide and an antibiotic agent.

17. The device of claim 16, wherein the device is a medical device.

18. A method of overcoming tolerance of a bacterium to an antibacterial agent, comprising: contacting the bacterium with a composition comprising the antibacterial agent and a cationic peptide, therefrom overcoming tolerance.

19. The method of claim 18, wherein the cationic peptide is selected from the group consisting of Abaecins, Andropins, Apidaecins, AS, Bactenecins, Bac, Bactericidins, Bacteriocins, Bombinins, Bombolitins, BPTI, Brevinins, CAP 18 and related peptides, Cecropins, Ceratotoxins, Charybdotoxins, Coleoptericins, Crabolin, alpha, beta, and insect defensins, Dermaseptins, Diptericins, Drosocins, Esculentins, Gramicidins, Histatins, Indolicidins, Lactoferricins, Lantibiotics, Leukocins, Magainins and related peptides from amphibians, Mastoparans, Melittins, Phormicins, Polyphemusins, Protegrins, Royalisins, Sarcotoxins, Seminal plasmins, Sepacins, Tachyplesins, Thionins, Toxins, Cecropin-Melittin chimeras and analogues thereof.

20. The method of claim 18, wherein the cationic peptide is an indolicidin analogue.

21. A method of overcoming inherent resistance of a microorganism to an antibiotic agent, comprising: contacting the microorganism with a composition comprising the antibiotic agent and a cationic peptide selected from the group consisting of Abaecins, Andropins, Apidaecins, AS, Bactenecins, Bac, Bactericidins, Bacteriocins, Bombinins, Bombolitins, Brevinins, CAP 18 and related peptides, Cecropins, Ceratotoxins, Charybdotoxins, Coleoptericins, Crabolins, Dermaseptins, Dipterics, Drosocins, Esculentins, Gramicidins, Histatins, Indolicidins, Lactoferricins, Lantibiotics, Leukocins, Magainins and related peptides from amphibians, Mastoparans, Melittins, Phormicins, Polypheusins, Protegrins, Royalisins, Sarcotoxins, Seminal plasmins, Sepacins, Tachypleins, Thionins, Toxins, Cecropin-Melittin chimeras and analogues thereof, therefrom overcoming inherent resistance.

22. The method of claim 21, wherein the cationic peptide is an indolicidin analogue.

23. A method of overcoming acquired resistance of a microorganism to an antibiotic agent, comprising: contacting the microorganism with a composition comprising the antibiotic agent and a cationic peptide selected from the group consisting of Abaecins, Andropins, Apidaecins, AS, Bactenecins, Bac, Bactericidins, Bacteriocins, Bombinins, Bombolitins, Brevinins, CAP 18 and related peptides, Cecropins, Ceratotoxins, Charybdotoxins, Coleoptericins, Crabolins, alpha, beta, and insect Defensins, Dermaseptins, Dipterics, Drosocins, Esculentins, Gramicidins, Histatins, Indolicidins, Lactoferricins, Lantibiotics, Leukocins, Magainins and related peptides from amphibians, Mastoparans, Melittins, Phormicins, Protegrins, Royalisins, Sarcotoxins, Seminal plasmins, Sepacins, Thionins, Toxins, Cecropin-Melittin chimeras and analogues thereof, therefrom overcoming acquired resistance.

24. The method of claim 23, wherein the cationic peptide is an indolicidin analogue.

25. A method of overcoming tolerance of a bacterium to an antibacterial agent, overcoming inherent resistance of a microorganism an antibacterial agent, overcoming acquired resistance of a microorganism an antibacterial agent or enhancing the activity of an antibiotic agent against a susceptible microorganism, comprising administering a pharmaceutical composition of lysozyme or nisin and an antibacterial agent, therefrom overcoming tolerance, inherent resistance, acquired resistance, or enhancing activity.

26. A method of enhancing activity of an antibiotic agent against a susceptible microorganism, comprising administering a pharmaceutical composition comprising the antibiotic agent and a cationic peptide selected from the group consisting of Abaecins, Andropins, Apidaecins, AS, Bactenecins, Bac, Bactericidins, Bacteriocins, Bombinins, Bombolitins, Brevinins, CAP 18 and related peptides, Ceratotoxins, Charybdotoxins, Coleoptericins, alpha, beta, and insect Defensins, Dermaseptins, Dipterics, Drosocins, Esculentins, Gramicidins, Histatins, Indolicidins, Leukocins, Mastoparans, Phormicins, Polyphemusins, Protegrins, Royalisins, Seminal plasmins, Sepacins, Thionins, Toxins and analogues thereof, therefrom enhancing activity of the antibiotic agent against the susceptible microorganism.

27. The method of claim 26, wherein the cationic peptide is an indolicidin analogue.

28. The method of claim 19, wherein the cationic peptide and antibacterial agents are selected from the group consisting of MBI 11A1CN and Chloramphenicol; MBI 11B4CN and Erythromycin; MBI 21A10 and Ampicillin; MBI 21A10 and Piperacillin; MBI 26 and Vancomycin; MBI 29 and Gentamicin and MBI 29A3 and Penicillin.

29. The method of claim 21, wherein the cationic peptide and antibiotic agents are selected from the group consisting of MBI 11B16CN and Amikacin; MBI 11D18CN and Gentamicin; MBI 11D18CN and Gentamicin; MBI 21A1 and Mupirocin; MBI 21A1 and Tobramycin; MBI 26 and Amikacin; MBI 26 and Gentamicin; MBI 29A3 and Amikacin; MBI 29A3 and Tobramycin and MBI 29F1 and Amikacin.

30. The method of claim 23, wherein the cationic peptide and antibiotic agent are selected from the group consisting of MBI 11A1CN and Vancomycin; MBI 11B16CN and Gentamicin; MBI 11D18CN and Gentamicin; MBI 11F3CN and Tobramycin; MBI 11F4CN and Piperacillin; MBI 21A1 and Tobramycin; MBI 26 and Ceftriaxone; MBI 26 and Vancomycin; MBI 29A2 and Ciprofloxacin and MBI 29A3 and Ciprofloxacin.

31. The method of claim 26, wherein the cationic peptide and antibiotic agent are selected from the group consisting of MBI 11B16CN and Amikacin; MBI 11CN and Piperacillin; MBI 11G13CN and Tobramycin; MBI 11G7CN and Piperacillin; MBI 11J02CN

and Ceftriaxone; MBI 21A2 and Gentamicin; MBI 28 and Mupirocin; MBI 29 and Vancomycin; MBI 29A2 and Ciprofloxacin and REWH 53A5CN and Tobramycin.

32. The method of any of claims 18-31, wherein the infection is due to a microorganism.

33. The method of claim 32, wherein the microorganism is selected from the group consisting of bacterium, fungus, parasite and virus.

34. The method of claim 33, wherein the fungus is a yeast and/or mold.

35. The method of claim 33, wherein the parasite is selected from the group consisting of protozoan, nematode, cestode and trematode.

36. The method of claim 35, wherein the parasite is selected from the group consisting of *Babesia spp.*; *Balantidium coli*; *Blastocystis hominis*; *Cryptosporidium parvum*; *Encephalitozoon spp.*; *Entamoeba spp.*; *Giardia lamblia*; *Leishmania spp.*; *Plasmodium spp.*; *Toxoplasma gondii*; *Trichomonas spp.*; *Trypanosoma spp.*; *Ascaris lumbricoides*; *Clonorchis sinensis*; *Echinococcus spp.*; *Fasciola hepatica*; *Fasciolopsis buski*; *Heterophyes heterophyes*; *Hymenolepis spp.*; *Schistosoma spp.*; *Taenia spp.* and *Trichinella spiralis*.

37. The method of claim 33, wherein the bacterium is a Gram-negative bacterium.

38. The method of claim 37, wherein the Gram-negative bacterium is selected from the group consisting of *Acinetobacter spp.*; *Enterobacter spp.*; *E. coli*; *H. influenzae*; *K. pneumoniae*; *P. aeruginosa*; *S. marcescens*; *S. maltophilia*; *Bordetella pertussis*; *Brucella spp.*; *Campylobacter spp.*; *Haemophilus ducreyi*; *Helicobacter pylori*; *Legionella spp.*; *Moraxella catarrhalis*; *Neisseria spp.*; *Salmonella spp.*; *Shigella spp.* and *Yersinia spp.*

39. The method of claim 33, wherein the bacterium is a Gram-positive bacterium.

40. The method of claim 39, wherein the Gram-positive bacterium is selected from the group consisting of *E. faecalis*; *S. aureus*; *E. faecium*; *S. pyogenes*; *S. pneumoniae*; coagulase-negative staphylococci; *Bacillus spp.*; *Corynebacterium spp.*; Diphtheroids; *Listeria spp.* and Viridans Streptococci.

41. The method of claim 33, wherein the bacterium is an anaerobe selected from the group consisting *Clostridium spp.*, *Bacteroides spp.* and *Peptostreptococcus spp.*

42. The method of claim 33, wherein the bacterium is selected from the group consisting of *Borrelia spp.*; *Chlamydia spp.*; *Mycobacterium spp.*; *Mycoplasma spp.*; *Propionibacterium acne*; *Rickettsia spp.*; *Treponema spp.* and *Ureaplasma spp.*

44. The method of claim 33, wherein the virus is an RNA virus selected from the group consisting of Alphavirus; Arenavirus; Bunyavirus; Coronavirus; Enterovirus; Filovirus; Flavivirus; Hantavirus; HTLV-BLV; Influenzavirus; Lentivirus; Lyssavirus; Paramyxovirus; Reovirus; Rhinovirus and Rotavirus.

45. The method of claim 33, wherein the virus is a DNA virus selected from the group consisting of Adenovirus; Cytomegalovirus; Hepadnavirus; Molluscipoxvirus; Orthopoxvirus; Papillomavirus; Parvovirus; Polyomavirus; Simplexvirus and Varicellovirus.

46. The method of any of claims 18-45, wherein the pharmaceutical composition is administered by intravenous injection, intraperitoneal injection or implantation, intramuscular injection or implantation, intrathecal injection, subcutaneous injection or implantation, intradermal injection, lavage, bladder wash-out, suppositories,

98

pessaries, oral ingestion, topical application, enteric application, inhalation, aerosolization or nasal spray or drops.

1/6




Fig. 1A




Fig. 1B

SUBSTITUTE SHEET (RULE 26)

2/6




Fig. 1C




Fig. 1D

3/6


MBI 26 & Vancomycin in Combination Against *E. faecium* EFM017

Fig. 1E

## Stability of MBI-11B7CN-Cl in Heat-inactivated Rabbit Serum





Fig. 2

4/6



SUBSTITUTE SHEET (RULE 26)

Fig. 3

5/6




Fig. 4

6/6





Fig. 5



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07K 7/06, 7/08, 14/47, A61K 38/04, G01N 33/50</b>		<b>A3</b>	(11) International Publication Number: <b>WO 98/40401</b>
			(43) International Publication Date: 17 September 1998 (17.09.98)
(21) International Application Number: <b>PCT/CA98/00190</b>		(74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).	
(22) International Filing Date: 10 March 1998 (10.03.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 60/040,649 10 March 1997 (10.03.97) US 08/915,314 20 August 1997 (20.08.97) US 60/060,099 26 September 1997 (26.09.97) US 09/030,619 25 February 1998 (25.02.98) US		(71) Applicant (for all designated States except US): MI-CROLOGIX BIOTECH INC. [CA/CA]; B.C. Research Building, 3650 Westbrook Mall, Vancouver, British Columbia V6S 2L2 (CA).	
(72) Inventors; and (75) Inventors/Applicants (for US only): FRASER, Janet, R. [GB/CA]; #12 - 1038 West 7th Avenue, Vancouver, British Columbia V6H 1B3 (CA). WEST, Michael, H., P. [CA/CA]; 2554 East 19th Avenue, Vancouver, British Columbia V5M 2S3 (CA). McNICOL, Patricia, J. [CA/CA]; 2559 Jasmine Court, Coquitlam, British Columbia V3E 2G5 (CA).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
		(88) Date of publication of the international search report: 17 December 1998 (17.12.98)	

(54) Title: COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS



## (57) Abstract

Compositions and methods for treating infections, especially bacterial infections, are provided. Cationic peptides in combination with an antibiotic agent are administered to a patient to enhance the activity of the antibiotic agent, overcome tolerance, overcome acquired resistance, or overcome inherent resistance.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/CA 98/00190A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07K7/06 C07K7/08 C07K14/47 A61K38/04 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 08199 A (UNIV BRITISH COLUMBIA) 6 March 1997  see page 11, line 8-16 see example V see page 5, line 14-17 see claims 1-3 ---	18-27, 32-35, 37,46
Y	WO 95 22338 A (UNIV CALIFORNIA) 24 August 1995 see page 7 ---	1-46
Y	WO 97 22308 A (UNIV CALIFORNIA) 23 December 1992 sequence 1 ---	1-17
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

9 October 1998

Date of mailing of the international search report

23.10.98

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

## Authorized officer

Deffner, C-A

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/CA 98/00190

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 38473 A (UNIV BRITISH COLUMBIA) 5 December 1996	18,19
Y	see page 32 - page 52 see example 8 see tables 8-17 ---	18-46
X	WO 91 12815 A (SQUIBB BRISTOL MYERS CO) 5 September 1991	18,19, 21,23, 25,26, 32-35
	see page 17-18	
	see table 4	
Y	see page 1-3	18-46
Y	see page 3, line 21 - line 29 ---	18-46
X	MARTTI VAARA ET AL.: "Group of Peptides That Act Synergistically with Hydrophobic Antibiotics against Gram-Negative Enteric Bacteria" ANTIBACTERIOL AGENTS CHEMOTHER., vol. 40, no. 8, 1996, pages 1801-5, XP002080197 see tables 1-3 ---	18,19,32
Y	ROBERT E.W. HANCOCK: "The Role of Fundamental Research and Biotechnology in Finding Solutions to the Global Problem of Antibiotic Resistance" CLINICAL INFECT. DISEAS., vol. 24, January 1997, pages s148-s150, XP002080198 see page S149, right-hand column, last paragraph - page S150, left-hand column, paragraph 1 -----	18-46

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 98/00190

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 18-46 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00190

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9708199	A 06-03-1997	AU 6940796 A EP 0846128 A		19-03-1997 10-06-1998
WO 9522338	A 24-08-1995	US 5547939 A AU 683725 B AU 1747895 A EP 0750506 A JP 9509175 T ZA 9501276 A		20-08-1996 20-11-1997 04-09-1995 02-01-1997 16-09-1997 23-10-1995
WO 9222308	A 23-12-1992	US 5324716 A AT 163429 T CA 2111336 A DE 69224524 D DE 69224524 T DK 590070 T EP 0590070 A ES 2112909 T JP 6510757 T US 5547939 A		28-06-1994 15-03-1998 23-12-1992 02-04-1998 02-07-1998 16-03-1998 06-04-1994 16-04-1998 01-12-1994 20-08-1996
WO 9638473	A 05-12-1996	CA 2222599 A EP 0842192 A		05-12-1996 20-05-1998
WO 9112815	A 05-09-1991	AU 650262 B AU 7485691 A CA 2076529 A CN 1054900 A EP 0516747 A FI 923747 A IL 97344 A NZ 237202 A PT 96859 A US 5409898 A PL 166731 B		16-06-1994 18-09-1991 24-08-1991 02-10-1991 09-12-1992 20-08-1992 31-12-1995 26-01-1994 31-10-1991 25-04-1995 30-06-1995